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Negli ultimi decenni sono stati sviluppati, in maniera sempre più consistente, drug 
carriers supramolecolari per la terapia tumorale capaci di aggregare in nanostrutture 
grazie all'utilizzo di polimeri "intelligenti". Questi sistemi sono stati progettati in 
modo tale da essere direzionati selettivamente al tessuto tumorale, mantenere 
l'efficacia terapeutica del farmaco caricato e ridurre gli effetti collaterali a livello 
sistemico. Polimeri con proprietà anfifiliche sono in grado di formare vescicole, 
chiamate anche polimerosomi, che possono essere caricate con farmaci 
idrofilici/idrofobici. 
Il progetto di ricerca qui riportato ha avuto come fine ultimo la sintesi di un 
copolimero pH-sensibile a tre blocchi in grado di aggregare in vescicole utilizzate 
per il delivery di specifici silencing RNA (siRNA) alle cellule cancerose con lo scopo 
di rendere silenti specifici meccanismi coinvolti nel processo di progressione 
tumorale. Grazie alle sue nano-dimensioni, il sistema di drug-delivery colloidale è 
previsto andare incontro ad accumulazione passiva nel tessuto tumorale per 
Enhanced Permeability and Retention Effect (EPR) ed avere accesso selettivamente 
al comparto cellulare citosolico grazie al bioriconoscimento da parte della cellula 
tumorale. Una volta all'interno degli endosomi, la capacità delle vescicole 
polimeriche di rispondere in maniera differente ai diversi pH renderà possibile la 
disaggregazione del carrier e il rilascio del siRNA caricato. 
I polimeri utilizzati sono stati sintetizzati in modo tale da rispondere con una rapida 
disaggregazione del nano-sistema una volta in contatto con l'ambiente acido 
caratteristico dei compartimenti endosomiali e lisosomiali, ottenendo quindi il 
rilascio del siRNA. 
I polimeri a tre blocchi utilizzati presentano due monomeri idrofilici alle estremità, 
chiamati poly-ethilenglycole (PEG) 1.9 kDa - 3.5 kDa e poly-glycerolmethacrylate 
(GMA), e inoltre un blocco centrale pH sensibile, poly-imidazole hexyl methacrylate 
(ImHEMA) che guida la formazione e la disaggregazione delle vescicole. Il polimero 
ottenuto con PEG 3.5 kDa verrà coniugato all'agente direzionante acido folico per 
conferire proprietà di bioriconoscimento cellulare ai polimerosomi. 
I polimerosomi sono stati preparati  miscelando i polimeri ottenuti con 1.9 e 3.5 kDa 
in rapporti adeguati. I copolimeri in rapporto 90:10 w/w formano vescicole stabili a 
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pH 7.4 e temperatura ambiente con un diametro medio di 100 nm. La stabilità dei 
polimerosomi a 37°C è stata modulata aumentando il rapporto del copolimero PEG 
3.5 kDa. Vescicole ottenute con rapporto di polimeri 90/10 w/w 1.9 kDa e 3.5 kDa 
sono state caratterizzate morfologicamente al microscopio elettronico a trasmissione 
TEM mettendo in evidenza forma sferica e alta omogeneità dimensionale. Le 
vescicole polimeriche caricano efficacemente sequenze di DNA doppia elica 
(dsDNA) con una resa molare del 14% come dimostrato da analisi 
spettrofotometriche. Il dsDNA viene rilasciato in 8 ore quando i polimerosomi 
vengono incubati a pH 5; a pH 7.4 invece il rilascio è risultato essere quasi nullo. La 
capacità del polimero di complessare il dsDNA è controllata dal pH esterno: studi di 
ritardo elettroforetico hanno evidenziato che il polimero e il dsDNA sono 
completamente associati per rapporti N (gruppi amminici del polimero) /P (gruppi 
fosfato del DNA) di 2/1 a pH 5. Nessuna formazione di complessi è stata osservata 
per N/P ratio fino a 20/1 a pH 7.4, condizioni cui l’unità imidazolica risulta 
pressochè neutra. 
Studi di citotossicità eseguiti su cellule B16F10 da melanoma di topo hanno 
mostrato una buona biocompatibilità delle vescicole polimeriche a concentrazioni di 
1, 2, 3 mg/mL. La alta attività emolitica del polimero a pH acido (pH 5) conferma la 
capacità del materiale nell’indurre la lisi della membrana endosomiale. In dettaglio, i 
risultati hanno mostrato un’attività emolitica pari al 70% a pH 5, mentre in 
condizioni fisiologiche (pH 7.4) non è stata rilevata alcuna lisi dei globuli rossi. 
Le formulazioni polimeriche, con e senza agente di targeting, sono state incubate 
con cellule KB  da cancro alla cervice uterina e cellule MCF7 da adenocarcinoma 
mammario, le quali rispettivamente sovreaesprimono e non sovraesprimono il 
recettore folato, in modo tale da studiare l’efficacia di direzionamento di 
polimerosomi aventi il folato sulla loro superficie. L’internalizzazione di vescicole 
caricate con dsDNA marcato per mezzo del fluoroforo cyanine-3, valutato mediante 
analisi fluorimetrica su lisato cellulare e per mezzo di citofluorimetria, ha dimostrato 
essere di circa 3 volte maggiore per cellule KB comparate a MCF7. Quindi, 
polimerosomi caricati con ds-siRNA per il silenziamento dell’enzima luciferasi sono 
state testate su cellule B16F10 trasfettate con il promotore per l’enzima e 
sovraesprimenti il recettore per il folato. L’esperimento ha mostrato una diminuzione 
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della bioluminescenza imputata all'attività luciferasica del 30% rispetto alle 
vescicole vuote. 
I risultati riportati sono stati confermati grazie a studi di microscopia confocale 
eseguiti sulle stesse linee cellulari sopra descritte. Le immagini hanno evidenziato un 
accumulo di dsDNA marcato in modo significativamente più elevato in cellule KB e 
con una maggiore localizzazione della macromolecola nel compartimento nucleare. 
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Supramolecular drug carriers based on  physical assembly of “smart” polymers have 
emerged in last decades to obtain novel carriers for the tumor therapy. These systems are 
designed to target cancer tissue, preserve the therapeutic activity of loaded drug and 
reduce their systemic side-effects. Amphiphilic copolymers can be assembled in vesicles 
that can be loaded with hydrophilic and/or hydrophobic drugs.  
The research project was aimed at synthesizing a triblock pH-responsive polymer to be 
assembled in vesicles for the delivery of specific siRNA to cancer cells to silence specific 
functions involved in the tumor progression. According to its nanometric size, the 
colloidal drug delivery system is intended to undergo passive accumulation in the cancer 
tissue by EPR effect and access selectively the cytosol by cancer cell biorecognition. 
Once the vesicles are localized in the endosomes, their pH responsiveness will guarantee 
for the disassembling of the carrier and the release of the siRNA payload.   
The vesicles forming polymer was synthesized in order to respond to the acid 
environment in the endosomal and lysosomal compartments with prompt disassembly of 
the nanocarrier and consequent siRNA release. The triblock copolymers include two 
hydrophilic blocks at the terminal ends, namely 1.9 kDa or 3.5kDa PEG and poly-
glycerolmethacrylate (GMA), and a central pH sensitive block, imidazole hexyl 
methacrylate (ImHeMA) that control the assembly and disassembly of the vesiscles. The 
polymer obtained with the 3.5kDa PEG  is intended to be conjugated with the targeting 
agent folic acid to confer biorecongnition properties to the polimersomes. The vesicles 
were prepared by mixing the polymers obtained with 1.9 kDa and 3.5 kDa at adequate 
ratios. The copolymers with ratio 90:10 w/w polymers 1.9 kDa and 3.5 kDa  self-
assemble in vesicles at pH 7.4 with a mean size of 100 nm as detected by light scattering 
analysis and are very stable at room temperature. At 37°C the stability of vesicles was 
modulated by increasing the ratio of the copolymer 3.5 kDa PEG. Vesicles obtained with 
ratio 90:10 w/w polymers 1.9 kDa and 3.5 kDa were imaged by TEM microscopy 
showing a spherical shape and high size homogeneity. The polymeric vesicles were found 
to loads very efficiently double stranded DNA (dsDNA) sequences with a 14% molar 
loading yield as shown by UV-Vis spectrometry and release them in 8 hours when 
incubated at pH 5, while vesicles showed very limited DNA release at pH 7.4. The 
Abstract 
 
 
 
physical assembly of the dsDNA with the pH responsive triblock copolymer was 
controlled by the environmental pH: gel retardation electrophoresis showed that the 
polymer and dsDNA completely associate at a N/P ratio of 2/1 at pH 5, while no 
association was observed up to a N/P ratio of 20/1 at pH 7.4 where the ImHeMA block is 
neutral. 
Cell viability assay performed on B16F10 mouse melanoma cells showed a remarkable 
biocompatibility of the polymeric vesicles at concentration of 1, 2, 3 mg/mL. The high 
hemolytic activity of the polymer at acidic pH (pH 5) support for the capacity of the 
material to induce endosomal membrane disruption. The results displayed a 70% 
hemolytic activity at pH 5, while in physiological condition (pH 7.4) no red blood cell 
lysis was detected. Polymer formulations, with and without the folate-tipped terminal 
ends, were incubated with KB human cervical carcinoma cell line and MCF7 human 
breast adenocarcinoma cell line, that overexpress and do not express the folate receptor 
respectively, to investigate active targeting properties of the folate tipped vesicles. The 
uptake of vesicles loaded  with cyanine 3 labeled dsDNA, that was evaluated by 
fluorescence spectroscopy on cell lisate and by cytometry, was 3 times higher in KB cells 
compared to MCF-7 cells. Vesicles loaded with double strand siRNA for the silencing of 
luciferase were investigated on luciferase transfected B16F10 cells that express the folate 
receptor. The decrease of bioluminescence in cell sample treated with siRNA loaded 
folate targeted vesicles was 30% with respect to control empty vesicles. 
The above results were confirmed by confocal microscopy carried out with the same 
cancer cell lines. Confocal microscopy showed a significantly higher accumulation of the 
fluorescently labeled dsDNA in KB cells and a major localization of the macromolecule 
at the nuclear compartment. 
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1.INTRODUCTION 
In recent years nanotechnology, described as manipulation of matter at the nanometric 
scale, has been applied to many different fields with encouraging results. The 
nanotechnology involves a variety of different files such as surface science, organic 
chemistry, molecular biology, semiconductor physics, micro fabrication, drug delivery 
and many more. 
Nanocarriers represent a valuable outcome of the nanotechnological investigations and  
have been considered for potential biomedical exploitation such as cancer therapy, where 
they can carry therapeutic agents safely to a targeted organ, particular tissue or cell (1).  
According to recent statistical analysis, cancer is one of the foremost causes of death 
worldwide with an overall mortality estimated of 1.596.670 diagnoses and 571.950 deaths 
in United States in 2011 alone (2) This disappointing report is in part ascribed to the lack 
of efficient and reliable therapies that allow to safely deliver therapeutic agents to the 
target sites selectively, without side effects involving the normal tissue. Nowadays, 
classical antitumor therapy involves the combination of surgical resection, radiation 
therapy and chemotherapy. These therapies are associated to high toxicity and patient 
mortality because of their unwanted effects on normal cells. Clinical benefits can stem 
from targeting anticancer agents selectively to disease tissues, from overcoming peculiar 
biological barriers and avoiding the accumulation in off target healthy tissues. 
The word “nanoparticle therapeutics” refers to carriers made by structural components 
such as lipids and polymers (3) that provide for a container to load the therapeutic 
molecules. These systems represent a challenge in cancer therapy, where nanotechnology 
is significantly involved in proposing and screening solutions to evident delivery issues. 
Many different kinds of nanovectors were developed in the last decades, such as 
liposomes, micelles, dendrimers, nanospheres and nanocapsules, and more recently 
polymer based vesicles, namely polymersomes (Figure 1.1).  
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Figure 1.1. Representative nanovectors under development in the last decades.  
 
These drug delivery systems, in virtue of their peculiar properties, have also been 
exploited for the delivery of macromolecules such as proteins and oligonucleotides with 
biological activity, which have emerged recently and can selectively target a variety of 
cellular processes involved in the carcinogenesis (4). These nanocarriers are particularly 
suitable for systemic administration because once the drug has been loaded is protected 
inside the vector. Thus the vehicle guarantees for the drug to reach the tumor site in the 
active form, avoiding possible enzymatic degradation in the bloodstream, which reduces 
the therapeutic efficacy. Moreover, nanocarriers protect the loaded drug from many 
phenomena that can reduce its activity and which take place during blood circulation. For 
instance, the extensive elimination attributed to lung blood filtration, renal filtration or 
biliary excretion;  and the important tissue distribution which involves both liver and 
spleen (5). 
Mechanisms as complement activation are also responsible for a drug reduced therapeutic 
effect. Indeed, xenobiotics recognized as pathogens are "covered" in vivo by a layer of 
proteins called opsonins. These adsorbed proteins are recognized by macrophages and 
trigger the xenobiotics (in our case the drug). Nanocarriers offer the advantage to protect 
drugs from all these degradative processes. 
The distribution of biotherapeutics (proteins and oligonucleotides) in the tumor site is 
often very limited and not sufficient to guarantee a satisfying therapeutic effect. 
Furthermore, these biotherapeutics require an adequate access to the cytosolic 
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compartment to achieve their subcellular target (6). The access to the cytosol is a very 
relevant issue for most of therapeutic macromolecules that being very soluble, do not 
cross the cell membrane by simple diffusion as is the case of small drugs. Even when 
biotherapeutics are able to cross the cellular membrane by endocytosis, these drugs are 
rapidly directed to early endosomes, where the environment pH is rather acidic due to the 
activity of the ATP-dependent proton pumps (7). Therapeutic agents from early 
endosomes are transferred to late endosomes and finally to lysosomes for degradation (8). 
In 2-3 minutes, molecules that have been uptaken by cells migrate from early endosomes 
to late endosomes, and are exposed to the pH decreasing from 6.8-5.9 to 6.0-5.0. Once the 
therapeutic molecules dispose in the lysosomes, drugs are confined in a compartment 
with pH between 5.5-4.5. Inside these organelles, enzymes degrade the exogenous 
molecules thus prohibiting the biological activity of most of the therapeutic molecules. 
In order to make the intracellular delivery of therapeutics possible, intelligent 
nanosystems were developed that are able to respond to biological signals or 
environmental alterations and provide controlled release at a specific site (6). Tumor sites 
present a variety of peculiar phatophysiological alterations such as abnormal pH profiles 
that can be exploited by "smart" responsive nanosystems to achieve site-selective 
deposition and confined action in the diseased site. 
The PhD project presented in this thesis, an intelligent polymer based pH sensitive 
nanovesicular system have been developed for the systemic delivery of small sequences 
of siRNA (small interference RNA) that selectively inhibit the expression of intracellular 
proteins and involved in the tumor growth.  
Many oncogenes were found to be involved in carcinogenesis and have been explored as 
targets for the treatment using RNA interference. The silencing of these oncogene 
products by RNAi technology has generated significant antiproliferative and/or 
proapoptotic effects in cell-culture settings and in animal models (9). The main obstacle 
to the use of oligonucleotides in cancer therapy stems from the very limited delivery to 
tumor cells for the free siRNA. In fact, when these oligonucleotide sequences are 
administered as un-formulated molecules, they undergo a very rapid degradation that 
reduce the activity. In vitro challenges of oligonucleotide delivery include the cellular 
uptake and escape from the internalizing endolysosomes that allow for the access to the 
cytosolic compartment where the molecular targets are; whereas in vivo challenges 
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concern avoiding clearance by the liver and spleen and the possibly selective-permeation 
of the target tissue (10). Encapsulation of siRNA in polymeric vesicles (named 
polymersomes) can provide protection against degradation, prolongs the plasma 
circulation time thus reducing the clearance, as well as enhance the cell entry and 
programmed oligonucleotides release into the cytosol according to an endosomolytic 
process (11). 
Polymersomes are physically assembled vesicles are obtained by using polymers that 
must possess very peculiar physic-chemical features.  Polymersomes are obtained with 
amphiphilic polymers, both diblock (12) and triblock copolymers (13), and possess an 
aqueous core, similarly to the liposomes, where hydrophilic macromolecules such as 
proteins and oligonucleotides can be loaded and protected from the external hostile 
environment. The loading of fragile therapeutic molecules in the core of these vesicles 
will preserve their activity until the release from the endosomal compartment into the 
cytosol.  
1.1 CANCER: CLASSIC AND INNOVATIVE THERAPEUTIC 
TREATMENTS 
1.1.1. CARCINOGENESIS 
"Carcinogenesis is a multistep process in which cells accumulate multiple genetic 
alterations as they progress to a more malignant phenotype" (14). A cell can, as 
consequence of a variety of genetic alterations, turns into an aberrant cell and start 
dividing without precise control. This process leads to the development of solid tumors or 
an abnormal increase of circulating blood cells (liquid tumors). Cancer development as a 
multi-step process, was proposed by Berenblum and Schubik in 1948 (15) and supported 
by further studies. Three main phases could be pointed out: initiation, promotion and 
progression. Initiation involves one or more stable cellular genetic changes arising 
spontaneously or induced by exposure to a carcinogen. This is considered to be the first 
step in carcinogenesis, where the cellular genome undergoes mutations, creating the 
potential for neoplastic development (16), which predisposes the affected cell and its 
progeny to subsequent neoplastic transformation. The human DNA sequences involved in 
the transformation of cells in cancer cells are called oncogenes. Promotion consists of the 
survival and clonal expansion of cells that underwent the initiation process. Indeed, 
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initiated cell is stimulated to further proliferation, which disturbs the cellular equilibrium. 
This neoplastic transformation may involve more than one step and requires repeated and 
prolonged exposures to promoting stimuli (17). The stage of progression involves both 
the growth of solid tumors in size and the formation and diffusion of  metastasis. In the 
first moment of this step, referred also as neoplastic conversion, the pre-neoplastic cells 
are transformed to a state in which they are more committed to malignant development. 
When this stage advances, cells lose their adherence property, detach from the tumor 
mass and invade closer tissues. The detached cells also enter the circulating blood and 
lymph and are transported to other organs/tissues away from the site of the primary 
growth and develop into secondary tumors at the new sites. These nucleation areas form 
metastases. The emergence of metastasis can enhance the tumor progression through 
different mechanisms: (a) invasion of local heathy tissues, (b) entry and neoplastic cells 
diffusion in the blood and lymphatic systems, and (c) the consequent origin of secondary 
tumor growth at distant sites (18).  
Figure 1.2 describe the chronological steps involved in the carcinogenesis. 
         
Figure 1.2. Steps involved in the carcinogenesis.  
As mentioned above, carcinogenesis is mainly due to irreversible changes in a gene 
(mutation point), which predispose the cells to malignant transformation. Genes involved 
in this mechanism are mainly regulatory genes as oncogenes and anti-oncogenes. 
Oncogenes are positive regulators of carcinogenesis and in non-transformed cells, they 
are inactive (proto-oncogenes). Gene mutations can activate proto-oncogenes, resulting in 
the activation of the gene function. On the other hand, anti-oncogenes, named also tumor 
suppressor genes, are negative growth regulators. In healthy cells, they regulate cell 
proliferation by surveying cell cycle progression. Mutations in these genes result in a loss 
of gene function (the protein product will not be produced), which promotes 
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carcinogenesis (19). One of the mostly known example of tumor suppressor genes is the 
p53 that possess a fundamental role in maintaining the genomic stability and cell cycle 
equilibrium. In healthy cells, this gene promotes apoptosis, regulates cell cycle and 
induces cell differentiation. This suppressor gene participates in a cell cycle checkpoint 
signal transduction pathway that can cause either a G1 phase arrest or apoptotic cell death 
after DNA damage (20). Mutations in p53, resulting in loss of function, will cause 
suppression of apoptosis and promote cell division leading to neoplasm development 
(21). These kind of mutations in p53 gene are the most common genetic change observed 
in a large number of human diseases (22) and these alterations made these genes a good 
target for cancer treatment involving gene therapy. 
1.1.2  PATHOPHYSIOLOGY OF CANCER 
1.1.2.1  EPR effect and passive targeting 
After the "magic bullet" concept proposed by Paul Ehrlich at the turn of the 20th century, 
underlying the need for drug to own a very specific activity and tropism, many attempts 
have been made to discover nontoxic and selective anticancer therapeutic agents. As an 
alternative, novel strategies that could deliver in a site-selective fashion conventional 
anticancer drugs were also widely investigated. This stimulate also the discovery of the 
tumor physiopathological unique features. 
Blood vessels in most solid tumors possess peculiar characteristics that are not commonly 
observed in normal tissues. Such characteristics are:  
 extensive angiogenesis and hence high vascular density (23);  
 extensive extravasation (vascular permeability) induced by various 
vascular mediators such as a) bradykinin, responsible for ascitic fluid 
accumulation, and which is produced via the activated kallikrein-kinin 
cascade involving various proteolytic steps (24) b) nitric oxide (NO) 
generated by the inducible form of nitric oxide synthase (iNOS) (25), c) 
VPF/VEGF and other cytokines (25) (26), d) prostaglandins involving 
cyclooxygenases (24), e) matrix metalloproteinases (MMPs/collagenases) 
(27);  
 defective vascular architecture (28);  
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 impaired lymphatic clearance from the interstitial space of tumor tissues 
(29)  
These characteristics enhance the permeability of blood vessels in tumor tissues to 
macromolecular components such as plasma proteins and macromolecular therapeutics as 
well as nanocarriers. Furthermore, the impaired clearance of macromolecules and 
nanoparticles from the interstitial space of tumor tissue contributes to the retention of 
these drugs in the tumor for prolonged time and can increase their intra tumor 
concentration by 70-fold (30). This phenomenon is called enhanced permeability and 
retention effect (EPR) (31, 32) and its representation is reported in Figure 1.3. 
                
Figure 1.3. Representation of EPR effect. 
 
According to the EPR effect, biocompatible macromolecules accumulate at much higher 
concentrations in tumor tissues than in normal tissues or organs. This EPR effect can be 
observed with macromolecules having an apparent size corresponding to molecular 
weight larger than 50 kDa which have long plasma half-lives (33). Most conventional 
drugs have a plasma half-life of less than 20 minutes in mouse or human. However, it 
takes at least 6 hours for drugs in circulation to undergo significant extravasation 
according to the EPR effect. In other words, any drug candidate must possess an adequate 
molecular size, above the renal clearance threshold, to circulate for an adequately long 
time. 
Maeda et al. described the EPR effect for albumin, immunoglobulin G, and transferrin. 
Other smaller proteins of less than 30 kDa do not exhibit the EPR effect. A synthetic 
polymer-conjugated anticancer agent, SMANCS, which is poly(styrene-co-maleic 
acid/half-n-butyl ester) (SMA) conjugated with neocarzinostatin (NCS), was produced 
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with a size of 16 kDa (34) and did show the EPR effect only because in vivo it is bound to 
albumin, which confers an overall molecular size of about 80 kDa.  
The EPR phenomenon was observed using a wide range of polymer conjugates such as 
poly(hydroxypropylmethacryl-amide) (HPMA) copolymer, polyethylene glycol, 
polyvinylalcohol, the lipid contrast agent Lipiodol (an iodized derivative of poppy seed 
oil used as an X-ray contrast agent) and other vegetable oils, and liposomes (35). 
Therefore, the EPR effect appears to be a key mechanism for tumor-selective drug 
delivery and and for anticancer drug design.  
Especially, macromolecules, including SMANCS (chemical conjugate of the synthetic 
copolymer of styrene maleic acid + neocarzinostatin) and neocarzinostatin, injected 
subcutaneously, accumulate in regional lymph nodes (36). Furthermore, as compared to 
macromolecules, lipids and Lipiodol showed greater accumulation in tumors (31).  
Transvascular migration of cancer cells observed in solid tumors is ascribed to the 
angiogenesis controlled by VEGF (25). In recent years attention has been focused on 
tumor angiogenesis control by vascular endothelial growth factor (VEGF), responsible of 
the tumor vessels architecture differentiation. In cancers, VEGF promotes rapid and 
random growth of vessels, characterized by structural leakage and high permeability. In 
this way it enhances the tumor growth because it supplies nutrients and oxygen to the 
tissue. Inhibition of angiogenesis using agents as endostatin and angiostatin has yielded 
promising results for tumor therapy. Angiogenesis inhibition has been in fact found to 
promote tumor cell death by apoptosis and necrosis.  
It has been demonstrated that exogenously administered bradykinin and its potentiators 
such as kininase inhibitors can enhance (up to 100-fold) the dissemination of bacteria 
from the peritoneal compartment to the blood, the liver, the spleen, and the kidney.  This 
effect is suppressed to 1/50-1/100 of the original level by bradykinin antagonists and the 
protease inhibitor ovomacroglobulin (37). Furthermore, NO derivatives such as 
peroxynitrite and 
.
NO2 can activate MMPs, or collagenases (38). MMPs are known to 
facilitate cancer metastasis and to enhance angiogenesis to support growth of solid 
tumors. Recently it has been found that MMPs also facilitate the vascular permeability of 
solid tumor in mice, and this effect is inhibited by many MMP inhibitors. The activation 
of the bradykinin-generating cascade by MMPs has been described; evidences showed 
that the activation involve the participation of kallikrein. Maeda et al. reported that 
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plasmin can trigger the kallikrein-kinin cascade in tumor tissue, which is induced by 
urinary-type plasminogen activator produced by almost all types of solid tumor cells (39). 
It has been shown (40) that MMPs can activate plasminogen to yield miniplasmin. 
Miniplasmin would probably activate Hageman factor or prekallikrein. Thus, here again 
the generation of bradykinin may be mediated by ONOO
-
 via MMP activation. 
In addition, oxidative stress inactivates 1-protease inhibitor, whose main target is 
neutrophil-derived elastase (41). In both inflammation and cancer, the proteolytic activity 
is greater than that in normal tissues, and thus these proteases would facilitate the 
dissemination of cancer cells in multiple ways. Prostaglandins, NO, and bradykinin exert 
their actions co-dependently, or by cross-talking, to up-regulate inflammatory mediators 
(42), so it may be beneficial to simultaneously suppress multiple mediators together.  
In summary, we can exploit the specific features of the tumor vasculature to selectively 
deliver macromolecular anticancer drugs. One example could be the macromolecular pro-
drug HPMA-doxorubicin conjugated PK-1 (43). 
1.1.2.2 Active targeting and endocytosis 
Active targeting takes advantage from ligand-receptor, antigen–antibody and other forms 
of molecular recognition to deliver a particle or drug to a specific site (44). In cancer 
therapy, ligands for active targeting are particularly used because they reduce or eliminate 
the potential drug toxicity to healthy tissue. Targeted nanoparticles delivering chemo-
therapeutics are interesting because they can increase therapeutic efficacy and reduce 
potential side effects (45). Active targeting exploits the over-expression of receptors on 
the tumor cell surface (6) and many of these targeted nanosystems (Figure 1.5) have been 
tested with a variety of cancers. These nanosystems showed to be much more effective if 
compared to their non-targeted counterparts exibiting an increased cytotoxicity to tumor 
cells and a reduction of side effects (46). The main advantage of the targeted systems is 
that they are expressly instructed to access the cancer cell cytosol, which is missing in 
non targeted carriers even though both systems can undergo the EPR effect.       
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Figure 1.4. Ligand decorated  nanoparticles are internalized not only by passive targeting but also 
by active targeting. This active targeting is more effective in the tumor tissue due to tumor cells 
overexpressing some receptors or antigens that allow for a better uptake of functionalized 
nanoparticles. 
 
The mechanism through which functional molecules are internalized into the cells by 
interaction with specific receptors on cell surface is called receptor-mediated endocytosis 
(RME). RME is a well-known process for cellular uptake of many endogenous and 
exogenous ligands (47). Specialized receptor proteins have been identified to operate for 
the transport in the cytosolic compartment of nutrients (LDL-cholesterol, Tf-iron), growth 
factors (EGF, insulin), viruses (influenza), toxins (diphtheria), glycoproteins (galactose-
terminating or mannose-terminating glycoconjugates) and negatively charged 
macromolecular ligands. Membrane receptors are heterogenous in structure but contain a 
common hydrophilic extracellular domain (ligand-binding domain), which possess a 
glycosylation site. After binding of the ligand to the receptor (or sometimes 
independently) at the cell surface and clustering in the coated pits, internalization of the 
receptor ligand complex occurs via a clathrin-coated vesicular intermediate (clathrin-
dependent pathways) which enters the cytosol (48). Sometimes the receptors along with 
the bound ligand are internalized without the coating of the clathrin protein (clathrin-
independent pathways). Clathrin from the plasma membrane was one of the first vesicular 
coat proteins to be identified by electron microscopy. It has a role in the endocytic 
process that it exert as vesicular coat and it cooperates in the sorting along the endocytic 
pathway (clustering of receptors in clathrin-coated pits).  Uptaken carriers are guided 
through different pathways; based on this evidence, it is conceivable that the endocytic 
cargo is processed in accordance with the hypothesis that coat proteins mediate vesicular 
transport and protein sorting. However, some clathrin-independent endocytic pathways 
have recently been explored (48). In contrast to RME, which appears to be independent of 
cellular cytoskeletal components, uptake through the non-clathrin-coated pit and 
BLOOD 
STREAM 
 Introduction   
 
11 
 
macropinocytic pathway appears to involve components of the cytoskeleton. Caveolae are 
also coated invaginations of plasma membranes but differ in the receptor disposition from 
clathrin-coated vesicles in that they do not separate from the plasma membrane while 
unloading their cargo through a process termed potocytosis (49). An alternative model 
that reveals the underlying mechanism suggests that, similar to the clathrin-mediated 
pathway, caveolae generate from the plasma membrane and fuse with the endosome. 
Intracellular transport and processing after receptor-mediated endocytosis and 
transcytosis vary markedly among different receptor-ligand systems and different cell 
types, and determine the fate of drug-carrier composites to specific intracellular 
destinations. Endogenous ligands and receptors can follow one of at least four pathways:  
 Receptors can provide for intracellular transport of ligand and return to the 
initial plasma membrane domain 
 Receptors can move to lysosomes and, with the ligand bound to them, 
share the fate of the ligand (lysosomal disposition). 
 Receptors can be recycled, along with the ligand, back to the site from 
where the receptor originated. 
 Receptors can return to a different domain of the plasma membrane 
(transcytosis). 
Followed by receptor-mediated internalization, the ligand-receptor complex is routed to 
an acidic compartment through a maturation and fusion mechanism, after internalization. 
This prelysosomal sorting compartment (compartment of uncoupling of receptor and 
ligand, CURL) is referred to as the endosome, or receptosome (50). Numerous events 
relevant to endocytic uptake of ligands and drug delivery occur in the endosomal and 
lysosomal compartment (pH 6-6.6 for endocytic vesicles, pH 5-6 for late endosomes, and 
pH 4-5 for lysosomal apparatus) and drive the intracellular migration of the ligand-
coupled carriers to their respective destinations. The endosomal and lysosomal 
compartment possess different pH conditions: pH 6-6.6 for endocytic vesicles, pH 5-6 for 
late endosomes, and pH 4-5 for lysosomal apparatus that can promote and control the 
events taking place within these vesicles. These include ligand-receptor dissociation, 
sorting and transport of internalized molecules and receptors to lysosome, plasma 
membrane, or Golgi apparatus or to other cellular targets as well as partial hydrolysis of 
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some ligands (51). Like the plasma membrane, the lysosomal membrane is a natural 
barrier to macromolecular ligands and/or ligand-appended carrier composites and only 
low-molecular-weight molecules are released as a consequence of lysosomal degradation. 
The degradation of the ligand-coupled drug-carrier composites in lysosomes is a key step 
in designing an intracellular delivered system and constitutes the “lysosomotropic” 
approach to drug targeting.  
The differences in the regulatory and metabolic requirements of metastatic cells 
compared with normal cells are reflected in the over-expression and up-regulation of the 
receptor portal systems which process these tumor-derived endogenous ligands: this is the 
only key-difference that can be reasonably addressed for specific anti-cancer drug 
targeting.  
1.1.2.3 Folic acid and folate receptor 
Folic acid is a low molecular weight pterin based vitamin of the group B (B9) required by 
eukaryotic cells for one-carbon metabolism and de novo nucleotide synthesis. Because 
animal cells lack key enzymes of the folate biosynthetic pathway, their survival and 
proliferation are dependent on their ability to acquire and utilize this vitamin (52).  
It consists of 2-amino-4-hydroxy-6-methylpteridine bound to p-aminobenzoic acid 
(PABA) and terminates with a glutamic acid molecules, as reported in Figure 1.5. 
                                   
Figure 1.5. Chemical structure of folic acid. 
 
Two carboxylic groups are present in the vitamin due to the glutamic acid and the one in 
α position is required for the biological activity. Together with B12 vitamin, folic acid 
acts as donator/acceptor of methylene groups in the methylation cycle that is central in 
regulating gene expression. For this reason, this vitamin is essential for synthesis of 
purine nucleotides (53). 
Owing to the two carboxylic groups positioned at the distal end of the folate molecule, 
passive membrane permeability at physiological temperature and pH is minimal. To 
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circumvent this obstacle, nature has evolved two mechanisms for the cellular uptake of 
the vitamin. The first mechanism involves a low-affinity (KD ~1-5 m) membrane-
spanning protein that transports reduced folates directly into the cell cytosol (54). The 
second mechanism uses a high affinity (KD ~100 pm) glycoprotein receptor, generally 
referred to as the folate receptor (FR), which preferentially mediates the uptake of 
oxidized forms of folate (e.g. folic acid) into the cell by endocytosis (55).  
Folate receptor (FR) is a glycosylphosphatidylinositol (GPI)-linked membrane 
glycoprotein with an apparent molecular weight of 38-40 kDa (56). Two membrane-
bound isoforms of FR have been identified in humans, designated  and . FR -isoform 
has a dissociation constant (Kd) for folic acid of ~0.1 nM, which is approximately 10-fold 
lower than its Kd for reduced folates (e.g., 5-methyltetrahydrofolate) (57). The role of FR 
in cellular folate transport is not well understood, although a clathrin-independent 
"potocytosis" model has been proposed (58). FRs were found to be clustered in non-
coated membrane regions called caveolae. Localization of FRs in caveolae and receptor 
internalization can be induced by receptor crosslinking and is regulated by cholesterol. 
From a mechanistic perspective, the FR functions to concentrate exogenous folates and 
various derivatives into the cell cytosol by endocytosis. As depicted in Figure 1.6, the 
endocytic vesicles (endosomes) that contain the FR-folate complex rapidly become 
acidified to ~pH 5 and thereby allow the FR to release the folate molecule (59).                                                       
 
                   
Figure 1.6. Endocytosis of folate–drug conjugates. Exogenous folate–drug conjugates bind 
specifically to folate receptors (FRs) presented on the surface of a target cell. The plasma 
membrane invaginates around the folate–FR complex to form an intracellular vesicle that is 
commonly referred to as an endosome.  
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While elevated expression of FR has frequently been observed in various types of human 
cancers, the receptor is generally absent in most normal tissues with the exceptions of 
choroid plexus, placenta, and low levels in lung, thyroid and kidney (60). Although FR 
type  has been found on CD34+ cells, the receptor curiously lack affinity for [3H] folic 
acid and folate derivatives (61). FR type  is frequently over expressed in tumor cells in 
culture and epithelial lineaged tumors such as ovarian carcinomas. Several studies show 
that over 90% of ovarian carcinomas overexpress the FR (62). In a study, a monoclonal 
antibody against the type  receptor, LK26, was used to determine the frequency of FR 
over expression in human tumors by indirect immunohistochemical staining. High 
frequencies of receptor over expression were found in many types of tumors, including 
ovarian (52 of 56 cases tested), endometrial (10 of 11), colorectal (6 of 27), breast (11 of 
53), lung (6 of 18), renal cell (9 of 18) carcinomas, brain metastases derived from 
epithelial cancers (4 of 5), and neuroendocrine carcinomas (3 of 21). FR type  is 
frequently over expressed in non-epithelial lineaged tumors such as sarcomas and acute 
myeloid leukemias but not in established cell lines of the same origin (63). The causes of 
FR over expression in cancers are unclear. Transfection and expression of FR on 
NIH/3T3 cells provide cells with the ability to survive in low folate medium and 
increased cell growth both in vitro and in vivo (64). Studies also show that high levels of 
FR expression are associated with increased biological aggressiveness of ovarian 
carcinomas as shown by a higher percentage of S-phase cells and increased resistance to 
chemotherapeutic agents (65). Thus FR elevation may be a useful prognostic factor.  
The prevalence of FR over-expression among human tumors makes it a good marker for 
targeted drug delivery to these tumors. High affinity FR binding is retained when folate is 
covalently linked via its -carboxyl group to a foreign molecule. It has been known for 
nearly a decade that simple covalent attachment of folic acid to virtually any 
macromolecule produces a conjugate that can be internalized by FR-bearing cells 
according to the same process involving free folic acid (66). Many authors have seen into 
this small molecular weight molecule an ideal substitute to monoclonal antibodies for site 
specific drug targeting, where possible (Table 1.1). 
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Table 1.1. Comparison between folic acid and antibodies main properties. 
Property Folic acid Antibody/protein 
Molecular weight 441 160 000/ variable 
Tumor permeability High Low 
KD for cell-surface receptor 10
-10
 M 10
-10
 to 10
-6
 M 
Immunogenicity Low Low to high 
Conjugation chemistry Easy Difficult 
Receptor recycles Yes No 
Stability to 
acids/bases/solvent 
High Low 
Stability during storage High Variable 
Lysosomal disposition Low High 
Toxicity of targeting ligand Low Variable 
Cost Low High 
 
Particles conjugated with folate or folic acid and bound to a folate receptor are 
internalized by the cell and introduced to the cytoplasm. Once inside the cell, they start to 
interact with intracellular components (67). 
Yoo and colleagues developed a folate conjugated nanoparticle developing biodegradable 
polymeric micelles loaded with doxorubicin. Micelles were assembled from a copolymer 
of poly(L-lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG). The 
advantageof using PLGA is its biodegradability after delivery of the payload, while PEG 
increases the circulation time of the particles. Doxorubicin was conjugated with chemical 
bond to the PLGA while the folate was bound to the PEG terminal end. The micelles 
were tested for cytotoxicity and cardiotoxicity (a side effect of Doxorubicine) compared 
to free doxorubicine on cell lines expressing folate receptor. The micelles showed 
increased cellular uptake, circulation time, and decreased cardiotoxicity (68). The 
targeting moiety managed to recognize between healthy and tumor tissue with greater 
specificity than untargeted doxorubicine and a decrease in cardiotoxicity was evaluated. 
A representation of the micelles is reported in Figure 1.7. 
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Figure 1.7. Folate-conjugated PLGA-PGA polymeric micelle loaded with encapsulated 
doxorubicin (68). 
1.1.2.4 Classic antitumor therapy 
Classical antitumoral therapy involves the use of chemotherapeutics. These agents are, in 
general, small molecules that interfere with the normal cell function by inhibiting the 
replication or inducing apoptosis (69). Because of their wide cytotoxicity, 
chemotherapeutic agents have been almost exclusively exploited for the treatment of 
cancer, where they exhibit deleterious effects mostly to rapidly proliferating cells (69). 
Paclitaxel, doxorubicin, daunorubicin, cisplatin, and docetaxel are examples of classic 
chemotherapeutics. Paclitaxel and docetaxel are taxanes, and they work stabilizing the 
microtubules during cell cycle, which prevents mitosis from progressing from metaphase 
to anaphase (70). Doxorubicin and daunorubicin belong to a class of chemotherapeutics 
known as the anthracyclines. Even if mechanisms of action of anthracyclines in cancer 
cells are not completely clear, a possible hypothesis could involve the drug intercalation 
between base pairs of the DNA/RNA strand, with consequent decreasing in replication of 
rapidly-growing cancer cells. These molecules are among the most effective drugs 
available, inducing the highest degree of cytotoxicity and used to treat most of tumors 
including aggressive lymphoma, breast cancer, and myeloblastic leukemia (71, 72). 
Doxorubicin has been shown to target the topoisomerase-II-DNA complex, disrupting the 
DNA and preventing cellular replication (73). Similarly, cisplatin, a platinum-compound, 
by modifying the cell DNA, activates signaling pathways that triggers apoptosis (74).  
The main problem with using the above mentioned chemotherapeutics is their inability to 
differentiate between healthy and tumor tissue (75). The biological activity of the drugs is 
indiscriminate, being particularly harmful to any rapidly proliferating cells in the body 
such as hair, intestinal epithelial cells, and bone marrow (69). The most cytotoxic agents 
are the most effective but often result in severe side effects. Doxorubicin is considered to 
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be one of the most used and efficient anti-cancer drug available today but gives side 
effects such as, nausea, fatigue, and extensive and often fatal cardiotoxicity (71). 
1.1.2.5 Gene therapy and siRNA interference 
Gene therapy is a therapeutic strategy that allow the treatment of acquired and inherited 
diseases by the transfer of genetic material into specific cells of the patient. 
Gene delivery refers to the use of DNA to obtain the expression of a protein that is not 
coded in the host genome, whereas delivery of RNA and antisense oligonucleotides are 
employed to decrease protein expression. 
At the really beginning,  gene therapy was employed to hit inherited monogenic disorders 
through the replacement of an abnormal gene with the one responsible of encoding the 
correct protein. Among the diseases that were considered for this type of therapeutic 
treatment, most clinical trials were performed in cystic fibrosis (76), hemophilia (77, 78) 
Duchenne muscular dystrophy (79), familiar hypercholesterolaemia (80), beta thalassemia 
(81), severe combined immunodeﬁciencies (SCID) (82) and chronic granulomatous 
disease (83). 
Thereafter, gene therapies have been extended to a wide spectrum of acquired diseases, 
cancer included. Indeed, DNA damages introduced by the carcinogenesis process, can be 
exploited as target for anticancer gene therapy. 
In particular, for this project we have focused on the exploitation of siRNA for 
therapeutic treatment. siRNA emulate a natural cellular process that involves the RNA 
interference (RNAi). "This physiologic process is a post-transcriptional mechanism of 
gene silencing through chromatin remodeling, inhibition of protein translation or direct 
mRNA degradation, and is ubiquitous in eukaryotic cells" (84,85). Previous biological 
studies showed that the introduction of exogenous double-stranded RNAs (dsRNA) in the 
cell cytosol can initiate a potent cascade of sequence-specific degradation of endogenous 
mRNAs that have homology with dsRNA introduced (86).  Once in the cytoplasm, 
dsRNAs are processed by the enzyme RNase-III Dicer, which cleaves the long dsRNAs 
into sequences of 21–28 nucleotides. 
These RNA duplexes are known as short interfering RNAs (siRNA). They associate with 
a multiprotein RNA-inducing silencing complex (RISC) present in the cytoplasm, guide 
the complex to a homologous target mRNA and trigger its endonucleolytic cleavage by 
Slicer (Argonaute-2), an enzyme located inside the RISC complex. As consequence, the 
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target mRNA is cleaved at a single site in the center of the duplex region between the 
guide siRNA and the target mRNA, resulting in gene silencing (Figure 1.8). 
                       
Figure 1.8. Mechanism of mRNA silencing. 
 
The silencing process is highly sequence specific. Furthermore the process is very 
efficient because, since the antisense strand of the dsRNA is protected within the RISC 
complex, its catalytic activity is preserved and it can thus degrade additional copies of the 
target mRNA. 
1.1.2.6 Molecular target: the α1 subunit of Na+/K+-ATPase pump 
In 1957 Jens Christian Skou (87) demonstrated that the different concentrations in Na
+
/K
+
 
ions outside and inside of the two sides of the cellular membrane is maintained by an 
energy-dependent mechanism mediated by the Na+/K+-ATPase pump. The Na
+
/K
+
-
ATPase pump is an enzyme that belongs to the P-type ATPase family of cation 
transporters, which reacts with Adenosine Triphosphate (ATP) involving a 
phosphorylation process, during the catalytic cycle. 
Sodium pumps can be classified in two groups with distinct functions:  
1) one is the ubiquitous trans-membrane enzyme that transports Na
+
 and K
+
 across the 
plasma membrane by hydrolyzing ATP (88, 89)  
2) the second and majority of the cellular Na/K-ATPase is engaged in cellular activities 
different from pumping ions (90). These ones  are located in caveolae and interact 
directly with multiple proteins including protein kinases, ion transporters, and structural 
proteins to exert their signal-transduction activity (91). 
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As mentioned above, when the Na/K-ATPase is located in the lipidic bilayer of the cell 
membrane it is responsible for maintaining the K
+
 and Na
+
 gradients between the intra 
and extracellular environment. These gradients are needed for the Na+ -coupled transport 
of various nutrients, as for instance glucose and aminoacids and contribute to regulate 
intracellular concentrations of ions. This regulating process is important because it is 
implicated in specialized cellular functions such as the muscle contraction and the 
transmission of nerve impulse, and for osmotic balance and the regulation cellular 
volume. 
When the enzyme is located in the caveolae, flask-shaped invaginations of the plasma 
membrane (92), it plays a signal transducer role and modulates cell proliferation, cell 
adhesion and migration pathways. 
In general, Na+/K+ pump is composed of two sub-units in equimolar ratios: 
1) The ‘α catalytic sub-unit’ is a multicomponent transmembrane protein (10 membrane-
spanning domains) which contains the binding sites for Na
+
, K
+
 and ATP. This sub-unit 
executes the functional properties of the Na+/K+ATPase. It binds and transports the 
cations, hydrolyzes ATP and is intermediately phosphorylated. 
2) The 'β regulatory sub-unit' is a type II glycoprotein with a single transmembrane 
segment. This protein has several glycosylation sites, required for the biogenesis and 
activity of the enzyme complex; it is important for the structural and functional 
development of the α sub-unit and is also involved in the Na+ and K+ activation kinetics 
of mature pumps. 
In nature exist 4 isoforms of α subunit (α1, α2, α3, α4) and 3 isoforms of β subunit (β1, 
β2, β3) (93, 94). In Figure 1.9 a simple model of Na+/K+ATPase with its pump function is 
reported. 
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Figure 1.9. Isoforms of α and β subunits of Na/K-ATPase pump. 
 
Many studies from literature (95) demonstrated that the activity of this enzyme can be 
affected in the course of malignant transformation such as cancer and this is even evident 
at the early phases of carcinogenesis (96). α and β isoforms are often involved in this 
mutation process, where β1 is very frequently down regulated in cells of human epithelial 
cancer (97), whereas α-subunits appear to be up-regulated in  malignant cells (98).  
As consequence, with the suppression or reduction of the sodium pump function 
correlated to the α or β subunits, a reduction in proliferation and migration of cancer cells 
is obtained (92). 
In particular, studies demonstrated that α1-subunit of Na-K-pump present in the caveolae 
is overexpressed in many kinds of tumor, as glioblastoma and non-small cell lung cancer 
(92). A strategy to block the expression of ATPase α1 subunit could be the delivery of a 
gene knockdown agent such as siRNA. We can conclude that the sodium pump, and in 
particular its α1 subunit, could be an important molecular target for anticancer therapy 
and in particular for the siRNA vesicular system developed in the course of this thesis. 
1.1.2.7 Nanocarriers for delivery of cancer therapeutics: state of the art 
Nanocarriers used for systemic cancer therapy and their latest stage of development are 
summarized in Table 1.2 (99).  
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Table 1.2. Nanoscaled systems for systemic cancer therapy. Adapted from (99) with 
DOI:10.1038/nrd2614. 
 
                    
PEG-containing proteins and PEG conjugated small molecules are considered 
nanosystems. Indeed, despite they are in some cases single molecules in solution, due to 
their size, they can be defined as nanoscale therapeutics, or even as nanoparticles if they 
have some degree of polymer–polymer interaction to induce some level of physical  
assembly. 
Liposomes (~100 nm and larger) represent a very relevant class of drug vehicles widely 
exploited to deliver chemotherapeutic molecules. They have been approved for cancer 
treatment since mid-1990s, and are mainly used to encapsulate water soluble drugs.  
Liposomes can also intercalate hydrophobic drugs in a small content, allowing to improve 
the biodistribution profile that promotes higher disposition in the tumor site than the free 
drug (99). 
However, conventional liposomes do not provide control over time of drug release, and in 
most cases do not achieve effective intracellular delivery of the drug molecules (100), 
therefore limiting their potential efficacy against multidrug resistant cancer cells. 
A typical example of liposomes for cancer treatment shown in Table 1 is Doxil (Ortho 
Biotech). This liposome formulation coated with PEG contains the cytotoxic drug 
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doxorubicin. Doxil was originally approved for the treatment of AIDS-related Kaposi’s 
sarcoma and is used in ovarian cancer and multiple myeloma. 
The longer blood circulation time of drug loaded nanosystems compared to the 
unformulated free drug can significantly improve tumor uptake since it allows for longer 
extravasation time at the tumor site where the vessels are leaky compared to normal 
tissues (99). Moreover, it was found that polymeric carriers with a size larger than 10 nm 
up to few hundred nanometers will avoid renal clearance and penetrate in the tumor 
interstitium. Therefore, careful control of size is basic for the pharmacokinetics, 
biodistribution, tumor penetration and tumor accumulation of the nanocarrier with its 
drug payload. 
Some of the nanocarriers that are under investigation in clinical trials also possess 
mechanisms to spatially and temporally control the release of the drug. The controlled 
release features base on the cleavage of specific chemical bonds linking the drug to a 
polymeric component of the carrier; on enzymes that are located within and outside cells. 
For instance, some interested enzymes could be lysozymes, esterases, or enzymes located 
only within cancer cells, for example, cathepsin b. Finally, the environment can control 
the dissociation of the nanocarrier matrix. 
Polymersomes, although they represent a quite recent system for drug delivery, are under 
development as "innovative products" for a wide range of diagnostic and therapeutic 
applications. An example is represented by the privately-held biotechnology company 
Vindico Pharmaceuticals Inc. Vindico’s polymersomes have been extensively utilized in 
medical applications, including as implantable biomaterials in drug delivery devices, 
bioresorbable sutures, adhesion barriers, and as scaffolds for injury repair via tissue 
engineering. These vesicles are made of "biodegradable polymers that enable: 1) high 
permeability to small drug molecules; 2) maintenance of neutral pH environments upon 
degradation; 3) facility in forming blends with other polymers; and 4) suitability for long-
term delivery afforded by slow erosion kinetics" (reported by Vindico Pharmaceuticals 
Inc.). All these features allowed the company the utilization of their polymersomes for in 
vivo studies (101).                      
 Introduction   
 
23 
 
1.2 ENVIRONMENTALLY RESPONSIVE CARRIERS FOR 
CANCER THERAPY 
In last decades highly specific biological pharmaceutical agents have been introduced in 
medicine, including proteins (monoclonal antibodies, hormones, growth factors, enzymes, 
synthetic oligopeptides) and nucleic acids (plasmid DNA, antisense oligonucleotides, 
siRNA, miRNA) that can be used to treat a huge spectra of tumors (6). However, as 
previously mentioned, these therapeutics needs to be delivered to their subcellular site of 
action in order to be active. Controlled release carriers sensitive to specific environmental 
features can make their effect possible. These “smart” drug delivery systems include 
polymer-drug conjugates, polymer micelles, polymer–drug polyplexes, nanohydrogels 
and have been investigated to ameliorate the efficacy of a variety of drugs by providing 
protection from clearance and enzymatic degradation, as well as offering the possibility 
for controlled release (102, 103). Recently many intelligent systems were developed, but 
the most interesting are the ones able to answer to biological signals for tissue specific 
targeting or controlled drug release. The design of these systems needs to consider 
parameters as the stability, administration, absorption, metabolism, and bioavailability at 
target site. Level control and localization of biotherapeutics within the body allow to 
decrease drug doses potentially harmful for their side effects. 
The idea of stimuli-responsive drug delivery was firstly suggested in the late 1970s with 
the use of thermosensitive liposomes for local release of drugs through hyperthermia 
(104). In the last decade research has been carried out on stimuli-responsive materials for 
drug delivery, especially regarding their design and application as nanocarriers. Stimuli-
responsive nanodevices may be sensitive to specific endogenous stimuli, such as a lower 
interstitial pH, a higher glutathione concentration or an increased level of particular 
enzymes such as matrix metalloproteinases (104). Inside the cell, pH sensitivity can either 
trigger the release of the carried drug into late endosomes or lysosomes, or promote the 
escape of the systems from the lysosomes to the cell cytoplasm. At the tissue level, 
microenvironmental changes associated with cancer are exploited as well as pathological 
conditions such as ischemia, inflammatory diseases or infections. Exogenous physical 
stimuli can be also applied to target the drug delivery system, as for instance the use of 
magnetic fields to target metallic nanoparticles. Drug release profiles can also be 
achieved by thermo-, light- or ultrasound-sensitive nanoparticulate systems (104).  
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In the next sections examples of stimuli-responsive drug-delivery nanocarriers are 
reported, divided into exogenous an endogenous stimuli-responsive drug delivery 
systems. 
1.2.1 EXOGENOUS STIMULI-RESPONSIVE DRUG DELIVERY: 
EXTERNALLY APPLIED STIMULI 
1.2.1.1 Thermoresponsive systems 
Thermoresponsive drug delivery has been explored since a long time in oncology. 
Thermoresponsiveness is usually controlled by a nonlinear sharp change in the properties 
of one or more components of the nanocarrier material with temperature. The variation in 
the surrounding temperature causes the release of the delivered drug. Ideally, 
thermosensitive nanocarriers should retain their drug load at body temperature (~37 °C), 
and rapidly deliver the drug within a locally heated tumor (~40–42 °C). 
Thermoresponsive systems that have received considerable interest are liposomes, or 
polymeric micelles, or nanoparticles (usually using poly(N-isopropyl acrylamide), 
PNIPAM) that exhibit a Lower Critical Solution Temperature (LCST) (104). Under this 
transition temperature, polymers present in the aqueous dispersion are soluble, whereas 
above the LCST, they become hydrophobic, collapse and aggregate. For liposomes, 
thermo-responsiveness usually comes from a phase transition of the constituent 
phospholipids and the consequent conformational variations in the lipid bilayers. In vivo, 
heat is generally provided by using temperature-controlled water sacks, radiofrequency 
oscillators or microwave applicators. In the past few years, the focus has been on rapid 
and quantitative drug-release performance. Thermosensitive liposomes (TSLs) are maybe 
the most advanced thermoresponsive nanosystems, as shown by their use in several 
clinical trials. Doxorubicin loaded TSLs (ThermoDox, Celsion Corporation), in 
association with hyperthermia or radiofrequency ablation, now are investigated in phase 
II trials for the treatment of breast cancer and colorectal liver metastasis, and passed to 
phase III trials for the treatment of hepatocellular carcinoma. More recently, improved 
liposomal formulations have been shown to release their loads quickly after applying 
hyperthermia (~40-45 °C) (105). An alternative approach was developed with leucine 
zipper peptide–liposome hybrids, which combine the advantages of traditional TSLs with 
the dissociative, unfolding properties of a temperature-sensitive peptide (104).  
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Promising results were obtained also by Al-Ahmady (106) et al. using thermoresponsive 
bubble-generating liposomal systems. These rely on the creation of permeable defects in 
the lipid bilayer by means of the generation of carbon dioxide bubbles through 
decomposition of ammonium bicarbonate at mild hyperthermia (~42 °C). After this 
effect, as reported in Figure 1.10, the payload can be released in the interested district. 
 
 
 
 
 
 
 
 
 
 
Figure 1.10. Temperature-based actuation mechanisms for liposomal drug delivery. a) The 
temperature-triggered unfolding of a leucine zipper peptide inserted in the membrane of a 
doxorubicin (Dox)-carrying liposome opens a channel through which the drug is released. b) 
Drug-permeable pores can also be created by the temperature-triggered generation of bubbles 
from the decomposition of encapsulated ammonium bicarbonate. Adapted from (104) with 
DOI:10.1038/nmat3776. 
1.2.1.2. Magnetically responsive systems 
Magnetical guidance is typically obtained by focusing an extracorporeal magnetic field 
on the biological and tissue target during the injection of a magnetically responsive 
nanocarrier. This concept has demonstrated great potential in experimental cancer therapy 
because of improved accumulation of drug inside solid-tumor models. Candidate 
nanosystems for such a therapeutic approach are core – shell nanoparticles (a magnetic 
core made of magnetite (Fe3O4) coated with silica or polymer) (107, 108), 
magnetoliposomes (Fe3O4 or maghemite (Fe2O3) nanocrystals encapsulated in liposomes 
(109) and porous metallic nanocapsules (110). Magnetically guided nanocarriers have 
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also found application in the delivery of oligonucleotides, including siRNA and genes. 
These experiments are generally performed using nanoassemblies with cationic coatings 
to condense nucleic acids, which results in higher transfection efficiencies under a 
permanent magnetic field. This technique led to improved effectiveness in the 
transfection of siRNA in vitro and/or in vivo when directed against prostate (111) and 
breast (112) cancers. The use of magnetically responsive nanoparticles is generally 
limited to accessible tumor nodules, but is not suitable for metastasis or disseminated 
tumors. Although most of these tumors are suggested for direct surgery, some are not 
surgically removable because they are too hemorrhagic or localized too near to healthy 
tissues, with high risk of injury these last ones (it could be the case of some brain 
cancers). In such cases, magnetically responsive nanoparticles could be a valid 
therapeutic option. However, the magnetic approach is prevented by the complexity 
involved in the set-up of external magnetic fields, which need adequate focusing and deep 
penetration into the tissues to reach the disease area and give the desired effect. In this 
respect, efforts to identify the best magnetic and irradiation technologies are required. 
1.2.1.3. Ultrasound-triggered drug delivery 
Ultrasounds are an effective method to obtain spatiotemporal control of drug release at 
the desired site, preventing deleterious side effects to healthy tissues. A second advantage 
is their non-invasiveness, the absence of ionizing radiations, and the easy regulation of 
tissue penetration depth by regulating frequency, duty cycles and time of exposure. 
Ultrasound waves can cause the release of the drug from nanocarriers through the thermal 
and/or mechanical effects generated by cavitation phenomena or radiation forces. Indeed, 
it has been shown that physical forces associated with cavitation can induce the 
destabilization of the nanosystem, drug release (113) and transient increase in vessel 
permeability, leading to the cellular uptake of therapeutic molecules (114). All these 
effects can be achieved when low ultrasound frequencies (kHz range) are used. However, 
ultrasound mediated enhancement of vessel permeability can generate drawbacks such as 
metastatic dissemination. For this reason, other ultrasound contrast agents as 
microbubbles, which efficiently interact with ultrasonic waves, have been used at 
diagnostic frequencies to reduce the threshold required for cavitation. However, short 
lifespan and absence of extravasation may still limit the use of microbubbles for tissue 
targeting. To solve this aspect, perfluorocarbon (PFC) nanoemulsions that convert into 
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microbubbles under the action of therapeutic ultrasounds were developed. The bubbles 
are formed through vaporization of droplets and are subjected to cavitation, triggering the 
drug release in the tumor site (Figure 1.11). This has resulted in significant therapeutic 
efficacy and suppression of metastatic process (115). 
                           
Figure 1.11. Drug delivery from echogenic perfluorocarbon (PFC)-containing nano-emulsions. 
Adapted from (104) with DOI:10.1038/nmat3776. 
 
1.2.1.4. Light-triggered drug delivery. 
A large variety of photoresponsive systems has been developed in the past few years to 
achieve drug release in response to illumination to a specific wavelength (in the 
ultraviolet, visible or near-infrared (NIR) regions) (116) The different strategies available 
are able to exercise an on–off drug-release event triggered by photosensitiveness-induced 
structural modifications of the nanocarriers. For instance, the ultraviolet–visible 
photoisomerization of the azobenzene group (and its derivatives) - from trans to cis on 
irradiation at 300 - 380 nm, and from cis to trans by shining light in the visible region - 
enables control of drug release in developed cyclodextrins and derivative. 
In the field of light-triggered drug delivery, the main disadvantage is given by the low 
penetration depth (~10 mm) that results from the strong scattering properties of soft 
tissues in the ultraviolet-visible region of the spectrum (below 700 nm). Unfortunally, 
conventional light-induced drug delivery can be applied only to regions of the body that 
can be directly illuminated (as eyes and skin). Anyway, using photosensitive groups that 
answer to higher wavelengths or exploiting two-photon technology (117), it is possible to 
replace the classical light source by a NIR laser (700–1,000 nm range) with deeper tissue 
penetration, lower scattering properties and minimal damage to tissues. In this way these 
light sensitive nanosystems become promising for clinical applications. An application of 
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these techniques are doxorubicin-loaded gold nanospheres, which showed faster drug 
release when irradiated at 808 nm, allowing anticancer activity and reducing systemic 
toxicity compared to the treatment with the free-drug (118).  
1.2.1.5. Electroresponsive systems 
Weak electric fields (typically about 1 V) can be used to have drug release. For instance, 
nanoparticles based on polypyrrole - a conductive polymer - showed release profiles that 
could be tuned by synergistic processes consisting of electrochemical reduction–oxidation 
and electric-field-driven movement of charged molecules (119). Montmorillonite, a 
mineral made of hydrate silicate of calcium, aluminium, magnesium and sodium, when 
introduced in a chitosan nanohydrogel, could provide drug release using  
electrostimulation, and preserved responsiveness and reversibility after consecutive on–
off exposure to the electric field. An electric field also activated the reversible 
disaggregation of polymersomes that obtained by host–guest complexation between β-
cyclodextrin and ferrocene attached at the terminal ends of a pair of different 
homopolymers (120) (Figure 1.12).  
                  
Figure 1.12. Voltage-responsive vesicles. Structure of polystyrene-β-cyclodextrin (PS-β-CD) and 
poly(ethylene oxide)-ferrocene (PEO-Fc), and representation of the voltage-responsive controlled 
assembly and disassembly of PS-β -CD–PEO-Fc supramolecular vesicles. Adapted from (104) 
with DOI:10.1038/nmat3776. 
 
In a similar way, an oxidizing voltage was used to activate the disaggregation of a vesicle 
membrane (composed of redox-responsive self-assembled amphiphilic rod-coil 
tetraaniline-PEG) into smaller micelles, which could reaggregate on the application of a 
reductive voltage (121). Electroporation - the application of voltage to cause the 
formation of pores in cell membranes and thus increasing their permeability to drugs - has 
been shown to be an efficient strategy to obtain drug delivery. In recent studies 
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electroporation has been applied to nucleic acid delivery to cancer, using PEG-coated 
silica nanoparticles with opposite polarities to enhance gene transfection (122) or by 
using transferrin-decorated liposomes loaded with exogenous oligonucleotides (123). 
Although the positive trend obtained in such kind of therapy, the limitation on 
electroresponsive nanocarriers is again the low tissue penetration depth and the need to 
avoid undesired tissue damage. 
1.2.2 ENDOGENOUS STIMULI-RESPONSIVE DRUG DELIVERY 
In this section systems that take advantage of microenvironmental alterations in pH, 
redox potential, concentrations of enzymes or specific analytes will be discussed. 
1.2.2.1. pH-sensitive systems 
The variation in pH have been exploited to control the delivery of drugs in specific organs 
(as the gastrointestinal tract) or intracellular compartments (as endosomes), or in order to  
cause the release of the drug after a change in the environmental pH in pathological 
situations, such as cancer or inflammation (104). Two main strategies can be used for the 
purpose. The first is the use of polymers (polyacids or polybases) which present ionizable 
groups that according pH variation are subjected to conformational or solubility changes 
in response to environmental. The second is the design of polymeric systems with acid-
sensitive bonds. Cleavage of this bonds allows the release of molecules anchored at the 
polymer backbone, the modification of the charge of the polymer or the exposure of 
targeting ligands. Many anticancer drug-delivery systems exploit the difference of pH 
existing between healthy tissues (~7.4) and the extracellular environment of solid tumors 
(6.5–7.2). This acidic pH in tumoral tissues is due to an irregular angiogenesis in fast-
growing tumors, which causes a rapid deficit of nutrients and oxygen and as result a pH 
switch towards a glycolytic metabolism. Acidic metabolites are produced and an acidic 
pH is obtained in the tumor interstitium. It is clear that efficient pH-sensitive systems 
must give a sharp response to a slight change of pH in the tumor tissue. For instance, 
swelling of chitosan nanospheres induced by the amino-group protonation (pKa ~6.3) 
brings to the release of encapsulated tumor necrosis factor alpha (TNFα) acidic 
environment of tumor tissues (124). A second example is given by the disassembly at pH 
6.4–6.8 of PEG–poly(β-amino ester) micelles with campthotecin release. In ischemic 
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areas the release of protein drugs was achieved with piperidine- and imidazole-modified 
PEG–poly(β-amino ester) micelles (125). 
Once reached the cell compartment, the acidification of endosomes (pH ~5–6) can be 
exploited in order to obtain a controlled and sustained release. Small pH variations toward 
acidic values can cause nanoparticle expansion with release of their payloads. This effect 
has been obtained either by masking the hydroxyl groups in the polymer backbone with 
acid-labile protecting groups (126) or using dimethylaminoethyl methacrylate monomer 
units that can be protonated. In this manner it was possible obtain a tuned DNA release 
kinetics within the endosomal pH range (127). On the other hand, the acid-sensitive 
bonds can be exploited in the polymer backbone (such as hydrazone (128), acetals (129) 
or the presence of acid-degradable crosslinkers to obtain the disaggregation of the 
nanocarrier. Drugs covalently conjugated to polymer backbones (128) or protein scaffolds 
(130) can also be released exploiting this acidic sensitive linkages. 
However, a strong acidic pH, as the one inside lysosomes, can be harmful to many drugs. 
For this reason systems have been designed able to escape the endosomal compartment 
by exploiting the proton sponge effect (where an increase in osmotic pressure caused by 
polymers leads to endosomal swelling and rupture). To obtain this, copolymers obtained 
with amine-containing polymers (such as poly-l-lysine, poly(β-amino esters) (131)) have 
been used to buffer the endosomal pH. For example, lipid-coated poly(β-amino ester) 
nanoparticles combined the endosomal escape and the delivery of mRNA in vivo with a 
good transfection after intranasal administration (132). The charge-reversal behavior of 
chitosan has also been exploited for pH-triggered drug release (133). PEG-coated 
liposomes with a positive charged surface were used to enhance the interaction with 
membrane of endosomes (134). pH sensitivity to the nanosystem can be obtained also 
through caging polymer chains that undergo phase transition in lysosomal acidic 
conditions, releasing the payload (135). 
1.2.2.2. Redox-sensitive systems 
Redox senstive systems can be obtained exploiting the different concentrations of GSH 
found in extracellular (~2–10 μM) and intracellular (~2–10 mM) compartments, and in 
tumour tissues compared with healthy ones. cit Disulphide bonds, susceptible to cleavage 
by glutathione (GSH), can be used to obtain drug carriers that can change their 
conformation, and release their content in cytosolic compartment, following redox 
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stimuli. Degradable micelles have been developed with self-assembled amphiphilic 
copolymers containing disulphide bonds a disulphide bond at the connection of the two 
polymer blocks (136). GSH-sensitive crosslinking agents could also be incorporated in 
the shell or in the core (137) of the micelles, leading to micelle disassembly followed by 
specific intracellular release of hydrophobic drugs. Redox-sensitive systems can also be 
obtained with thiol-cleavable bonds (138) or quinone-lipid conjugate (139). 
1.2.2.3. Self-regulated systems 
A last option in developing of stimuli responsive systems, could be the exploitation of 
specific analytes concentration in order to achieve self-regulated drug delivery. This 
strategy could be important in the non-invasive management of diabetes, which requires a 
system that triggers the release of insulin according to glucose levels in the blood. A quite 
common strategy to design glucose-responsive systems exploit the capability of 
phenylboronic acid (PBA) to combine reversibly with cis-diol units. The equilibrium in 
aqueous solution between neutral (hydrophobic) and charged (hydrophilic) PBA is shifted 
towards the second one when charged PBA form complexes with glucose, resulting in the 
swelling of PBA containing polymers. As consequence the release of insulin from 
poly(ethylene glycol)-block-poly(acrylic acid-co-acrylamidophenylboronic acid) micelles 
(140) and poly(ethylene glycol)-b-poly(styrene boroxole) polymersomes is obtained 
(141). Anyway, this kind of responsiveness required high glucose concentrations (up to 
50 mg/ml), quite far from the concentration present in physiological conditions (1–3 
mg/ml). A greater glucose sensitivity was obtained by rearrangement of the polymer 
structure with introduction of non-responsive solubilizing groups (142). When these 
molecules are introduced, the interaction of PBA with the glycopolymer is weakened in 
the presence of glucose by competition, resulting in a matrix swelling and insulin release.  
 
Despite the huge progresses achieved in this field, the translation of stimuli-responsive 
drug-delivery systems from the bench to the bedside is not so easy. This could be due to 
their sophisticated designs, which makes the potential pharmaceutical development more 
complex, especially in terms of the manufacturing, reproducibility and quality control 
(104). Moreover, non trivial optimizations and improvements are often required and have 
to be studied for the translation of each stimulus from preclinical experimental models to 
daily clinical practice. In particular, endogenous triggers are really difficult to control 
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because they may vary from one patient to another. The pH in the interstitium of a tumor 
or the presence of reducing agents in the blood stream can also be rather dishomogeneous 
among patients. 
Although systems responsive to external stimuli are interesting and promising, major 
improvements would be needed to improve both tissue-penetration depth and focusing of 
the physical trigger in order to avoid damages at normal tissues. At the moment, the two 
stimuli-responsive nanosystems that have reached the clinical stage (Table 1.3 (104)) are 
responsive to exogenous stimuli, whereas no immediate success is expected for the many 
systems responsive to external stimuli under development. 
  
Table 1.3. Stimuli responsive drug-delivery systems in clinical trials. Adapted from (104) 
with DOI:10.1038/nmat3776. 
 
                   
As we can deduce from the above table, the thermosensitive liposomes ThermoDox are at 
present in clinical trials for the treatment of breast cancer (phase II) and hepatocellular 
carcinoma (phase III). Iron oxide NanoTherm has been approved for the treatment of 
glioblastoma. ThermoDox have been recently suspended because it did not show to 
overcome the threshold of 33% in life span, nevertheless these trials have demonstrated 
the safety profile of the liposomes, which were well tolerated by patients. Iron oxide-
based MTC–DOX (magnetic target carrier–doxorubicin, developed by FeRX) entered 
phase II and III clinical trials for the treatment of liver cancer and unresectable 
hepatocellular carcinoma, respectively, but no updated data have been published since 
2005 (104).  
 Introduction   
 
33 
 
1.3 POLYMER VESICLES 
1.3.1 AMPHIPHILIC POLYMERS AND NANOSTRUCTURE FORMATION 
Development of drug delivery systems based on water-soluble polymers is one of the 
main goal of research in the fields of polymer chemistry and physics, since water is the 
solvent of first choice if we want to deliver natural macro-molecules, such as protein and 
DNA (143). If  polymers are designed as amphiphilic materials, they should be able to 
assemble, form nanosized structures and stabilize systems susceptible to macrophase 
separation. Amphiphilicity is the key feature that influences a variety of  properties of 
water soluble polymers in aqueous solutions. Totally hydrophilic compounds are soluble 
in water while the hydrophobic ones are not. Moreover, amphiphilic compounds possess 
an intermediate feature, being able to stabilize the unprofitable interactions between water 
and hydrophobic fractions of the molecules.  
First attempts to describe the principles of spatial organization of amphiphilic polymers 
led to the development of a simple (at first sight) Hydrophobic - Polar (HP) (144). The 
inspiration to this model came studying the different existing protein conformations,  
where protein design experiments showed that groups of hydrophylic (more polar, P) and 
hydrophobic (less polar, H) amino acids have an important role in determining the final 
secondary (145) or tertiary protein structure (146). Taking inspiration from proteins, the 
HP model was transferred on copolymers, that distinguishes only two kinds of monomers, 
namely hydrophilic (P) and hydrophobic (H). This scheme allowed simulation studies 
about the thermodynamics and stability of aggregated systems obtained with these 
macromolecules. The obtained result is a minimalist model, based on the physical 
principle of Hydrophilic/Hydrophobic definition. 
The disadvantage of this HP model is that it does not take into account the fact that the 
monomer units themselves, which are considered as hydrophilic, consists actually of 
hydrophilic and hydrophobic parts, and are actually amphiphilic. Possibly, the spatial of 
amphiphilic polymers will organize at the interface between hydrophobic and hydrophilic 
media.  
A second model, reported in Figure 1.13, concerns a two-dimensional thermodynamic 
classification for amphiphilic monomers, which took into account three possible 
preferential dispositions of a monomer unit in two non-miscible liquids. This model is 
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based on an affinity scale to polar and non polar phases and allows to study the behavior 
of a selected monomer (147). 
 
 
 
 
 
 
 
Figure 1.13. Two dimensional diagram of phase affinity and interfacial activity, general view. 
Adapted from (147) with DOI:10.1007/12_051. 
In this model, each monomer is defined by two dimensional coordinates: the abscissa 
corresponds to the affinity to the polar (water) or the non polar phase (hexane) while the 
ordinate corresponds to the interfacial activity. The standard free energy of partition 
beetween water and hexane is used as a control for the abscissa axis (ΔFpart), whereas the 
standard energy of adsorption at the interface is used for the ordinate axis (ΔFads). On the 
bases of this diagram, studies performed by Okhapkin and colleagues (143) on synthetic 
monomers N-vinylcaprolactam (VCL), N-vinylpyrrolidone (VP), N-isopropylacrylamide 
(NIPA) and 1-vynilimidazole (Vim), showed that the interfacial activity increases as the 
hydrophobicity of the amino acid residues increases. Since the amino acids possess two 
major hydrophilic groups, namely the amino and carboxyl groups that are constant in all 
aminoacids, it can be concluded that the increase in hydrophobicity enhances the 
amphiphilic character of aminoacids. Thus, it was shown that many building blocks of 
natural and synthetyc polymers are amphiphilic and interfacially active, and are able to 
provide spontaneous nanostructures assembly in aqueous solution (143). 
1.3.2 POLYMERSOMES 
Amphiphilic polymers, by structure, are mostly copolymers since they are made of 
repetitive hydrophilic blocks and a hydrophobic blocks. In the previous section, we 
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underlined that amphiphilic polymers can form nanostructures in aqueous conditions. 
Furthemore, all block copolymers, if made of suitable amphiphilic proportions, can self-
assemble into vesicles when hydrated (148). The hydrophobic blocks of each polymer 
chain tend spontaneously to associate with each other to minimize direct exposure to 
water, whereas the more hydrophilic blocks stick toward the water phase in and out the 
vesicle, are hydrated by water. The assembly of the copolymer generate a layer with two 
interfaces with water. It must be highlighted here that the generation of micelles or a 
bilayer of a vesicle is strongly dictated by the hydrophilic and hydrophobic weight ratio 
of the polymer blocks as described below. The colloidal system generated is rather similar 
to a liposome and for this reason it is named polymersome (148). Liposomes are 
assembled with components with Molecular Weight of less than 1 kDa, whereas 
copolymers have MW of at least 5-10 kDa.  
In the case of liposomes, phospholipids aggregate forming vesicles in many aqueous 
solutions, because water exalts their amphiphilicity, while they fail to do so in solvents 
that do not exalt their amphiphilicity (as chloroform). Solubility of amphiphilic polymer 
also depends in general on chain MW, which suggests that vesicles can also be assembled 
using weakly hydrophobic polymers (12). 
Lipids and small amphiphiles can differ considerably for what concern their hydrophilic 
component, also named head group, but the most of the times they contain one or two 
strongly hydrophobic chains composed of multiple ethylene units (–CH2–CH2–)n (with n 
= 5 to 18 typically). The minimal concentration at which lipids and polymers aggregate to 
give liposomes, or polymersomes, or micelles can be provided measuring the CAC or 
CMC (Critical Aggregation Concentration or Critical Micelle Concentration 
respectively): 
                                                  CCAC/CMC = exp(–nεh/kbT),  
 
where kbT is the thermal energy and εh is the effective interaction energy of the monomer 
with the bulk solution. Only at concentrations of  the amphiphilic component above 
CCAC/CMC colloidal aggregates can form. For ethylene groups at the physiological 
temperature Tbiol, εh ≈1 to 2, kBTbiol ~ 4 to 8 pN·nm.  Thus values of CCMC for lipids and 
related amphiphiles in aqueous solutions range from micromolar to picomolar (148) 
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As reported above, copolymers have the amphiphilic character as lipids but consist of 
polymer chains where a series of two or more blocks are covalently linked (Figure 1.14). 
             
Figure 1.14. Schematic representation of block copolymers and polymersomes. 
 
One of the earliest examples of a semi synthetic diblock copolymers that self-assembles 
in aqueous conditions is a dipeptide construct PolyStyrene40 (PS40)-poly(isocyano-L-
alanine-L-alanine)m (149). Under acidic conditions and for m = 10, vesicles with 
diameters ranging from tens to hundreds of nanometers were observed. (Figure 1.15).  
                                 
Figure 1.15. Example of vesicles obtained with block copolymer PS40-poly (isocyano-L-alanine-
L-alanine)m.. Adapted from (12) with DOI:10.1126/science.1074972. 
 
A fully synthetic diblock copolymers of PEOm-PBDn (PEO, polyethylen oxide; PBD, 
polybutadiene) and the hydrogenated homologue of PBD, namely the poly(ethylethylene) 
(PEO-PEE), led to formation of polymer vesicles first referred to as polymersomes (150) . 
The effective shape of obtained vesicles can be predicted thank to the hydrophilic fraction 
f.  Liposomes have a f value around 50% referred to their total mass. In general, in order 
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to obtain polymersomes fhydrophilic ≈ 35% ±10% (151). Polymers with fhydrophilic ≈ 45% are 
expected to form micelles, whereas molecules with fhydrophilic ≈ 25% generally form 
inverted microstructures (12). These general rules allow to design polymers with adequate 
hydrophilic/hydrophobic balance depending on the colloidal structures that are desired. 
How the polymer chain chemistry and the MW affect these rules have not been fully 
elucidated. However, copolymers complying these rules and assembling in polymersomes 
have MWs ranging from ~ 2700 to 20.000 g/mol. Furthermore, cryogenic transmission 
electron microscopy (cryo-TEM) of 100 to 200 nm vesicles showed that membrane 
thickness increases with MW increase from 8 to 21 nm (152, 153). Lipid membranes of 
liposomes have a far more limited range of tickness (3 to 5 nm). Polymersome 
membranes thus offer a novel opportunity to study membrane properties and membrane 
associated proteins as a function of the membrane tickness. Polymersomes can be 
generated with a low permeability membrane, able to retain encapsulated molecules over 
periods of months. These polymersomes had ~100-nm in size and were prepared by 
extrusion techniques similar to those exploited to prepare liposomes (154) as well as with 
~10 μm giant vesicles. Figure 1.15 shows that lateral diffusivity (12, 155) as well as 
apparent membrane viscosity studies (12, 151, 156) point out that membrane fluidity 
decreases increasing MW of the polymer. Moreover, the decreases are most relevant 
when the chains are long enough to entangle (Figure 1.16).  
                                       
Figure 1.16. Schematic of membrane properties versus amphiphile molecular weight. Adapted 
from (12) with DOI:10.1126/science.1074972. 
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Measurements of the area elasticity gives an indirect measure of εh as γ (~ 25 mN/m) and 
shows that the elasticity of the membrane is independent from the MW of the polymer. 
Also water permeation through the polymersome membranes has been measured (156) 
and compared to phospholipid membranes. A considerably reduced transport rate was 
obtained in the case of polymersomes. These results are in agreement with early 
measurements on liposomes made by Bangham on a narrow MW-series of lipids (157). 
What we can deduce from these studies is that liposome membranes appear fluider than 
stable. In this context, cholesterol is a useful component for membranes because it both 
toughens and fluidizes the cell membranes (158). To investigate the effect of polymer 
structure on the strength and fluidity of polymeric membranes, several triblock 
copolymers have been investigated in detail, and the differences in membrane properties 
have offered important insights.  
Polymersomes are versatile carriers because they allow loading of both hydrophilic and 
hydrophobic drugs. Hydrophobic agents can be trapped in the hydrophobic layer while 
hydrophilic therapeutics can be disposed into the aqueous core. In addition, the 
hydrophilic corona can be used to easily conjugate biomolecules with the external faceing 
layer in order to selectively target specific cell types. Literature reports samples of 
polymer vesicles obtained with ABC triblock copolymers (159, 160). 
A and C are two different hydrophilic blocks and B is the hydrophobic block which can 
mimic the characteristic structure of the physiological membrane with a surface 
hydrophilic section (head groups of phospholipids), an hydrophobic internal core (alkyl 
chains of phospholipids), and another hydrophilic section (head groups of phospholipids). 
The phase segregation and the organization of amphiphilic polymers that self-assemble 
into polymeric membranes yielding polymersomes affect the interaction of the colloidal 
system with cells. Thus the interface features of the system is paramount in dictating its 
biological properties. In particular, it has been demonstrated that by systematically 
varying the blocks of the triblock copolymer by varying the monomers or the block 
length, polymersomes can undergo rapid endocytosis, can induce cell apoptosis or can 
exhibit relatively slow cellular uptake and low cytotoxicity (160). Thus the polymer 
blocks features possess a double role: on one side they dictate the arrangement of the 
polymer chains to yield the polymersomes, on the other side they are the primary 
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responsible for the surface properties of the vesicles that will interface with the biological 
environment after administration. 
To ensure efficient therapeutic activity, delivery systems must be able to circulate for 
long periods of time in the bloodstream and avoid the elimination by the mononuclear 
phagocytic system (MPS, also known as reticulo-endhotelial system). Hydrophobic or 
charged nanoparticles usually are removed by the immune system and rapidly cleared. 
Coating surface techniques involving hydrophilic polymers have been used to solve this 
problem and often require additional conjugation efforts to coat the preformed carriers 
with polymers (e.g.: nanoparticles or liposomes). Due to their amphiphilic nature, 
polymeric vesicles already possess an hydrophilic shielding layer as soon as they are 
assembled. An example is given by polymersomes assembled with an appropriate 
synthesized biocompatible hydrophilic block, usually poly(ethylene glycol) (PEG) or 2-
methacryl-oyloxyethyl phosphorylcholine (PMPC) (161). 
Due to their ability to load simultaneously hydrophilic and hydrophobic therapeutics, 
these nano-sized carriers are also good candidates for combinational-therapies, that is 
regarded as a promising frontier for the treatment of cancer. Compared to lipid-based 
vesicles, polymersomes are in general more stable. Liposomes have been widely 
exploited as delivery vehicles despite their limits including the short circulation time and 
lack of efficient mechanism for controlled drug release. On the contrary, polymersomes 
offer a more versatile system. The stability of the polymersomes can be programmed by 
designing and synthesizing proper block copolymers. Furthermore, polymersomes are 
more flexible than liposomes for what concern the modulation of their physical features 
and their biological behavior. Polymeric vesicles for this reason have been recently 
explored as novel in vivo delivery vehicles. 
Furthermore, in virtue of their versatility, polymersomes can be generated using 
positively charged polymers (162), which is very helpful for the formulation and delivery 
of oligonucleotides. An efficient non viral vector for gene delivery or oligonucleotide 
delivery should ideally guarantee for specific and efficient cell transfection, for high level 
and period of expression and for low immunogenicity. Unfortunately, a non viral vector 
that satisfies these requirements has not been produced yet. On the other hand, while viral 
vectors have great transfection activity, they can also transfer viral genome traces, which 
trigger severe immunogenic responses. For this reason, non-viral vectors are regarded as a 
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safer alternative to viruses. In virtue of their stability, the polymeric vesicles can protect 
oligonucleotides or proteins and they can be easily functionalized to integrate 
mechanisms for targeting as well as controlled release. Encouraging early results in 
clinical trials with polymer conjugates have promoted the development of synthetic 
systems the intracellular delivery according to a viral mimic activity.  
1.3.3 pH SENSITIVE POLYMERSOMES 
In order to achieve effective controlled release or site-selective uptake, the materials 
designed for the assembly of polymersomes can be tailored to respond to external physic-
chemical stimuli, such as pH variations, alteration of the environment redox potential, 
temperature changes (163) (Figure 1.17). 
 
 
 
 
 
 
 
 
Figure 1.17. Schematic representation of the assembly and the dissociation of stimuli-responsive 
polymersomes. 
 
Among the realm of the stimuli-sensitive systems, pH responsive nanocarriers have been 
the most investigated because of the wide range of pH gradients available in different 
tissues and subcellular compartments in physiological and pathological conditions, which 
can be used to activate the programmed response of the carriers. 
Controlled drug release can be triggered in tumor tissues or intracellularly in the 
endosomal or lysosomal compartment in virtue of their peculiar lower pH with respect to 
the blood. In order to be effective, these systems are required to respond to a rather 
narrow pH range. The responsiveness to environmental pH shift can be achieved with 
protonable polyionic materials including polyacids or polybases in the blocks of the 
copolymer used to assemble polymersomes. The capability of these polymers to respond 
is provided by peculiar functional groups that can switch their ionization state between 
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protonated and deprotonated depending on the external environment. The ionic/non ionic 
conversion dictated by the external environment can affect the solubility and the special 
conformation of the copolymer (164). 
Functional "titratable" groups with pKa from 3 to 11 are generally exploited to 
synthesized pH responsive polymers for the assembly of pH sensitive polymersomes. 
They include a variety of small molecules that are used to generate monomers for the 
material polymerization. These small molecules usually possess  carboxylic acids or 
primary secondary and tertiary amine (165). 
Different methods can then be exploited to induce the assembly of the pH responsive 
polymers into polymersomes. General methods of assembly include the processing of the 
polymer in organic solvents or a mixture of organic solvent/water or aqueous media 
(166). The “solvent-switch” method is representative of this family of techniques to 
assemble polymersomes and has been used because often the amphiphilic block 
copolymers are not directly water soluble. This method involves the dissolution of the 
copolymer in an organic solvent suitable for the polymer blocks and and miscible with 
water. Then slowly the organic solution is diluted with water (167, 168). The hydrophilic 
blocks of the polymeric chains are hydrated once the polymer assemble in water and form 
the external coronas, while the hydrophobic block associates to minimize the contact 
surface with water and form the polymersome membrane core. The “solvent- switch” 
method requires the removal of the organic co-solvent by dialysis.  
An alternative technique to the “solvent-switch” method involves the rehydration of a dry 
polymeric film by the addition of a buffer solution containing the therapeutic molecules 
(169). The copolymer is firstly dissolved in a highly volatile organic solvent, such as 
chloroform, and then it is evaporated obtaining a copolymer thin film. The film is then 
rehydrated, leading to vesicles formation.  
The systems obtained with these procedures have usually micrometer-sizes and tend to 
have wide distribution in particle size (170, 171). Some examples of innovative methods 
that allow the formation of polymersomes using charged polymers have been reported in 
literature. Here we mention the work of Du and Armes (166) which obtained vesicles 
with tunable membrane permeability at different pH. The amphiphilic block copolymer 
poly (ethylene oxide)-b-poly[2-(diethylamino)ethylmethacrylate-s-3-(trimethoxysilyl) 
propyl metha-crylate] [PEO-b-P(DEA-s-TMSPMA)] was synthesized in THF/water 
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mixture using PDEA. The PDEA block is responsible for the pH response of the vesicles 
since it is protonated and becomes hydrophilic at low pH, which increase the 
polymersome membrane permeability. By increasing the pH, the PDEA block becomes 
hydrophobic and gradually decreases the membrane permeability by strong hydrophobic 
interactions. This allows both controlled encapsulation and release. Poly[3-
(trimethylsilyl) propyl methacrylate] (PTMSPMA) was added as a cross-linking agent in 
order to preserve the vesicular morphology.  
The complete removal of the organic solvent from formed vesicles can be problematic, 
can require long time and may originate following toxicity, therefore recently solvent-free 
preparation have been investigated. A reported example is the formation of vesicles from 
poly(2-methacryloyloxyethylphosphorylcholine)-block-poly[2-(diisopropylamino)ethyl 
methacrylate] (PMPC-block-PDPA) used for the delivery of Doxorubicin (166). MPC is 
the biocompatible and hydrophilic monomer, and DPA is the hydrophobic and responsive 
monomer. When the pH of the PMPC-block-PDPA solution is lower than the pKa of 
PDPA, the PDPA becomes hydrophilic due to the protonation of the tertiary amine and 
becomes fully soluble in water. By increasing the pH, the block loses its protons, turns 
hydrophobic and spontaneously form vesicles in aqueous media.  
1.3.4 POLYMERSOME APPLICATION FOR RNA INTERFERENCE DELIVERY 
Small interfering RNA (siRNA), discovered only in the 1990s, has rapidly been applied 
as a potential therapeutic for a wide array of diseases (77, 78, 172). siRNA molecules, 
double-stranded RNA typically  of 20−25 nucleotides in length, act to down-regulate 
expression of a specific target genes. This down-regulation is obtained with participation 
of the cell own RNA interference machinery. A single strand of the siRNA molecule with 
a precise sequence, typically the antisense strand, is incorporated into endogenous protein 
complex RISC (RNA-induced silencing complex) assembly in the cytosol, which then is 
able to degrade complementary messenger RNA (mRNA) (173). 
The advantage of RNAi technology is that it can be used to target different genes 
responsible for different cellular pathways. This is particularly relevant for a complex 
disease as cancer. The major cellular pathways that have been identified as altered in 
cancer include the receptor protein tyrosine kinase (PTK) pathway, adenomatous 
polyposis coli (APC) pathway, glioma-associated oncogene (GLI) pathway, 
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phosphoinositide 3-kinase (PIK3) pathway, SMAD pathway, hypoxia-inducible 
transcription factor (HIF) pathway, retinoblastoma (Rb), p53 pathway, and apoptosis 
(APOP) pathway (9, 174). All these and even more pathways are good candidates for the 
application of siRNA as therapeutic molecule. Most of the cancer genes exploited as 
targets for RNAi candidates are involved in pathways involved in tumor growth. While 
mRNAs expressed from mutated cancer oncogenes can be directly targeted by exogenous 
RNAi, the process of siRNA interference can also be used to target and silence gene 
products that negatively regulate the function of endogenous tumor suppressor genes thus 
counterbalancing the deregulated growth of tumors. Anyway, RNAi can also work on 
proteins involved in cellular senescence, or protein stability and degradation.  
Table 1.4 summarizes some of the genes that have been targeted by RNAi until now (9). 
 
Table 1.4. Genes involved in oncogenesis. Adapted from (9) with DOI: 10.1038/sj.gt.3302694. 
     
 
 
Although RNAi has always been a fascinating process in the field of research, effective 
delivery of siRNA molecules to tumors and cancer cells presents a number of unique 
challenges (175, 176). First, RNA is rapidly degraded in the presence of serum and any 
ribonuclease (RNase). Consequently, effective delivery of the siRNA molecules requires 
the protection from degradation (177, 178). Secondly, because siRNA is a quite big 
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molecule (∼13 kDa) and highly negatively charged, its intracellular delivery has to be 
assisted because he has not access into cells as free molecule. 
Finally, siRNA has to reach the cytosolic compartment in order to assemble with the 
RISC protein complex. In most cases means that the siRNA must escape the endosomal 
intracellular compartments to be released in the cytosol. The above cited requirements are 
needed both for delivery of siRNA in vitro and in vivo. However, for the case of in vivo 
delivery, we have also to consider that siRNA has to arrive to the appropriate tissue in the 
body, evading host immune response and phagocytosis, colloidal stability, toxicity, and 
avoiding filtration in the kidneys (172). 
It is conceivable that adequate and efficient non viral carriers for siRNA delivery are 
paramount to guarantee the biological activity of the siRNA at the site of action. For this 
reason, siRNA complexes with positively charged liposomes (lipoplexes), polymers 
polyplexes, and polymersomes are under investigation. With oligonucleotides 
encapsulated inside the aqueous lumen of polymersomes, protection from the external 
environment has been clearly demonstrated and it was shown to be an efficient strategy. 
Furthermore, polymer vesicle coronas, composed of a dense PEO brush layer, have been 
shown to effectively prohibit the opsonization of the vesicles and therefore reduce the host 
immuneresponse and clearance from the body (179, 172).  An example of siRNA loaded 
polymersomes is given by Kim et all. (10) which used various block copolymers such as 
PEG-polycaprolactone (OCL), PEG-polylactic acid (OLA), and inert PEG-polybutadiene 
(OB). Polymersomes were prepared according a co solvent dialysis method, which 
exploits the miscibility of DMSO (where copolymer are dissolved) with water (suitable 
environment for siRNA). Briefly, to a DMSO copolymers solution, the siRNA in PBS 
was added. Following, dialysis was performed in order to have a graduated polymersomes 
formation with a parallel siRNA encapsulation. This method showed a siRNA 
encapsulation efficiency up to 30% by the  prepared polymersomes.  
Pangburn et al. (172) prepared polymersomes for siRNA delivery using poly(1,2-
butadiene)-b-poly(ethylene oxide) according the film rehydration method. Copolymers 
were placed in a vial with chloroform to form a polymer concentrated solution and shaken 
for 24 hours. The film was then prepared drying the solvent and an aqueous solution of 
the oligonucleotides was added to the film that was in this manner rehydrated forming the 
loaded vesicles. These polymersomes showed an encapsulation efficiency of even 50%. 
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The use of polymeric vesicles has some advantages if compared to siRNA delivery by 
liposomes. Firstly, as reported in previous sections, polymersomes are bigger than 
liposomes and can allow a higher loading of siRNA. Furthermore, polymersomes can 
circulate in vivo longer than lipid vesicles (10). Finally, polymers can be synthesized de 
novo with the features needed and desired, whereas number of phospholipids is limited in 
the market. 
A last very important example of nanocarriers for siRNA delivery, although it does not 
concern polymersomes, is given by cyclodextrin based targeted polyplexes. Cyclodextrins 
are toroidal shape molecules with structure similar to a truncated cone. They have an 
hydrophobic inner cavity and a hydrophilic outer surface (180). In literature many 
interesting in vivo studies are reported using this nanovector for RNAi application. 
Bartlett et all. inoculated mice with an Ewing’s sarcoma family tumors (EFT) and treated 
them with targeted Transferrin-PEG-polyplexes-cyclodextrins loaded with a siRNA 
sequence for tumor suppression (siEFBP2). As result, a significant inhibition against 
implanted malignant cells was obtained (181). The biodistribution and the 
pharmacokinetic profiles of these cyclodextrins loaded with 
64
Cu-labelled siRNA 
targeting luciferase were also investigated on NOD/scid mice bearing luciferase 
transfected Neuro2A tumour cells. The in vivo bioluminescence imagining showed that 
targeted cyclodextrines reduced the luciferase expression increase by 50% compared to 
non targeted polyplexes (182).The following step was the evaluation of the best dosing 
schedule for the system. This aspect was studied injected the loaded system into A/J mice 
bearing a subcutaneous Neuro2A tumour cell line. Results showed that tumor growth 
inhibition was achieved when the siRNA concentration threshold inside the cells was 
reached. The best therapeutic performance was obtained by three single administrations 
over three consecutive days of 2.5 mg/kg siRNA formulated with the transferrin targeted 
cyclodextrins (183). To conclude, Davis showed the absence of severe side effects after 
administration of siRNA loaded transferrin-PEG polyplexes to cynomolgus monkeys. The 
siRNA loaded ciclodextrins were injected to healthy animals at 3 to 27 mg/Kg per 
siRNA, reaching in this way a 100 times higher concentration than the one which showed 
efficacy in the mouse model. The animals did not show any alteration as loss of weight or 
modified food consumption. Moreover, serum markers and coagulation parameters were 
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in the physiological range and only the highest dose exhibited mild toxicity to kidney and 
liver. No response in terms of complement activation were underlined (184). 
The above described studies are a good example to show that targeted siRNA loaded 
nanosystems, if well designed, have a really good chance to reach the phase of clinical 
trials in the field of anticancer therapy. 
1.4 REVERSIBLE ADDITION FRAGMENTATION CHAIN 
TRANSFER POLYMERIZATION (RAFT)  
The generation of novel materials and polymers require the exploitation of very 
sophisticated techniques to produce them in small and subsequently at large scale. The 
production of polymers is critical for what concern the capacity to fully control their 
physic-chemical features and the process has to be reproducible. 
Among the most recent chemical strategies to synthesize polymers, Reversible Addition-
Fragmentation Chain Transfer (RAFT) radical polymerization was set up by 
Commonwealth Scientific and Industrial Research Organization (CSIRO) and firstly 
reported in 1998 by Chiefari J (185). 
A RAFT polymerization system consists of an equilibrium between the addition and 
fragmentation reactions that occur in the presence of a chain transfer agent, 
conventionally named as a RAFT agent. RAFT agents provide the living feature to this 
process by their high transfer constant, which provides the rapid exchange between the 
dormant and active species. Thus their structure needs to be chosen based on the features 
and reactivity of the chosen monomer (186). This is usually obtained using 
thiocarbonylthio compounds of generic structure as shown in Figure 1.17. 
                                                  
Figure 1.17. General structure of RAFT agents. 
 
The key features of RAFT agents are a reactive C=S double bond and a weak S-R single 
bond. Transfer constants are strongly dependent on “Z” and “R” substituents. The R 
group is the free radical leaving group and it is chosen so that it undergoes b scission 
from the RAFT-adduct radical and it is still able to re-initiate polymerization. The 
reactivity of the transfer agent is highly influenced by the Z group. It should be able to 
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activate or deactivate the thiocarbonyl double bond in order to provide radical addition 
and to modify the stability of the intermediate radicals. 
A variety of functionalities can be used to synthesize polymers containing end or side 
chain functionality in a one-step process (187). 
Initiation and radical-radical termination processes take place as in a conventional radical 
polymerization. The most common used initiator are peroxy- and azo- compounds, such 
as AIBN, that decomposes thermically to provide two radical species and release N2. In 
the early stage of the process the radical reacts with a monomer unit to generate a radical 
specie that starts an active polymerizing chain (Pn*). The propagating radical reacts with 
the C=S bond of the transfer agent to produce a carbon-centered radical. This radical 
specie undergo b-scission and is converted to a poly-RAFT agent while liberating a new 
radical that consists of the ‘leaving group’(R) of the RAFT agent. As mentioned before, R 
is a key group since it must be able to reinitiate polymerization when in contact with new 
monomer and create a new propagating chain (Pm*). The central step in the RAFT 
polymerization process is the establishment of equilibrium between active and dormant 
species. To achieve control over polymerization it is required that the dormant species 
concentration is favored than that of the active one but in rapid exchange with one 
another. In this way the radical-radical termination is minimized and all the chains have 
equal probability to grow, ensuring polymers with narrow polydispersity (Mw/Mn) and 
low termination rate, usually < 10%. Scheme 1.1 summarize the steps involved in the 
RAFT polymerization process.  
                             
 
 
 
 
 
 
 
 
 
 
Scheme 1.1. Schematic representation of the mechanism of the RAFT polymerization. 
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Since radicals are not formed nor destroyed during the chain-transfer reaction, RAFT is 
usually carried out with an external source of free radicals (initiator). The concentration 
of the active species is maintained low related to the dormant species. This is obtained 
with the control of amount of initiator and capping agent, which should limit termination 
steps and increase polymer length. Termination rate is of second order as in conventional 
free radical polymerizations, while propagation steps show a dependency of first order 
with respect to the radical species concentration. Thus, if we reduce the concentration of 
radical species will promote propagation over termination.  
Transfer agent addition to the reaction mixture can affect the polymerization kinetics 
through an “inhibition period”, where the polymerization is slow or absent, or through a 
“rate retardation”, which consists of a polymerization rate slower than the one of the same 
reaction without the use of the RAFT agent. Inhibition can be ascribed to a pre-
equilibrium phase, known as initialization, where the RAFT agent is converted to a 
polymeric RAFT agent. RAFT agents that mostly generate this inhibiting phenomena of 
polymerization are the ones that stabilize the radical adduct, e. g. Z=phenyl or other 
aromatic compounds. This issue can be solved using more reactive RAFT agents, e.g. 
trithiocarbonates. The “R” group of the RAFT agent co-determines the stability of the 
adduct during the initializing phase. A transfer agent with a weak leaving group or 
inefficiently reactive will not be able to control the polymerization or will induce strong 
inhibiting phenomena. The advances in RAFT polymerization procedures, the knowledge 
of mechanism and structure-reactivity correlations have made possible the production of 
narrow polydisperse polymers with high conversion and commercially acceptable 
polymerization rates. The opportunity to carry out the reaction with a wide range of 
monomers, solvents and initiators make this technique extremely fascinating for the 
production of polymer with complex design, like stars, blocks and hyper branched 
materials, polymeric micelles and vesicles (188). In particular with blocks copolymer, 
that are the main point for polymersome assembly, the RAFT polymerization process 
allow to fully control features as the molecular weight and numbers of monomers of each 
single block since the growth of the polymer can be stopped at the end of each block and 
re-started with the following block.  
 Introduction   
 
49 
 
1.5 AIM OF THE PROJECT 
The aim of this thesis was the development of a novel pH sensitive targeted polymeric 
vesicular system for the delivery of siRNA to specific cancer cells. In virtue of the 
specific features of the polymers used to assemble the vesicles, once inside the cells, 
siRNA is released in order to carry out the RNA silencing process to inhibit the 
translation of aberrant proteins involved in carcinogenesis. As a molecular target, we aim 
to silence the synthesis of the 1 Na+/K+ ATPase subunit that has been reported to have a 
role in the tumor growth and homeostasis. The polymeric nanosystem assembled using 
pH responsive block copolymers is designed to achieve the tumor site in virtue of the 
EPR effect. Then the vesicles are internalized by cancer cells according to receptor 
mediated endocytosis involving the interaction between a selected ligand (folate) 
conjugated on the surface of the vesicles and folate receptor over expressed on target cell 
surface.  
The project was supported by the European NanoSci ERA-net transnational collaborative 
funding scheme and was developed in collaboration with the University of Nottingham 
(UK) and the Centro de Investigacion Principe Felipe (CIPF) of Valencia (Spain).  
A new family of N-alkyl imidazole monomers was designed to produce pH-responsive 
block copolymers able to assemble in drug nanocarriers. Molecules with imidazole 
moieties are common in biology and are known to possess useful tunable acid/base 
behavior. The amino acid histidine, for example, exhibits a wide range of pKa values 
associated to its imidazole side-chain, ranging from 2.3 to 9.2, depending on its specific 
location and proximity to other residues within proteins (189). In addition, N-alkyl 
imidazole moieties are present in a number of clinically prescribed drugs, ranging from 
antifungal lanosterol 14 α-demethylase inhibitors - e.g. ketoconazole, miconazole, and 
clotrimazole - to nitroimidazole antibiotics such as metronidazole and tinidazole (190). 
With a pKa in the 6.5–7.5 range, N-alkyl imidazoles appeared to be ideal precursors for 
the synthesis of pH responsive drug nanocarriers. An imidazole based monomer should, 
when present in a block co-polymer, alter the aggregation state of polymers across this 
pH range in virtue of its protonated/deprotonated shifting that dictates a 
hydrophilic/hydrophobic switching. In turn, this should result in conformational changes 
of the polymers when migrating from the systemic circulation (pH 7.4), to more acidic 
conditions such as those found in hypoxic tumor tissue (pH 6.5–7.0) or 
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endosomal/lysosomal acidic conditions (from 6.5 to 4.5) following cellular uptake (191). 
The pH response of these systems may thus provide from local entrapment of drugs in the 
carriers at physiological pH and the controlled release of therapeutically relevant loaded 
molecules under acidic conditions.  
We intend to generate such polymeric vesicles by using amphiphilic di- and triblock pH 
responsive polymers. The first designed polymers for this purpose were diblock 
copolymers; literature reports a variety of studies where amphiphilic diblock co-polymers 
were investigated to obtain polymersomes (12). Nevertheless, the diblock copolymers 
produced for this project and consisting of polyglicerolmethacrylate and polyC6-
imidazole-methacrylate blocks generated vesicles with limited stability. However, the 
physico-chemical characterization of this first set of materials provided valuable 
information that were successfully exploited to generate the triblock copolymers.  
The triblock copolymers were generated from the diblock and were constituted by two 
hydrophilic terminal blocks, polyethilenglycole (PEG) and polyglicerolmethacrylate 
(polyGMA), and a central pH sensitive polyC6-imidazole-methacrylate that promotes the 
self-assembly of the polymeric vesicles at neutral pH and dictates the dissociation of the 
vesicles under acidic pH. 
Once the polymeric vesicles have been endocitosed, the endosomal transit exposes 
polymersomes to such an environment that the midazole side chains of the pH sensitive 
block of the polymer will be protonated, inducing the dissociation of polymersomes. As a 
result, the therapeutic payload, namely siRNA, will be released inside the cytosolic 
compartment. Figure 1.18 schematizes the delivery mechanism intended for the carrier 
proposed in this thesis. 
              
Figure 1.18. Graphical representation of one of the delivery mechanism for the pH responsive 
polymersomes proposed in this thesis. Adapted from (205) with DOI: 10.1039/c3py00744h - 
Reproduced by permission of the Royal Society of Chemistry.        
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The aim of the project is thus to generate novel materials with peculiar physico-chemical 
features, assess the assembling properties of the newly synthesized triblock copolymers, 
evaluate the loading and pH controlled release of model dsDNA and siRNA, and the 
targeted delivery of oligonucleotides to model cancer cells over expressing the folate 
receptor by a variety of spectroscopic and microscopic techniques. The biopharmaceutical 
properties of the carriers will also be investigated by delivering biologically active siRNA 
to the cells which will prove the capacity of the polymeric vesicles to protect the activity 
of the fragile siRNA, the targeting efficiency and the cytosolic release of siRNA.  
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2. MATERIALS AND METHODS 
2.1 REAGENTS 
 Tetrahydrofuran anhydrous (THF), azobisisobutyronitrile (AIBN), imidazole, 
ethylene carbonate, sodium hydride (NaH), sodiumhydroxide (NaOH), 
methacryloyl chloride, carbon disulfide, glycidyl methacrylate, 6-chloro-1-
hexanol, acetic anhydride, magnesium sulfate, K2CO3 (potassium carbonate), N,N 
dimethylamino pyridine (DMAP), dimethyl formamide anhydrous (DMF), 
dimethylsulfoxide anhydrous (DMSO), tetrahydrofuran anhydrous (THF), 
chloroform, dichloromethane (DCM), ethyl acetate (EtOAc), methanol (MeOH), 
diethylether (Et2O), petroleum ether (b.p. 40-60 0C), triethylamine (Et3N), 2,2’-
dithiopyridine, propylamine, PEG2000SH, β-alanine, acetic acid, low melting 
point agarose gel, Blue/Orange (loading dye) 6X, SafeView (nucleic acids 
staining), (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) were 
obtained at the highest purity available from Sigma- Aldrich, Alfa Aesar, Promega 
and Fisher Scientific, NBS biological, Gibco BRL companies and used without 
further purification unless stated. 
 Folic acid, N,N'-Dicyclohexylcarbodiimide, N-Hydroxysuccinimide, were 
obtained from Fluka (Buchs, Switzwerland).  
 Vectashield® mounting medium with 4‘6-diamidine-2-phenylindole  (DAPI) was 
provided by Vector Laboratories Inc (Burlingame, CA).  
 Fluoresceine-DHPE and Rhodamine-DHPE were bought from VWR International 
PBI s.r.l. (Milan, Italy).  
 Double strand DNA 19 nucleotides, cyanin-3 labelled DNA were obtained by 
biomers.net GmbH (Ulm, Germany) 
 siRNA Luciferase GL3 Duplex and control siRNA with 21 nucleotides were 
provided by Fisher Scientific  (Madrid, Spain) 
 Quant-iT™ RiboGreen® RNA Assay Kit for siRNA quantification was bought by 
Life Technologies S.A. (Madrid, Spain) 
 Folate receptor alpha, monoclonal primary Antibody from mouse 1 mg/mL in 
PBS 804-439-R100 and secondary antibody 1 mg/mL in PBS, Alexa fluor 488 
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labeled α-mouse monoclonal antibody were purchased from Enzo Life Sciences 
Inc. 
 All products for cell biology comprising Dulbecco's modified Eagle medium 
(DMEM), L-glutamine, trypsin, antibiotic and antimicotic solution, bicinchoninic 
acid, solution of copper (II) sulfate, fetal bovin serum (FBS), phosphate saline 
buffer with and without Ca/Mg and plastics Greiner were obtained from Sigma-
Aldrich (St. Louis, MO, USA). Chamber slides BD Falcon
TM
 for confocal 
microscopy were bought from SACCO S.r.l. (Cadorago, Italy).  
 Cell lines from human breast cancer (MCF7) and cervical cancer (KB) come from 
cell bank ATCC-USA.  
 B16-F10-luc-G5 Bioware® Cell Line from mouse melanoma were obtained from 
Xenogen Corporation (Alameda, California) 
 All aqueous solutions were prepared using deionized water (milliQ-grade, 0.06 
μSiemens cm-1) obtained trough Millipore MilliQ (MA, USA).  
 Salts for buffer preparation and paraformaldehyde were provided by Riedel-de-
Haen (Seelze, Germany), Fluka Analytical (Buchs SG, Switzerland) and Sigma-
Aldrich (St. Louis, MO, USA).  
2.2 INSTRUMENTATION 
 Spectrophotometric analysis were carried out with spectrophotometer UV-Vis λ25 
Perkin Elmer (Norworlk, CT, USA).  
 Multiwell plate detections were carried out with Microplate Autoreader Biotek 
Instruments inc., mod. EL311SK (Highland, Vermont U.S.A.) and  Victor
2
 Wallac 
plate reader Perkin Elmer (Norworlk, CT, USA). 
 HPLC system Jasco, equipped with two pumps PU-2080 Plus, a detector UV-
2075 Plus and Hercule 200 JMBS, and analytic column Luna (C18, 5 μ, 300 Å, 
250 x 4.6 mm) from Phenomenex (Torrance, U.S.A.) was used for reverse phase 
chromatographic analysis (RP-HPLC). 
 Samples were maintained under stirring with Rotating stirrer, MOD 708, of ASAL 
S.r.l..  
 Lyophilization was carried out with freeze-dryier Hetossic HETO Lab Equipment. 
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 Solvents were evaporated with Rotavapor R114 of BÜCHI Labortechnik AG 
(Postfach, Switzerland).  
 pH measurements were carried out with pHmeter Seven Easy S20-K Mettler 
Toledo with electrode Mettler Toledo Inlab 413 (Schwerzenbach, Switzerland) 
and pHmeter Fischerbrand Hydrus600. 
 Centrifuges were carried out with CENTRIKON T-42K Kontron Instruments, 
Z300 Hemle and with ALC microcentrifughette 4214 della ALC international 
(Cologno Monzese, Italy).  
 Polymerizations were carried out using standard Schlenk techniques under a 
nitrogen atmosphere. Thin layer chromatography (TLC) was performed using pre-
coated plates (silica gel 60 ALUGRAM SIL G/UV254) and eluted in the solvent 
system indicated.  Compounds were visualized by using UV light (254 nm) or 
stained with a basic solution (10% w/w K2CO3 in water) of KMnO4. Across 
Organic 60 Å (0.035-0.070 mm) silica gel was used for column chromatography. 
 1H and 13C NMR spectra were recorded on a Bruker DPX400 Ultrashield 
spectrometer and Bruker Spectrospin AMX 300 MHz (Fallanden, Switzerland). 
All NMR data were processed using MestreNova 6.2.1 Software. All chemical 
shifts are reported in ppm (d) relative to tetramethylsilane. The following 
abbreviations were used for NMR peak multiplicities: s = singlet, bs = broad 
singlet, d =doublet, t = triplet, m = multiplet. 
 Polymersomes size analysis were performed by Dynamic Light Scattering 
Zetasizer NanoZS ( Malvern Instruments Ltd, UK ) or Dynamic Light Scattering 
Particle Sizing System NICOMP 380ZLS (Santa Barbara, CA, USA).  
 Gel electrophoresis of dsDNA/polymer mixtures were performed with an 
Amersham Biosciences miniVE Electrophoresis and Electrotransfer Unit system, 
GE Healthcare (Milan, Italy). Gel images were obtained with UV transilluminator 
ChemiDoc™ XRS + imaging system with Image Lab™ image acquisition and 
analysis software (Bio-Rad Laboratories, Headquarters, CA). 
 Transmission electron microscopy (TEM) was performed using a Tecnai G2 (FEI, 
Oregon, USA). Samples were placed on copper grid, the excess was removed with 
filter paper and then stained with uranyl acetate (1% in deionized water). 
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 Biological studies were carried out in biological safety cabinet Space, cells were 
grown using the incubator from PBI International and imaged with optical 
microscope Axiovert 40CFL Zeiss.  
 Buffers were filtered with Millipore systems (Bendford, MA, USA) using 0.22 μm 
cellulose acetate filter.  
 Fluorimetry analyses were performed using a LS 50 B Perkin-Elmer fluorimeter 
(Norworlk, CT, USA).  
 Cytometric analyses were performed using a BD FACSDiva flow cytometer 
(Becton, Dickinson and Company, Buccinasco, Milan) and results were processed 
with BD FACSDiva Software. 
 Pictures of confocal microscopy were obtained using confocal microscope Leica 
TCS SP5 Leica Microsystems GmbH (Wetzlar, Germany) and software Leica 
Application Suite advanced fluorescence 2.0.2 for image elaboration.  
 Bioluminescence studies were performed using a Victor2 Wallac plate reader 
Perkin Elmer (Norworlk, CT, USA). 
2.3 METHODS 
2.3.1 SYNTHESIS OF MONOMERS, INTERMEDIATES AND BLOCK CO-
POLYMERS 
A novel family of N-alkyl imidazole monomers and block copolymers was synthesized to 
produce the pH-responsive domains of the intended nucleic acids nano-carriers. 
2.3.1.1 Synthesis of glycerol methacrylate monomer (GMA) 
Glycidyl methacrylate (10.0 g, 70.4 mmol, 9.34 mL) in H2SO4 (0.5 equiv.) and distilled 
water (420 mL) was stirred at 60ºC for 2 hours. The reaction was monitored by TLC. 
After completion, the mixture was extracted with DCM (3 x 150 mL), washed with brine, 
dried over MgSO4 and then concentrated to give the crude product. Purification by silica 
gel flash chromatography, eluting with EtOAc 100%, provided the monomer (8.50 g, 53.0 
mmol, 75%). 
1
H NMR (400 MHz, DMSO-d6): δ 6.06 (q, J = 1.8 Hz, 1H, CH2=C), 5.68 
(q, J=1.6Hz, 1H, CH2=C), 4.93 (d, J=5.3Hz, 1H, OH-CH2), 4.66 (t, J= 5.7Hz, 1H, 
OHCH2), 4.13-3.99 (m, 2H, CH2OC), 3.70 (m, 1H, CH), 3.38 (m, 2H, CH2OH), 1.89 (s, 
3H, CH3). 
13
C NMR (400 MHz, CDCl3): δ 167.13 (1C), 136.41 (1C), 126.25 (1C), 69.63 
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(1C), 66.54 (1C), 63.02 (1C), 18.39 (1C). ESI-Tof mass spectrometry: expected for m/z 
[M-H]+1 161.08 Da, found 161.26 Da. 
2.3.1.2 Synthesis of 2-(1H-imidazol-1-yl) ethyl-methacrylate monomer (ImEMA) 
 Synthesis of 6-chlorohexyl acetate 
A solution of 6-chloro-1-hexanol (40.0 g, 293 mmol), acetic anhydride (44.0 g, 428 
mmol), Et3N (88.0 g, 870 mmol) and DMAP (3.5 g, 29 mmol) in DCM (100 mL) were 
reacted at 0 °C for 30 minutes and then left to react for an hour at room temperature. The 
volume of DCM was reduced to ~70 mL, then the mixture was poured in a separating 
funnel containing 200 mL of H2O. The aqueous layer was extracted twice with Et2O (2 × 
150 mL) and the organic layers were combined and washed with water (2 × 150 mL) then 
dried over MgSO4. The mixture was filtered and the solvent was removed under reduced 
pressure to give (49.4 g, 276 mmol, 94%) of crude product as pale yellow oil that was 
used for the next step without further purification. 
1
H-NMR (400 MHz, CDCl3): δ 3.98 (t, 
J = 6.6 Hz, 2H, CH2), 3.47 (t, J = 7.1 Hz, 2H, CH2), 1.97 (s, 3H, CH3), 1.71 (m, 2H, CH2), 
1.57 (m, 2H, CH2), 1.40 (m, 2H, CH2), 1.31 (m, 2H, CH2). 
13
C-NMR (101 MHz, CDCl3): 
δ 171.48 (1C) 64.68 (1C), 45.25 (1C), 32.72 (1C), 28.65 (1C), 26.64 (1C), 25.40(1C), 
21.43 (1C). 
 
 Synthesis of 6-(1H-imidazol-1-yl)-hexan-1-ol 
NaH (6.59 g, 276 mmol) was suspended in 200 mL of anhydrous DMSO. Imidazole (18.0 
g, 264 mmol) was added under stirring, at room temperature. The mixture was heated to 
100 °C and then 6-chlorohexyl acetate (49.40 g, 276 mmol) was added. The reaction was 
carried out for 3 hours at 100 °C and monitored by 
1
H NMR in DMSOd6. The reaction 
mixture was added to a solution (500 mL) of K2CO3 (111 g, 803 mmol) at room 
temperature, under vigorous stirring. The product was extracted (5 x 100 mL) with 
EtOAc, washed with basic water and dried over MgSO4. After removal of MgSO4 by 
filtration, the product was recovered from EtOAc solution by rotary evaporation of 
solvent. The product was added to 250 mL of NaOHaq 10% (w/v) and the mixture heated 
to 70 °C and reaction was continued for 2 hours at 70 ºC, until complete deacetylation of 
the alcohol was confirmed by 
1
H NMR. The mixture was then extracted with DCM (3 × 
200 mL) and dried over MgSO4. After removal of MgSO4 by filtration, the solvent was 
removed under reduced pressure and the crude product (21.0 g, 125 mmol, 45%) was 
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used in the next step without further purification. 
1
H NMR (400 MHz, CDCl3): δ 7.39 (s, 
1
H, H-aromatic), 6.96 (s, 
1
H, Haromatic), 6.85 (s, 
1
H, H-aromatic), 3.89 (t, J = 7.1 Hz,  
2H, CH2N), 3.55 (t, J =6.4 Hz, 2H, CH2OH), 1.72 (m, 2H, CH2), 1.49 (m, 2H, CH2), 
1.34 (m, 2H, CH2), 1.25 (m, 2H, CH2).
13
C NMR (101 MHz, DMSO-d6): δ 137.63 (1C), 
128.70 (1C), 119.66 (1C), 61.01 (1C), 46.35 (1C), 32.82 (1C), 31.10 (1C), 26.27 (1C), 
25.42 (1C). ESI-Tof mass spectrometry: expected for m/z [M-H]+1 169.25 Da, found 
169.85 Da. 
 
 Synthesis of 6-(1H-imidazol-1-yl) hexyl methacrylate hydrochloride (ImHeMA) 
6-(1H-imidazol-1-yl)-hexan-1-ol (21 g, 125 mmol) was dissolved in DCM (40 mL) and 
kept at -20 °C. A solution of methacryloyl chloride (26.0 g, 250 mmol, 24.5 mL) in DCM 
(50 mL) was added dropwise under stirring over 1 hour. The reaction was stirred at this 
temperature 30 minutes, then left at room temperature overnight. Purification was carried 
out firstly by precipitation of the monomer in petroleum ether and then by flash column 
chromatography on silica gel eluting with 100% EtOAc and subsequently with 
EtOAc/MeOH 3:1. The volatiles were removed under reduced pressure and the product 
(21.3 g, 78.0 mmol, 63%) stored at -20 °C. 
1
H NMR (400 MHz, CDCl3): δ 9.22 (s, 1H, H-
aromatic), 7.81 (s, 1H, Haromatic), 7.67 (s, 1H, H-aromatic), 5.99 (m, 1H, C=CHH), 5.66 
(m, 1H, C=CHH), 4.19 (t, J = 6.6 Hz, 2H, OCH2), 4.05 (t, J = 7.1 Hz, 2H, NCH2), 1.89 (s, 
3H, CH3), 1.81 (m, 2H, CH2), 1.60 (m, 2H, CH2), 1.35 - 1.23 (m, 4H, CH2). 
13
C NMR 
(101 MHz, DMSO): δ 166.38 (1C), 136.17 (1C), 135.27(1C), 125.78 (1C), 121.85 (1C), 
119.71 (1C), 63.98(1C), 48.18 (1C), 29.46 (1C), 27.83 (1C), 25.16 (1C), 24.70 (1C), 
18.17 (1C). ESI-Tof mass spectrometry: expected for m/z [M-H]+1 238.17 Da, found 
238.92 Da. 
2.3.1.3 Synthesis of Reversible Addiction-Fragmentation Chain Transfer (RAFT) 
Agent / macro Chain Transfer Agent (CTA)  
 Synthesis of 2-cyanopropan-2-yl 2-hydroxyethyl carbonotrithioate 
2-mercaptoethanol (2.80 g, 70.4 mmol) was added dropwise to a suspension of NaH (60% 
w/w, stabilized in mineral oil) (5.0 g, 64 mmol), in Et2O (50 mL) cooled to 5-10°C using 
an ice bath, over 15 minutes. Then, the mixture was further cooled at 0°C and carbon 
disulfide (7.30 g, 96.1 mmol) was added dropwise. After 2 hours, the product was 
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filtered, washed with Et2O and dried overnight under reduced pressure. The product (7.0 
g, 40 mmol, 57%) was used in the next step without further purification. 
1
H NMR (400 MHz, DMSO-d6): δ 4.66 (s, 1H), 3.46 (t, J = 5.6 Hz, 2H), 3.11 (t, J = 7.2 
Hz, 2H). 
 
 Synthesis of 2,2’- (disulfaneyl-bis (carbonothioylsulfanedyl) bis (hydroxyethane) 
Sodium 2- hydroxyethyl carbonotrithioate (7.0 g, 40 mmol) was dissolved in 50 mL of 
deionized water. K3Fe(CN)6 (14.4 g, 44.0 mmol) was slowly added under constant 
stirring. The crude product was isolated by precipitation as yellow viscous oil, dissolved 
in Et2O and dried over MgSO4. The solution was then filtered and the volatiles removed 
under reduced pressure. The yellow residue (5.70 g, 18.5 mmol, 46%) was used for the 
next step without further purification. 
1
H NMR (400 MHz, DMSO-d6): δ 5.20 (s, 2H), 
3.67 (t, J = 6.1 Hz, 4H), 3.49 (t, J = 6.1 Hz, 4H). 
- Synthesis of 2-cyanopropan-2-yl 2-hydroxyethyl carbonotrithioate 
2,2'-(disulfanediylbis(carbonothioylsulfanediyl)]bis(hydroxyethane) (5.70 g, 18.5 mmol) 
and AIBN (4.6 g, 28 mmol) were dissolved in EtOAc (60 mL) and the resultant solution 
was degassed by bubbling N2 over 30 minutes. Then, the mixture was left overnight at 80 
°C, under stirring. The formation of the RAFT agent was monitored by TLC (petroleum 
ether/EtOAc 7:3) and 
1
H-NMR in DMSO-d6. After completion, the solvent was removed 
under reduced pressure and the yellow residue was purified by flash chromatography on 
silica gel, before eluting with petroleum ether/EtOAc 9:1 and then petroleum ether/EtOAc 
7:3. The product (6.50 g, 29.3 mmol, 78%) was obtained as orange insoluble oil. 
1
H NMR 
(400 MHz, DMSO-d6): δ 5.08 (m, 1H, OH), 3.62 (t, J = 5.92 Hz, 2H, CH2), 3.50 (t, J = 
6.60 Hz, 2H, CH2). 13C NMR (100 MHz, CDCl3): δ 217.53 (1C, C=S), 120.13 (1C, C-
N), 60.04 (1C, C-OH), 42.51 (1C, CH2 ), 38.86 (1C, CH2), 26.87 (2C, CH3). 
2.3.1.4 Synthesis of RAFT macro Chain Transfer Agent (CTA) 
 Synthesis of poly[GMA] macro-CTA 
GMA (2.40 g, 14.9 mmol), 2-cyanopropan-2-yl 2-hydroxyethyl carbonotrithioate (94.0 
mg, 0.43 mmol) and AIBN (35.0 mg, 0.21 mmol) in DMF (6 mL) were sealed in a 
Schlenk tube, deoxygenated by argon bubbling for 30 minutes and then heated at 70 ºC. 
The conversion of the polymer was calculated via 
1
H NMR following the decrease of the 
integrals of the monomer vinyl signals (6.03 and 5.68 ppm) using the singlet at 7.95 ppm 
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of the DMF as an internal standard. Polymerization was stopped after 150 minutes at 87% 
conversion. The polymer was purified by precipitation in THF.  
1
H NMR (400 MHz, DMSO-d6): δ 4.90 (broad s, 1H, OH), 4.66 (broad s, 1H, OH), 3.92 
(broad s, 
1
H, CH), 3.69 (broad s, 2H, CH2) , 3.39 (broad, 2H, CH2,), 1.80 (broad s, 2H, 
CH2,), 0.85 (broad d, 3H, CH3).  
The number of the repeat units in a polymer is defined by the Degree of Polymerisation 
(DP) and it is provided by the general formula: 
                                                          DPn = Mn/M0 
where Mn is the number- average molecular weight, whereas M0 is the molecular weight 
of the monomer unit. 
DP [GMA] = 30 
 
 Synthesis of mPEG1.9 kDa macro-CTA 
mPEG-OH1.9 kDa (2.20 g, 1.16 mmol) was dried from water by azeotropic distillation with 
toluene under reduced pressure. mPEG-OH1.9 kDa was dissolved in DCM (30 mL) and 
CPADB (969 mg, 3.47 mmol), DMAP (0.05 g, 0.4 mmol) and DCC (716 mg, 3.47 mmol) 
were added. The mixture was left to react overnight. The precipitate was filtered to 
remove the DCU by-product and the solution added dropwise under stirring to 100 mL of 
petroleum ether to give mPEG1.9 kDa macro-CTA as a pink powder.  
1
H NMR (400 MHz, D2O): d 7.90 (s, 2H, CH-Ar), 7.57 (m, 1H, CH-Ar), 7.40 (m, 2H, 
CH-Ar), 4.26 (t, 2H, CH2O), 3.66 (bs, 204H, PEG repeating unit), 3.38 (s, 3H, OCH3), 
2.72–2.60 (m, 4H, CH2CH2C), 1.94 (s, 3H, CN(C)CH3). 
 
 Synthesis of t-Boc–NH–PEG3.5 kDa macro-CTA 
t-Boc-NH-PEG-OH3.5 kDa (400 mg, 0.114mmol) was dissolved in DCM (10mL) and 
CPADB (0.096 g, 0.350 mmol), DMAP (0.009 g, 0.07 mmol) and DCC (0.071 g, 0.34 
mmol) were added. The mixture was left to react overnight, the resultant precipitate was 
filtered to remove the DCU by-product and the solution added dropwise under stirring to 
100 mL of petroleumether to give t-Boc–NH–PEG3.5 kDa macro-CTA as a pink powder.  
1
H NMR (400 MHz, D2O): d 7.90 (s, 2H, CH-Ar), 7.57 (m, 
1
H, CH-Ar), 7.40 (m, 2H, 
CH-Ar), 4.27 (t, 2H, CH2O), 3.65 (bs, 342H, PEG repeat unit), 2.63 (m, 4H, 
COCH2CH2C), 1.94 (s, 3H, CN(C) CH3), 1.72 (s, 9H, t-Boc).  
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2.3.1.5 Synthesis of diblock co-polymers 
 Synthesis of poly[GMA]30-block-poly[ImHeMA] 
Two syntheses of this block co-polymer, using the same poly[GMA]30 macro-CTA, were 
performed with the aim of obtaining a different degree of polymerization (DP) on the 
poly[ImHeMA] block. 
 
1) ImHeMA (1.30 g, 11.3 mmol), p[GMA]30 macro-CTA (0.60 g, 3.74 mmol of GMA 
repeating units) and AIBN (10.0 mg, 0.06 mmol) in DMF (5 mL) were sealed in a 
Schlenk tube, deoxygenated by argon bubbling for 30 minutes and then heated at 70 ºC. 
The experimental degree of polymerization was calculated by 
1
H-NMR following the 
decrease of the integrals of the monomer vinyl signals (d= 5.99 and 5.66 ppm) using the 
singlet at d= 7.95 ppm of the DMF as an reference. The polymer was obtained by 
precipitation in Et2O. 
1H NMR (400 MHz, MeOD): δ 9.14 (bs, 1H, H-Ar), 7.80 (bs, 1H, H-Ar), 7.65 (bs, 1H, H-
Ar), 4.38 (bs, 2H, CH2OC), 3.99 (bs, 2H+3H, CHCH2+ NCH2), 3.65 (t, 2H, CH2OH), 
2.00 (bs, 2H+ 2H, CH2+CH2), 1.70 (bs, 2H, CH2), 1.48 (bs, 2H, CH2), 0.95 (bs, 6H, 
CH3+CH3). 
DP[ImHeMA] = 42 
 
2) ImHeMA (1.30 g, 11.3 mmol), poly[GMA]30 macro-CTA (0.30 g, 1.87 mmol of GMA 
repeating units) and AIBN (5.00 mg, 0.03 mmol) in DMF (5 mL) were sealed in a 
Schlenk tube, deoxygenated by argon bubbling for 30 minutes and then heated at 70 ºC. 
The experimental degree of polymerization was calculated by 
1
H-NMR following the 
decrease of the integrals of the monomer vinyl signals (d= 5.99 and 5.66 ppm) using the 
singlet at d= 7.95 ppm of the DMF as an internal standard. Polymer was obtained by 
precipitation in THF/petroleum ether 1:1. 
1H NMR (400 MHz, MeOD) δ 9.09 (bs, 1H, H-Ar), 7.75 (bs, 1H, H-Ar), 7.61 (bs, 1H, H-
Ar), 4.33 (bs, 2H, CH2OC), 3.95 (bs, 2H+3H, CHCH2+ NCH2), 3.60 (t, 2H, CH2OH), 
1.95 ((bs, 2H+ 2H, CH2+CH2), 1.69 (bs, 2H, CH2), 1.45 (bs, 2H, CH2), 0.89 (bs, 6H, 
CH3+CH3). 
DP[ImHeMA] = 682.1.5 
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 Synthesis of diblock co-polymer mPEG1.9 kDa-block-poly[ImHeMA]67  
ImHeMA (3.570 g, 12.69 mmol), mPEG1.9 kDa macro-CTA (4) (330 mg, 0.151 mmol) and 
AIBN (12 mg, 0.08 mmol) in DMAC (10 mL) were sealed in a Schlenk tube, 
deoxygenated by argon bubbling for 30 minutes and then heated at 65 °C. The conversion 
of the polymer was calculated via 
1
H NMR following the decrease of the integrals of the 
monomer vinyl signals (5.99 and 5.66 ppm) relative to the broad singlet of the PEG1.9 kDa 
repeat unit protons (3.71 ppm). Polymerization was stopped at 50% of conversion. The 
desired polymer was recovered by precipitation in Et2O–petroleum ether (1 : 1 v/v) and 
used for the next reaction as a macro-chain-transfer agent (CTA) without further 
purification.  
1
H NMR (400 MHz, D2O): d 8.82 (bs, 
1
H, H-Ar), 7.51 (bs, 2H, H-Ar), 4.32 (bs, 2H, 
CH2OC), 4.04 (bs, 2H, NCH2), 3.71 (bs, 204H, PEG repeat unit), 3.66 (t, 2H, CH2O), 
3.35 (s, 3H, CH3), 2.00 (bs, 2H, CH2), 1.70 (bs, 3H, CH3). 
 
 Synthesis of diblock co-polymer t -Boc-NH-PEG3.5 kDa-block-poly[ImHeMA]20 (8). 
ImHeMA (910 mg, 3.30 mmol), t -Boc-PEG3.5 kDa macroCTA (150 mg, 0.04 mmol) and 
AIBN (3.00 mg, 0.02 mmol) in DMAC (5 mL) were sealed in a Schlenk tube, 
deoxygenated by argon bubbling for 30 minutes and then heated at 65 °C. The conversion 
of the polymer was calculated via 
1
H NMR following the decrease of the integrals of the 
monomer vinyl signals (5.99 and 5.66 ppm) relative to the broad singlet of the t-Boc-
PEG3.5kDa repeat unit protons (3.71 ppm). Polymerization was stopped at 54% of 
conversion. Polymers were obtained by precipitation in Et2O–petroleum ether (1 : 1 v/v) 
and used in the next reaction as a macro-CTA.  
1
H NMR (400 MHz, D2O); d 8.57 (bs, 1H, H-Ar), 7.43 (bs, 2H, H-Ar), 4.20 (bs, 2H, 
CH2OC), 4.00 (bs, 2H, NCH2), 3.71 (bs, 342H, PEG repeat unit), 2.23–1.84 (bs, 2H, 
CH2), 1.65 (s, 9H, t-Boc), 1.44–1.28, 1.02–0.86 (bs, 2H, CH2). 
2.3.1.6 Synthesis of tryblock co-polymers 
 Synthesis of triblock co-polymer mPEG2kDa-poly[GMA]-block-poly[ImHeMA] 
through pyridyl intermediate conjugate 
1) The diblock copolymer poly[GMA]-block-poly[ImHeMA] underwent aminolysis 
reaction in order to cleavage the RAFT agent from the polymer and obtain a free thiol 
group able to react with mPEG-SH2kDa (192). 100 mg of block copolymer (6.48 × 10
-3 
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mmol) were solubilized in 500 μL of MeOH and the mixture was deoxygenated by N2 
bubbling for 20 minutes. 17.13 mg of 2-2’-dithiodipyridine (0.0778 mmol) and 5.30 µL 
of propylamine (1171.79 mM) were added under stirring to the polymer solution to obtain 
a final molar ratio of 2,2'-dithiodipyridine/propylamine/polymer of 12:10:1. The reaction 
was left under stirring overnight.  
After solvent removal under reduced pressure, the polymer was firstly solubilized in 2 mL 
of water acidified at pH 3 adding 1M HCl. Then the pH was led to 12 adding 1 M NaOH 
to induce polymer fractionated precipitation. Diblock copolymer pirydil intermediate 
conjugate activation yield (%) was determined by 
1
H NMR and determining the amount 
of thiopyridine conjugated through a colorimetric assay. In detail, 4.8 mg of polymer 
were solubilized in 750 μL of MeOH (0.415 mM) in presence of the reducing agent DL-
dithiothreitol 0.1 M. The released 2-thiopyridine was quantified by spectrophotometric 
analysis at λ= 370 nm. 
 
2) During the second step of the synthesis, the above activated diblock copolymer (76.6 
mg) was solubilized in 1.7 mL of MeOH (4.96×10
-3 
mM). mPEG-SH2kDa (36.98 mg, 
0.0198
 
mM) and Et3N (6.9 µL, 0.0496 mM) were added to the mixture to obtain the final 
molar ratio mPEG-SH 1.9kDa /Et3N/ poly[GMA]-block-p[ImHeMA]-thiopyridine of 
4:10:1. The mixture was deoxygenated by N2 bubbling for 20 minutes and was left 
reacting for 12 hours under stirring. The solvent was removed under reduced pressure and 
the crude product was solubilized in water acidified at pH 3 adding HCl 1M. Then the pH 
was led to 12 adding 1 M NaOH obtaining a colloidal opalescent suspension consisting in 
the partially soluble product mPEG2kDa-block-poly[GMA]-block-poly[ImHeMA]. The 
unreacted mPEG-SH2kDa was eliminated by 24 hours dialysis with float a-lyzer
® 
membrane cut off 100 kDa against water pH 12. The triblock copolymer was obtained by 
lyophilization of the purified colloidal suspension and the yield of mPEG-SH2kDa 
conjugation was determined by 
1
H NMR amalysis.  

 Synthesis of triblock co-polymer mPEG2 kDa-block-poly[ImHeMA]67-block-
poly[GMA]36 
Diblock co-polymer mPEG2kDa-block-poly[ImHeMA]67 macro-CTA (2.18 g, 0.11 mmol), 
GMA (1.13 g, 7.08 mmol) and AIBN (9.6 mg, 0.06 mmol) in DMAC (5 mL) were sealed 
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in a Schlenk tube, deoxygenated by argon bubbling for 30 minutes and then heated at 65 
°C. The conversion of the polymer was calculated via 
1
H NMR following the decrease of 
the integrals of the monomer vinyl signals (6.35 and 5.68 ppm) using the broad singlet 
(8.82 ppm) of the aromatic repeat unit protons of the imidazole ring as an internal 
standard. Polymerization was stopped at 50% conversion and the desired material 
obtained by precipitation in Et2O–petroleum ether (1:1 v/v). The dithioester end-group 
was removed by reaction with AIBN (mPEG2kDa-block-poly[ImHeMA]67-block-
poly[GMA]36/AIBN = 1/20) at 80 °C in DMSO for 3 hours and the resulting polymer 
recovered by repeated precipitations in THF.  
1
H NMR (400 MHz, D2O): d 7.64 (bs, 
1
H, H-Ar), 7.13 (bs, 1H, H-Ar), 6.88 (bs, 1H, H-
Ar), 3.91 (bs, 2H, CH2OC), 3.83 (bs, 2H, NCH2), 3.66 (t, 2H, CH2O), 3.50 (bs, 204H, 
PEG repeat unit), 3.35 (bs, 3H + 2H, CH3 + CH2), 1.63 (bs, 2H, CH2), 1.48 (bs, 2H, CH2), 
1.29 (bs, 3H, CH3), 1.19 (bs, 3H, CH3). 
 
 Synthesis of triblock co-polymers t-Boc-NH-PEG3.5kDa-block-poly[ImHeMA]20-
block-poly[GMA]58. 
Block copolymer macroCTA t-boc-NH-PEG3.5kDa-block-poly[ImHeMA]20 (586 mg, 0.04 
mmol), GMA (370 mg, 2.43 mmol) and AIBN (164 mg, 0.02 mmol) in DMAC (5 mL) 
were sealed in a Schlenk tube, deoxygenated by argon bubbling for 30 minutes and then 
heated at 65 °C. The conversion of the polymer was calculated via 
1
H NMR following the 
decreasing of the integrals of the monomer vinyl signals (6.35 and 5.68 ppm) using the 
broad singlet (8.57 ppm) of the aromatic repeat unit protons of the imidazole ring as 
internal standard. Polymerization was stopped at 60% conversion. Polymers were 
obtained by precipitation in Et2O–petroleum ether (1:1 v/v). The dithioester end-group of 
the block copolymer was removed by reaction with AIBN (molar ratio polymer (t-boc-
NH-PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58/AIBN = 1/20) at 80°C in 
DMSO for 3 hours and the polymer was recovered by precipitation in THF.  
1
H NMR (400 MHz, D2O): d 8.32 (bs, 1H, H-Ar), 7.37 (bs, 2H, H-Ar), 4.15 (bs, 4H, CH2 
+ CH2), 3.99 (bs, 4H, CH2 + CH2), 3.71(bs, 342H, PEG repeat unit), 2.30–1.93 (bs, 2H + 
2H, CH2 + CH2), 1.70 (s, 9H, t-Boc), 1.20–0.83 (bs, 6H, CH3 + CH3). 
 Synthesis of folate-terminated triblock co-polymers -Folate-NH-PEG3.5 kDa-
block-poly[ImHeMA]20-block-poly[GMA]58. 
 Materials and Methods     
  
65 
 
The conjugation of Folic Acid to the triblock co-polymer t-boc-PEG3.5 kDa-block-
poly[ImHeMA]20-block-poly[GMA]58 was carried out following protocols reported 
elsewhere by three steps reaction (193, 194). 
 
1) t-boc-PEG3.5 kDa-block-poly[ImHeMA]20-block-poly[GMA]58  (20 mg, 0.0011 mmol) 
was dissolved in a 1 : 1 (v/v) CF3COOH–DCM mixture (1 mL/1 mL) at room 
temperature. The solution was stirred at room temperature for 2 hours and then TFA and 
DCM were removed by evaporation under reduced pressure. The reaction was monitored 
by 
1
H NMR in MeOD by following the disappearance of the t-Boc protons at 1.44 ppm. 
The reaction yielded NH2-PEG3.5 kDa-block-poly[ImHeMA]20-block-poly[GMA]58  
1
H 
NMR (400 MHz, MeOD): d 9.02 (bs, 1H, H-Ar), 7.70 (bs, 1H, H-Ar), 7.61 (bs, 1H, H-
Ar), 4.48 (bs, 4H, CH2 + CH2), 4.29 (bs, 3H, CH2 + CH), 3.91 (bs, 2H, CH2), 3.64 (bs, 
342H, PEG repeat unit), 1.94 (bs, 2H + 2H, CH2 + CH2), 1.42–0.93 (bs, 6H, CH3 + CH3). 
  
2) folic acid (100.0 mg, 0.226 mmol) was dissolved in anhydrous DMSO (2 mL). NHS 
(26 mg, 0.23 mmol) and DCC (47 mg, 0.23 mmol) were added to the folic acid solution 
(folic acid/NHS/DCC 1:1:1 molar ratio). The reaction was carried out overnight at room 
temperature in the dark. N-Hydroxysuccinimidyl-ester-activated folic acid was 
precipitated by dropwise addition to 40 mL of cold Et2O under stirring. The obtained 
yellow precipitate was washed with Et2O (3 × 30 mL) and then dried under vacuum. 
 
3) NH2-PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58 was dissolved in 
anhydrous DMSO and N-hydroxysuccinimidyl-ester-activated folic acid (1.8 mg, 0.0034 
mmol) was added to the polymer solution (1 : 4 polymer/activated folate molar ratio). The 
reaction was performed overnight under stirring at room temperature in the dark. The 
product was recovered by dropwise precipitation in Et2O and dried after solvent removal. 
The resulting dried product was dissolved in 2 mL high purity water (resistivity > 18 
MΩ); the solution was acidified by 5 M HCl addition in order to precipitate the free folic 
acid (which is not soluble under acidic conditions). The polymer aquous solution was 
recovered by centrifugation (5 minutes, 14 000 rpm) and then dialyzed (MWCO 3500 Da) 
and water was removed by lyophilization.  
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Folate-PEG3.5-block-poly(ImHeMA)20-block-poly[GMA]58 was characterized by spectro-
photometric methods. The conjugate was dissolved in high purity water, then diluted to 
0.5 mg/mL in 20 mM phosphate buffer, 150 mM NaCl, at pH 7.0 and the absorbance at 
363 nm was measured to quantify the folate concentration in the modified polymer. The 
folate concentration was derived using the εM of folic acid reported in the literature (6197 
mol
-1
cm
-1
) (195) The polymer solution was also diluted in water and tested by the iodine 
assay in order to determine the PEG concentration based on a calibration curve obtained 
with PEG (196). The quantification tests showed a conjugation yield of folic acid of 96% 
and thus a 1 : 1 folate/polymer molar ratio. 
The presence of residual free folic acid in the synthesized conjugate was tested by reverse 
phase high-performance liquid chromatography (RP-HPLC). The system was equipped  
with a RP-C18 column eluted with 10 mM ammonium acetate buffer, pH 6.5 (eluent A) 
and acetonitrile (eluent B), in a gradient mode from 10 to 40% of eluent B in 40 minutes 
(197). The UV detector was set to 363 nm. Free folic acid was not detected in the 
chromatogram confirming the high degree of purity of the conjugate folate-PEG3.5 kDa-
block-poly[ImHeMA]20-block-poly[GMA]58. 
2.3.2 POLYMER TITRATION AND TURBIDIMETRY ASSAYS 
2.3.2.1 Titration assay of poly[GMA]30-block-poly[ImHeMA] 
Apparent pKa values of poly[GMA]30-block-poly[ImHeMA] (1) and (2) were determined 
from mid-points between titration start and equivalence points, using first derivatives of 
the titration curves to aid in measurement of equivalence points. Poly[GMA]30-block-
poly[ImHeMA] (1) and (2) were dissolved in deionized water (1 mg/ mL solution). The 
titration was performed by adding 10 μL aliquots of 0.1 M NaOH under stirring, starting 
from pH ~3 until pH ~11. The back titration was started from the pH value reached at the 
end of the titration by adding 10 μL aliquots of 0.1 M HCl until pH 3 was achieved. 
Variations of pH were registered after each addition. 
2.3.2.2 Turbidimetry assay of poly[GMA]30-block-poly[ImHeMA] 
To a highly dilute polymer solutions 10 L aliquots 0.1 M NaOH were added and the 
intensity of light scattered by the dispersed particles of aggregated polymer was plotted as 
function of the amount of precipitan. Scattered light was measured by Uv-Vis 
spectroscopy. Poly[GMA]30-block-poly[ImHeMA] (1) and (2) (1 mg/mL) was dissolved 
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in 150 mM aquous NaCl. The value of turbidity (%T) registered at 500 nm was found to 
be 100% at pH 3, then, the NaOH was added until ~pH 10, registering the % T at each 
addition. 
2.3.2.3 Titration assay of mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 
Polymer mPEG1.9 kDa-block-poly[ImHeMA]67-block-poly[GMA]36 (20 mg) was dissolved 
in 150 mM aquous NaCl (1 mg/mL). Potentiometric titration was carried out by adding 
10 μL aliquots of 0.1 M NaOH under stirring over a pH range of 3-10. The back titration 
was started from the pH value reached at the end of the titration by adding 10 μL aliquots 
of 0.1 M HCl until pH 3 was achieved. Variations of pH were recorded after each 
addition. 
2.3.2.4 Turbidimetry assay of mPEG1.9 kDa-block-poly[ImHeMA]68 and mPEG1.9 kDa-
block-poly[ImHeMA]67-block-poly[GMA]36  
mPEG1.9kDa-block-poly[ImHeMA]68 and mPEG1.9kDa-block-poly[ImHeMA]67-block-
poly[GMA]36 (1 mg/mL) were dissolved in 150 mM aqueous NaCl. The value of turbidity 
(T, %) was registered at 500 nm and was found to be 100% at pH 3. Transmittance was 
recorded after each addition of 10 L aliquots of 0.1 M NaOH. 
2.3.3 POLYMERSOME ASSEMBLY  
Polymersomes formulations were prepared using: a) PEG1.9kDa-block-poly[ImHeMA]67-
block-poly[GMA]36; b) different PEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36/ 
PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58 mixtures [99:1, 95:5, 90:10 
w/w%]; c) 90:5:5 w/w % PEG1.9kDa-boly-poly[ImHeMA]67-block-
poly[GMA]36/PEG3.5kDa-block-poly[ImHeMA]20-boly-poly[GMA]58 / Folate-PEG3.5kDa-
block-poly(ImHeMA)20-block-poly[GMA]58 mixture following a protocol adapted from 
prior literature (166, 198). 
Polymer solutions (1 mg/mL) were prepared in 20 mM phosphate buffer, 150 mM NaCl, 
at pH 5 and the pH was increased to 6.5 and pH 7.4 by addition of suitable aliquots of 0.1 
M NaOH solution. The slow increase of the pH induced the self-assembly into 
polymersomes.  
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The resulting colloidal dispersions were analyzed by DLS at 25°C to determine the mean 
size ± standard deviation (SD). ζ-potential measurements were performed after diluting 
samples 10-fold in high purity mQ water. 
2.3.4. KINETIC STABILITY STUDIES 
Polymersomes formulations obtained with mPEG1.9kDa-block-poly[ImHeMA]67-block-
poly[GMA]36/ t-boc-PEG3.5kDa-block-poly[ImHeMA]20-b-p[GMA]58 mixtures [99:1, 95:5, 
90:10 w/w%] (1 mg/mL) generated in 20 mM phosphate, 150 mM NaCl, at pH 5, 6.5 and 
7.4 were tested for stability over time by Dynamic Light Scattering (DLS) at scheduled 
intervals up to 5  hours at 37°C.  
 
Polymersome formulations obtained with 90:10 w/w% of mPEG1900-block-
poly[ImHeMA]-block-poly[GMA]/ Folate-PEG3.5kDa-block-poly[ImHeMA]20-block-
poly[GMA]58, 90:5:5 w/w% of mPEG1.9kDa-block-poly[ImHeMA]-block-poly[GMA]/ t-
boc-PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58 / Folate-PEG3.5kDa-block-poly 
[ImHeMA]20-block-poly[GMA]58 and 90:10 w/w% of mPEG1.9kDa-block-poly[ImHeMA]-
block-poly[GMA]/ t-boc-PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58 (1 
mg/mL) generated in 20 mM phosphate, 150 mM NaCl, pH 7.4, were incubated at 37 °C 
and analyzed by dynamic light-scattering (DLS) at scheduled time intervals. The choice 
of using the 90:5:5 w/w% ratio of mPEG1.9kDa-block-poly[ImHeMA]-block-poly[GMA]/ 
t-boc-PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58 / Folate-PEG3.5kDa-block-
poly [ImHeMA]20-block-poly[GMA]58 was determined by the preliminary stability study 
performed with dsDNA loaded polymersomes.  
 
The 90:10 w/w% mPEG1.9kDa-block-poly[ImHeMA]-block-poly[GMA]/ t-boc-PEG3.5kDa-
block-poly[ImHeMA]20-block-poly[GMA]58 and 90:5:5 w/w % mPEG1.9kDa-block-
poly[ImHeMA]-block-poly[GMA] / t-boc-PEG3.5kDa-block-poly[ImHeMA]20-block-
poly[GMA]58/Folate-PEG3.5kDa-block-poly(ImHeMA)20-block-poly[GMA]58 formulations 
(1 mg/mL) were incubated in 20 mM phosphate, 150 mM NaCl, pH 7.4, in the presence 
of 10% v/v of fetal bovine serum for 8 hours at 37 ºC. At scheduled times, the samples 
were analyzed by DLS. 
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2.3.5 BLOCK CO-POLYMER pH RESPONSE  
mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 and t-boc-NH-PEG3.5kDa-block-
poly[ImHeMA]20-block-poly[GMA]58 solutions (1 mg/mL) were prepared in D2O, 150 
mM NaCl. The pH was set by adding aliquots (5 L) of NaOD (100 mM in D2O). 
Analysis was carried out by 
1
H-NMR (400 MHz or 500 MHz), 1024 or 256 scans for 
each sample submitted. 
pH responsiveness of polymersomes prepared according the pH-switching method 
described above with mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 was 
evaluated also through DLS analysis. Polymersomes were prepared in phosphate saline 
buffer 20 mM NaCl 150 mM pH 7.4 and the formulation was splitted in three parts. The 
pH of the three formulations was corrected to reach the values of 7.4, 6.5 and 5. The size 
and polydisperity index (PDI) of vesicles was collected up to 96 hours at scheduled times. 
2.3.6 POLYMER CRITICAL AGGREGATION CONCENTRATION (CAC)  
The CAC of mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 was determined 
using pyrene as a fluorescent probe. The polymer vesicle dispersion was prepared as with 
the method described above in 20 mM phosphate, 150 mM NaCl, pH 7.4 was diluted with 
the same buffer yielding different polymer concentrations ranging from 0.2 to 100 μg/mL. 
Pyrene (5 μL) dissolved in acetone (0.18 mM) was added to 0.75 mL of the polymer 
dispersions. The samples were incubated overnight at room temperature in the dark to 
allow equilibration. Prior to the measurements, the dispersions were incubated at 37 °C 
for 15 minutes. The excitation spectra of pyrene were recorded at 37 °C from 300 to 360 
nm with the emission wavelength set at 390 nm. The excitation and emission band slits 
were 4 and 2 nm, respectively. The intensity ratio of I338/I333 was plotted versus the 
logarithmic concentration of the polymer to determine the CAC. 
2.3.7 POLYMERSOMES LABELLING WITH FLUORESCENT PROBES 
Polymersomes were loaded with 5(6)carboxyfluorescein (hydrophilic probe) and N-
(fluorescein-5-thiocarbamoyl)-1,2-dihexadecanoyl-snglycero-3-phospho-ethanol-amine 
triethyl-ammonium salt (fluorescein-DHPE) used as hydrophilic and hydrophobic probes, 
respectivelly. A mixture of 90:10 w/w% mPEG1.9kDa-block-poly[ImHeMA]67-block-
poly[GMA]36 / t-boc-PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58 was 
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prepared at 1 mg/mL in 20 mM phosphate, 150 mM NaCl, pH 5 and 1 mL solution was 
added of 0.1 mg of 5(6)carboxyfluorescein or 2 μL of 5 mg/mL fluorescein-DHPE in 
chloroform. The pH of the solutions was increased to 7.4 by stepwise addition of 0.1 M 
NaOH to induce the polymersome assembly and excess 5(6)carboxyfluorescein and 
fluorescein-DHPE were removed by dialysis against 20 mM phosphate,150 mM NaCl, 
pH 7.4, for 24 hours using a regenerated cellulose dialysis membrane with 3500 Da MW 
Cut-Off. The dialysis method was validated by treating the 5(6)-carboxyfluorescein or 
fluorescein-DHPE in polymer-free solutions at the same concentration used for the 
loading procedure. The validation test showed that after 24 hours, complete release of the 
fluorescent probes occurred. After dialysis, the polymer formulations were analysed with 
a spectrofluorimeter (λex 490 nm and λem 520 nm) and 5(6)carboxyfluorescein and 
fluorescein-DHPE were quantified referring to a standard calibration curve. The results of 
the analysis were reported in terms of Loading Capacity mol% (LC% = moles of loaded 
fluorophore / moles of polymer %) and Encapsulation Efficiency wt% (EC%= loaded 
fluorophore /initial fluorophore concentration).  
2.3.8 ELECTROPHORETIC MOBILITY SHIFT ASSAY 
dsDNA sequence used for the loadind studies (Section 3.1.2.14) was used to study the 
retardation induced by association with the triblock copolymers on a gel electrophoretic 
setting. The study was performed with mPEG1.9kDa-block-poly[ImHeMA]67-block-
poly[GMA]36  at pH 5 in 0.08 M citrate buffer and in 20 mM phosphate, 150 mM NaCl, 
pH 7.4. Polyacrylamide gel was prepared at 12% w/v concentration of acrylamide 
monomer, according to the following recipy: 3 mL of 30% w/v Acrylamide/Bis-
acrylamide in water solution, 1.5 mL 0,08 M citrate buffer pH 5, 54 μL of ammonium 
persulfate 10% w/v in water, 5 μL of N,N,N′,N′-Tetramethylethylenediamine (TEMED, 
0.775 g/mL) and 3 mL of deionized water. All the reagents were mixed in the water 
volume under magnetic stirring. 3 μL of a solution containing 2.9 × 10-10 mol of dsDNA 
were mixed to 7 microliters of a mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 
solution at increasing concentration in order to prepare the mixtures at different N/P ratios 
(0.1:1, 0.5:1, 1:1, 2:1, 3:1, 5:1, 20:1). The N/P ratio was calculated assuming the 
mPEG1.9ka-block-poly[ImHeMA]67-block-poly[GMA]36 nitrogen content to be 5.26 × 10
-5
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Mols/mg. The samples prepared at different N/P ratio were loaded into the wells of the 
polyacrylamide gel.  
The first well was loaded with 6 microliters of a low range DNA-Ladder dissolved in 10 
mM Tris-HCl pH 7.6, 1 mM EDTA, concentration 0.5 mg DNA/ml and composed of 11 
chromatography-purified individual DNA fragments (from 10 to 300 base pairs). The 
second well was loaded with 3 microliters of the above dsDNA solution and a third one 
with 7 microliters of the polymer at the same concentration used to generate the different 
N/P ratios. All the volumes inside the wells were adjusted to the total volume of 10 μL 
with the 0,08 M citrate buffer pH 5 used to prepare and run the gel. To all the wells, 5 μL 
of gel loading buffer, containing bromophenol blue, xylene cyanol FF and glycerol in 
water, were added. The gel was run at 100 mV for 1 hour. After the gel was run, it was 
dipped in a staining medium containing the DNA intercalating agent Gel Red® 10000X 
diluted 3300 fold to make a 3X staining solution in H2O for 1 hour. The gel was imaged 
with the UV-Transilluminator. The same gel electrophoresis assay was performed at 
neutral conditions using 45 mM Tris-borate/1 mM EDTA buffer pH 7.4. 
2.3.9 DNA LOADING STUDIES 
A dsDNA, 19-bp oligonucleotide, sequence was used as a model to simulate ds-siRNA. 
The sequences chosen for the experiment were GAGATGTAAGGCCAGGCCG and its 
complementary strand. When hybridized, the dsDNA had a total molecular weight of 11.5 
kDa. dsDNA was loaded into polymer dispersions at different N/P feed ratios, where N is 
the number of imidazole groups of the triblock copolymer and P is the number of 
phosphate groups of DNA. N/P feed ratios of 10:1 and 1:1 were investigated. To a 
solution of 90:10 w/w% of mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 / t-
boc-PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58  mixture (1 mg/mL) in 20 
mM phosphate, 150 mM NaCl pH 27 or 265 μL of dsDNA solution (100 μM in 10 mM 
TRIS HCl, 50 mM NaCl, 1 mM EDTA, pH 7.8) were added to achieve 10:1 N/P and 1:1 
N/P feed ratio, respectively. The polymer was induced to self-assemble by increasing the 
pH to 7.4. The assembly into colloidal nanostructures was confirmed by DLS as reported 
above. Non encapsulated dsDNA was removed from polymersome assemblies using a 
Float-A-lyzer® system equipped with a 100 kDa MW cut-off membrane. The dialysis of 
dsDNA-loaded polymersomes was performed for 24 hours against 20 mM phosphate, 150 
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mM NaCl, pH 7.4. The purification method was validated by introducing in the device 
free dsDNA or empty polymersomes at the same concentration used for the loading test. 
dsDNA was completely removed by dialysis in 24 hours while the polymer was totally 
retained.  
z-potential of polymersome formulations loaded with dsDNA diluted 10 times in high 
purity mQ water was determined.  
dsDNA loading quantification within the polymer assemblies was performed by UV-vis 
spectroscopy. The dsDNA loading polymersome dispersion was diluted 1:5 in 20 mM 
phosphate, 0.15 M NaCl at pH 7.5, the pH was decreased to 5 by 1 M HCl addition in 
order to disassemble the polymers and eliminate the contribution of larger particle 
scattering and the solutions underwent UV-Vis spectroscopic analysis at 263 nm.  
2.3.10 DNA RELEASE STUDIES 
DNA release studies were performed in 20 mM phosphate, 150 mM NaCl at pH 7.4 and 
5.0. Two (1 mg/mL) dsDNA-loaded 90:10 w/w % mPEG1.9kDa-block-poly[ImHeMA]67-
block-poly[GMA]36 / t-boc-PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58 based 
formulation samples in PBS pH 7.4 were prepared with a 1:1 N/P feed ratio. 1 mL of the 
first sample was transferred in a Float-A-lyzer® 100 kDa MW Cut-Off and dialyzed 
against 20 mM phosphate, 150 mM NaCl at pH 7.4. One mL of the second sample was 
acidified to pH 5 with 0.1 N HCl and dialyzed against in a Float-A-lyzer® 100 kDa MW 
Cut-Off 20 mM phosphate, 150 mM NaCl at pH 5. The release study was performed at 37 
°C. At scheduled times 100 microliters of each sample were withdrawn, adequately 
diluted with 20 mM phosphate, 150 mM NaCl pH 5 and spectrophotometrically 
monitored at 263 nm for DNA concentration. The variation of concentration was plotted 
versus time. 
2.3.11 siRNA LOADING STUDIES 
Because of ds-siRNA sensitivity to degradation by RNAses, all the buffers employed for 
the procedure were autoclaved before use to degrade RNAses traces and polymer 
solutions were filtered using 0.22 μm filters before polymersomes assembling. 
Polymeric vesicles were loaded with ds-siRNA luciferase GL3 duplex with a specific 
sequence for the inhibition of the intracellular luciferase synthesis. To a solution of a 
90:10 w/w % mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 / t-boc-PEG3.5kDa-
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block-poly[ImHeMA]20-block-poly[GMA]58 mixture (1 mg/mL in 20 mM phosphate, 150 
mM NaCl, pH 5) 70 μL of ds-siRNA 100 μM in 60 mM KCl, 0.2 mM MgCl2, 6 mM 
HEPES-pH 7.5 were added. The co-polymer was induced to self-assemble by increasing 
the mixture pH to 7.4. The generation of colloidal nanostructures was confirmed by DLS 
analysis. Non-encapsulated ds-siRNA was removed from polymeric assemblies using a 
Float-A-lyzer® system equipped with a 100 kDa MW cut-off membrane. The dialysis of 
ds-siRNA loaded polymersomes was performed for 24 hours using 20 mM phosphate, 
150 mM NaCl, pH 7.4 as releasing buffer. 
The intercalating reagent Quant-iT™ RiboGreen® was used to quantify the ds-siRNA 
encapsulation yield in polymersomes. The assay was performed on a black 96 wells plate 
transferring 170 μL of the ds-siRNA loaded polymersome suspensions per well at the two 
different concentrations of 1 mg/mL and 0.5 mg/mL in PBS pH 7.4. 10 μL of 0.5 M HCl 
were added to the polymer suspensions in the wells followed by 10 μL of the intercalating 
reagent solution. Three minutes after the acidification, the pH was increased to 7.4 with 
10 μL of 0.5 M NaOH to allow for intercalation. The samples underwent fluorescence 
analysis (λex 485 nm/ λem 530 nm) that was performed using the microplate reader. The 
ds-siRNA concentration was derived by substracting the emission intensity of the 
polymer contribution associated to ds-siRNA free polymersomes from the emission 
intensity associated to the ds-siRNA loaded polymersomes. A calibration curve with 
known dilutions of siRNA and same samples treatment was prepared in RNAses free 10 
mM Tris-HCl, 1 mM EDTA, pH 7.5. 
2.3.12 TRANSMISSION ELECTRON MICROSCOPY (TEM) 
dsDNA-free and dsDNA-loaded 90:10 w/w % mPEG1.9kDa-block-poly[ImHeMA]67-
block-poly[GMA]36 / t-boc-PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58 
polymersomes were prepared according to the previously described protocol with final 
polymer concentrations of 2 mg/mL in 20 mM phosphate, 150 mM NaCl, pH 7.4 and 
analyzed by TEM. Samples were observed in negative staining mode, using small copper 
grid (400 mesh), covered by a "holey film" carbon layer. Samples were deposited on the 
grids and the contrast staining was performed with a uranyl acetate solution 1% w/v. 
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2.3.13 CELL CULTURE  
KB cells (human cervical carcinoma) were grown at 37 °C, in 5% CO2 atmosphere, using 
folic acid free DMEM medium supplemented with 15% FBS, 2 mM L-glutamine, 100 
IU/mL penicillin, 100 μg/mL streptomycin and 0.25 μg/mL of amphotericin B (Sigma-
Aldrich). MCF7 (human breast adenocarcinoma) were grown at 37 °C, in 5% CO2 
atmosphere, using RPMI-1640 medium supplemented with 10% FBS, 100 IU/mL 
penicillin, 100 μg/mL streptomycin and 0.25 μg/mL of amphotericin B. B16-F10-luc-G5 
from mouse melanoma were grown at 37 °C, in 5% CO2 atmosphere, using DMEM 
medium supplemented with 10% FBS, 2 mM L-glutamine, 100 IU/mL penicillin, 100 
μg/mL streptomycin. These cells were transfected with the North American Firefly 
Luciferase gene whose expression is under the control of SV40 promoter. 
2.3.14 FOLATE RECEPTOR EXPRESSION IN KB AND MCF7 CELL LINE 
KB and MCF7 cells were seeded in 25 cm
2
 cell colture flasks at a density of 5 × 10
5 
cells/well and grown for two days at 37°C and 5% CO2. Medium was then removed, cells 
washed with PBS and detached from the flasks by scraping. Cells were pipetted and 
tranferred in tubes for cytometric analysis and centrifuged at 1000 rpm for 3 minutes. The 
supernatant was removed leaving a cell pellet in a minimal volume (100 μL) of PBS. Two 
μl of primary antibody for folate receptor detection in PBS (1 mg/mL, 804-439-R100 - 
Folate receptor alpha, monoclonal Antibody from mouse) were added to cell samples and 
incubated at room temperature for 5 minutes. Then, 2 μL of secondary antibody in PBS  
(1 mg/mL, Alexa fluor 488 labeled α-mouse monoclonal antibody) were added to cell 
samples and incubated at room temperature in the dark for 5 minutes. After incubation, 
samples were centrifuged at 1000 rpm for 5 minutes and repeatedly washed with PBS to 
remove the secondary antibody excess and resuspended in 300 μL of PBS buffer. 
Untreated cells were also prepared while the controls were prepared by treating the cells 
with the secondary antibody only. Samples were analyzed by flow cytometry using λex 
and λem of 499/519 nm respectively. 
 Materials and Methods     
  
75 
 
2.3.15 mPEG1.9KDA-BLOCK-POLY[IMHEMA]67-BLOCK-POLY[GMA]36 AND 
FOLATE-PEG3.5KDA-BLOCK-POLY[IMHEMA]20-BLOCK-POLY[GMA]58 
BIOCOMPATIBILITY STUDY  
The effects of mPEG1.9kDa-block-poly[ImHeMA]67-boly-poly[GMA]36 and Folate-
PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58 were evaluated by MTS (3-(4,5-
dimethylthiazol-2-yl)- 5- (3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
inner salt) cell viability test using B16-F10-luc-G5 cells. Cell viability was detected after 
24 and 48 hours. Cells were seeded in 96-wells plate at density of 10000 cell/well and 
treated with increasing concentrations [1, 2 and 3 mg/mL] of the two triblock co-
polymers. After the established incubation times, 10 μL of a mixture 20:1 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-phenyl)-2H-tetrazolium/ 
Phenazine methosulfate (MTS/PMS; 2 mg/mL MTS, 0.92 mg/mL PMS) were added to 
each well and the plate incubated for 2 hours at 37°C. Then, the medium was removed 
and DMSO was added to each well and the plate was shaken for 4 hours. The absorbance 
was measured at 492 nm by microplate reader. The cytotoxicity was expressed as the 
percentage of cell viability refers to untreated cells. 
2.3.16 POLYMER HEMOLYTIC ACTIVITY 
Heparinized blood from mices was diluted with PBS at pH 7.4 to 2% w/v hematocrit in a 
15 mL tube. The tube was gently shaken and centrifuged at 3000 rpm for 10 minutes at 
4°C for three times, removing the supernatant after each centrifugation. The pellet was 
used to prepare 3 red blood cell (RBCs) suspensions in three phosphate saline buffers at 
pH 7.4, 6.5, 5.5. mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 was dissolved 
in PBS at pH 7.4, 6.5, 5.5 at concentrations 0.5, 1, 2, 3 mg/mL and 100 μL of each 
dilution were transferred in a 96 multiwell plate. 80 kDa Dextran was used as negative 
control, whereas polyethylenimine (PEI) was used as positive control. 1% w/v Triton X-
100 was employed as reference for 100% hemolysis. 100 µl of the RBCs dilutions at one 
of the three different pH values were added to each sample prepared in the well with the 
corresponding pH and the plate was incubated at 37°C for 1 hour. Afterwards, the plate 
was centrifuged at 3000 rpm for 10 minutes at room temperature and the supernatant of 
each well was transferred in a second plate. The absorbance at 570 nm was measure with 
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a microplate reader and the absorbance was correlated to the hemolitic properties of the 
polymer at different pH conditions. 
2.3.17 CELLULAR UPTAKE STUDIES  
2.3.17.1 Fluorescence spectroscopy on cell lisates  
KB and MCF7 cells were seeded in a 12 well plate at a density of 5 × 10
5
  cells per well. 
dsDNA–cyanine 3 loaded polymer assemblies obtained with 90 : 5 : 5 w/w of polymers 
mPEG1.9kDa-block-poly[ImHeMA]-block-poly[GMA] / t-boc-PEG3.5kDa-block-
poly[ImHeMA]20-block-poly[GMA]58/Folate-PEG3.5kDa-block-poly(ImHeMA)20-block-
poly[GMA]58 and control 90 : 10 w/w of polymers mPEG1.9kDa-block-poly[ImHeMA]67-
block-poly[GMA]36 / t-boc-PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58 (500 
mL of 1 mg/mL) were added to the cells in the wells, and incubated at 37°C for 2 hours in 
the dark to prevent photo-bleaching of labelled DNA. A control solution containing PBS 
(500 mL, 20 mM phosphate, 150 mM NaCl, pH 7.4) was also added to specific wells. 
After incubation, polymer dispersions were discharged and wells were washed with PBS. 
Cells were detached by treatment with 1% (w/v) trypsin in PBS. Cell suspensions from 
each well were transferred in microtubes and recovered by centrifugation at 1000 rpm for 
5 minutes. The pellets were treated with 6 mL of 0.1% v/v Triton X-100 and lysates were 
analysed by fluorimetry (λex 550, λem 570). 
2.3.17.2 FACS analysis 
The study was performed at the University of Padova using KB and MCF7 cells only for 
an incubation time of 30 minutes at 37°C. The same study was performed at Centro de 
Investigacion Principe Felipe of Valencia on B16-F10-luc-G5 cells evaluating the 
internalization of the folate targeted vesicles over time up to 5 hours both at 3°C and 4°C. 
Cells were seeded in a 6 well plate at a density of 28 × 10
4 
cells/well. The medium was 
then removed, cells were washed twice with PBS and 1 mL of a 1 mg/mL of dsDNA-
cyanine loaded polymer assemblies obtained with 90:5:5 w/w% of mPEG1.9kDa-block-
poly[ImHeMA]67-block-poly[GMA]36 / t-boc-PEG3.5kDa-block-poly[ImHeMA]20-block-
poly[GMA]58/Folate-PEG3.5kDa-block-poly(ImHeMA)20-block-poly[GMA]58 and 90 : 10 
w/w of polymers mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 / t-boc-
PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58 was added to the wells. Cells were 
incubated at 37 °C and 4°C. At incubation times of 0, 15 minutes, 30 minutes, 2 hours 
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and 5 hours wells were washed with PBS and cells collected in cytometer tubes scraping 
on ice. After incubation, the polymer dispersions were discharged and wells washed with 
PBS. To detach cells from the wells, 300 µL of 1% v/v trypsin were added and cells were 
incubated 4 minutes at 37°C. One mL of PBS containing CaCl2 and MgCl2 was added to 
each well and cells were recovered, centrifuged at 1000 rpm for 5 minutes. The cellular 
pellet was resuspended, washed twice with PBS and centrifuged eliminating the 
supernatant. Samples were recovered in 300 μL of 1% w/v freshly prepared 
paraformaldehyde in PBS and analyzed by flow cytometry (λex 550, λem 570).  
2.3.18 CONFOCAL MICROSCOPY 
Glass BD Falcon™ chamber slides were pretreated with a poly-D-lysine hydrobromide 
solution (0.2 mg/mL) in strile water to increase cell attachment. The poly-D-lysine 
solution was sterilized with a 0.22 μm filter and added to each well. Chamber slides were 
incubated for 1 hour at room temperature in the safety cabinet and afterwards the poly-D-
lysine solution was removed. Wells were rinsed three times with PBS and KB and MCF7 
cells were seeded at a density of 10 × 10
4 
cells/well and grown for 24 hours at 37°C and 
5% CO2. The medium was then removed, cells were washed with PBS and 500 μL of 
Cyanine 3 labeled ds DNA loaded polymersomes were prepared with 90:5:5 w/w% of 
mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 / t-boc-PEG3.5kDa-block-poly 
[ImHeMA]20-block-poly[GMA]58 / Folate-PEG3.5kDa-block-poly(ImHeMA)20-block-poly 
[GMA]58 and 90 : 10 w/w of polymers mPEG1.9kDa-block-poly[ImHeMA]67-block-
poly[GMA]36 / t-boc-PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58 polymer 
mixture (non targeted polymersomes) in PBS pH 7.4 as described previously were added 
to each well and incubated at 37°C in the dark for 30 minutes. Polymersome suspension 
was the removed and wells were gently washed  three times with PBS. Cells were fixed 
with 500 μL of freshly prepared 1% w/v paraformaldehyde for 20 minutes at 4°C, washed 
with PBS and incubated with 200 μL of 5 μg/mL fluorescein-DHPE in PBS for 10 
minutes in the dark. Cells were washed three times with PBS, chamber slides were 
disassembled and 20 μL of Vectashield® mounting medium containing DAPI for nuclei 
staining were added to each slide. Finally, slides were covered with coverslips. Samples 
were analyzed by confocal microscopy using an immersion lens. Lasers with an emission 
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wavelength at 405, 488 e 561 nm were used to detect DAPI, fluorescein-DHPE and 
cyanine-3 labeled DNA. 
2.3.19 SILENCING STUDIES 
B16F10 cells from mouse melanoma, transfected with luciferase and over expressing 
folate receptor (199, 200) were seeded in a 96 well plate at a density of 10 × 10
4 
cells/well. ds-siRNA-loaded polymer assemblies obtained with 90:5:5 w/w% of 
mPEG1.9kDA-block-poly[ImHeMA]67-block-poly[GMA]36 / t-boc-PEG3.5kDa-block-
poly[ImHeMA]20-block-poly[GMA]58 / Folate-PEG3.5kDa-block-poly(ImHeMA)20-block-
poly[GMA]58 and control 90:10 w/w % mPEG1.9kDa-block-poly[ImHeMA]67-block-
poly[GMA]36 / t-boc-PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58 (100 μL of 1 
mg/mL) in PBS pH 7.4 were added to the wells, and incubated at 37 °C for 30 minutes. 
Cells were also treated with ds-siRNA free targeted polymersomes, targeted 
polymersomes loaded with a scrambled ds-siRNA sequence, free luciferace silencing ds-
siRNA and free scrambled ds-siRNA as controls. After incubation, polymer dispersions 
were discharged and replaced with DMEM medium supplemented with 10% FBS. Cells 
were grown for 24 and 48 hours. Afterwards, 16 μL of the luciferin (150 μg/mL) in PBS 
was added to each well and the Luciferase activity was spectrofotometrically quantified 
using a microplate reader at λem 535 nm. 
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3. RESULTS AND DISCUSSION 
3.1 SYNTHESIS OF MONOMERS, INTERMEDIATES AND BLOCK 
CO-POLYMERS 
3.1.1 SYNTHESIS OF GLYCEROL METHACRYLATE MONOMER (GMA) 
                               
Scheme 3.1. Reaction of the glycidyl methacrylate in acidic water, at 60° C to yield the glycerol 
methacrylate. 
The synthesis of GMA monomer was carried out using protocol already reported (201, 
202) in the literature for the hydrolysis of epoxides. Hydrolysis of epoxides is one of the 
most exploited methods for synthesizing vicinal diols. The reaction can be performed 
under mild conditions by using solid or solid-supported Lewis acids, one-electrontransfer 
reagents and a variety of recently discovered reagents (202). 
Glycidyl methacrylate was left to react in water at 60 ºC in the presence of aqueous 
H2SO4 (0.5 equiv.) to yield the expected product. 
1
H-NMR, 
13
C-NMR and mass 
spectroscopy analysis confirmed the GMA structure. Hot water and high-diluted H2SO4 
were used as nucleofilic-acid catalysts and solvents and were efficient in promoting the 
ring opening of the epoxide to yield the diol. 
3.1.2 SYNTHESIS OF IMIDAZOLIC MONOMER 
The preparation of the pH-sensitive block co-polymers involved the synthesis of 
polymers featuring a pKa in the 6-7 ranges. The polymers were generated with a central 
block bearing pendant imidazolic groups. Here, the synthesis of 6-(1H-imidazol-1-yl) 
hexyl-methacrylate hydrochloride monomers is discussed. These monomers were chosen 
because of their aromatic amine functionality with a pKa in the range of interest for 
intratumoural and endosomal protonation. In fact, the imidazole is an analogous to 
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histidine (pKa 6.5) (190). The imidazole side chain of this amino acid exhibits a non 
charged, neutral status in physiologic environment at pH 7.4 (namely the blood) thus 
relatively small shifts in pH may change its ionization status with the protonation of the 
aromatic ring that can occure in the slightly acid tumor interstitium or in net acid 
environment of the intracellular endosomes and lysosomes. Hence, the idea to synthesize 
block co-polymers from histidine-alike monomers to prepare polymersomes that are 
designed to release nucleic acids/drugs at acidic pH into tumors. 
The synthesis of the ImHeMA was performed according to a three step protocol. 
 
Step 1: 
                                     
Scheme 3.2. Reaction of the 6-chloro-1-hexanol with the acetic anhydride to give the 6- 
chlorohexyl acetate. 
The first intermediate synthesised was 6-chlorohexyl acetate, following an adaption of 
reported methods (203). Commercially available, 6-chloro-1-hexanol and acetic 
anhydride were reacted in DCM in the presence of DMAP, that was employed as 
nucleophilic catalyst, and Et3N to yield the acetylated product. The reaction was carried 
out for 30 minutes at 0ºC, then for an hour at room temperature. An extraction with Et2O 
and water was performed to remove the water-soluble Et3NH
+
 
-
O-COCH3 salt and the 
DMAP catalyst. The solvent was changed from DCM to Et2O for the low solubility of 
Et3NH
+ -
O-COCH3 salt in Et2O, which facilitated the extraction process. Evaporation of 
the organic phase under reduced pressure gave the product that was used without further 
purification in Step 2. 6-chlorohexyl acetate was fully characterized by 
1
H-NMR, 
13
C- 
NMR, and mass spectroscopy. 
Step 1 of synthesis allowed to protect the hydroxyl group of 6-chlorohexanol, forming the 
acetate derivate, in order to guarantee the reaction with the imidazole at the chlorine 
bearing carbon in the next step. 
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It is well known that reactions of alcohols with an excess of anhydride proceed in inert 
solvents at 0ºC. Furthermore, DMAP, by activating the acetic anhydride, provides a 
strong catalytic effect to the process (204). Its catalytic effect is due to the dimethylamino 
group that acts as electrondonor substituent, which increases the nucleophilicity and the 
basicity of the pyridine nitrogen. 
                                               
Scheme 3.3. Effect of dimethyl amino group on the pyridine nitrogen  
 
Et3N, employed to deprotonate the starting alcohol, leads to the formation of the Et3N 
ammonium salt. The general mechanism of the reaction is exemplified in Scheme 3.4. 
          
Scheme 3.4. Mechanis of the reaction between 6-chloro-1-hexanol and acetic anhydride with 
DMAP and Et3N as catalysts, to give 6-chlorohexyl acetate. 
Step 2: 
                                 
 
 
 
 
Scheme 3.5. Reaction of the 6-chlorohexyl acetate with the imidazole to give the 6-(1H-imidazol-
1yl) hexan-1-ol. 
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Initially, imidazole was treated with the strong base NaH. The resulting imidazolium 
sodium salt was N-alkylated with the α-ω O-acetyl chloroalcohol, 6-chlorohexyl acetate, 
in DMSO at 100 °C for 3 hours, followed by hydrolysis in 10% aqueous NaOH to give 
the alcohol intermediates. Imidazole, acting as a “weak Brønsted acid”, was deprotonated 
by NaH yielding the imidazolium sodium salt derivative with the development of H2. 
(Scheme 3.6) The process was carried out at room temperature. 
                                    
Scheme 3.6. Mechanism of the reaction between imidazole and NaH to form the imidazolium 
sodium salt, as nucleophilic intermediate with high reactivity with 6-chloro acetate. 
The reaction between the imidazolium sodium salt and 6-chlorohexylacetate is a classic 
example of nucleophilic substitution (SN2) in anaprotic polar solvent (DMSO). (See 
Scheme 3.7). In the reaction, the nucleophilic nitrogen of the imidazole react with the  
carbon bearing the chlorine, with following elimination of Cl
-
, as leaving group, to form 
6-(1H-imidazol-1-yl) hexyl acetate and NaCl. 
  
Scheme 3.7. Mechanism of the SN2 reaction between imidazolium sodium salt and 6-
chloroacetate. 
Deacetylation reaction of the acetate derivative was performed by hydrolysis with 
aqueous NaOH at 70ºC and yielded the 6-(1H-imidazol-1-yl) hexan-1-ol. Esters can be 
easily hydrolysed in alkaline aqueous solutions and in these conditions the process is 
always irreversible. 
Step 3: 
6-(1H-imidazol-1-yl) hexan-1-ol could react with methacryloyl chloride using Et3N, as 
catalyst, to form the methacrylic monomer ImHeMA as reported in Scheme 3.8. 
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Scheme 3.8. Reaction of the imidazolic alcohol and methacryoloyl chloride to obtain the 
ImHeMA monomer. 
The use of standard acid scavengers for this latter step was found to reduce dramatically 
the yields (< 10%) and shelf life of the monomer (205). This last step was then carried out 
exploiting the imidazole ring of the reagent as a base, yielding the desired monomer as its 
hydrochloride salt. This methodology allowed to minimize a number of side-reactions 
previously observed when Et3N was also employed and led to a simplification in the 
purification process by flash column chromatography. 
Furthermore, obtaining the ImHeMA as a salt allowed to an easier solubilization in 
aqueous media. The molecule was also found to be chemically stable at -20 °C for several 
months as confirmed by the 
1
H-NMR analysis and mass spectroscopy. 
3.1.2 SYNTHESIS OF REVERSIBLE ADDICTION-FRAGMENTATION CHAIN 
TRANSFER (RAFT) AGENT / (CTA) 
Controlled/living radical polymerisations (CRP) were carried out using the glycerol 
methacrylate monomer and the imidazolic monomer synthesized in the previous sections 
to obtain a well-defined AB diblock co-polymers. In particular, in this work RAFT 
polymerization was chosen for its experimental simplicity compared to other 
polymerization techniques and because it allows for the precisely control molecular 
weight of the polymers. RAFT polymerization, as previously described in Chapter 1, 
involves the use of a chain transfer agent (CTA), where the transfer of the S=C(Z)S- 
moiety from the RAFT agent provides the living character to the process (185). The 
reaction of the CTA with a radical monomer results in a polymer containing the same 
S=C(Z)S-functionalities from the initial RAFT agent. Moreover, this polymer is capable, 
under appropriate conditions, to reinitiate, acting as a macroCTA, a new polymerization 
reaction. In this study, a series of hydrophilic macroCTAs were synthesized to obtain a 
starting material that can be used to grow the pH responsive imidazole based monomers, 
producing a variety of well-defined block co-polymers. 
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3.1.2.1 Synthesis of 2-cyanopropan-2-yl 2-hydroxyethyl carbonotrithioate RAFT 
Agent 
This RAFT agent was synthesised following and adapting previously reported procedures 
for the same kind of products (206). 
Scheme 3.9. Synthesis of 2-cyanopropan-2-yl 2-hydroxyethyl carbonotrithioate. 
Firstly, 2-mercaptoethanol was treated with NaH in Et2O at 0°C, then carbon disulfide 
was added dropwise to yield the trithio-salt intermediate. This Na
+
 salt was oxidised by 
using K3Fe(CN)6 to give the 2,2'(disulfanediylbis(carbonothioylsulfanediyl)] 
bis(hydroxyethane) intermediate. ‘Radical-induced’ decomposition of this intermediate 
via reaction with AIBN gave the 2-cyanopropan-2-yl 2-hydroxyethyl carbonotrithioate 
desired as confirmed by 
1
H-NMR and 
13
C-NMR. 
3.1.2.2  Synthesis of poly[GMA] macroCTA 
 
Scheme 3.10. RAFT polymerization of GMA to obtain the poly[GMA] macro-CTA. 
The polymerization of GMA was performed using glycerol methacrylate (GMA) 
monomer, AIBN as radical initiator and 2-cyanopropan-2-yl 2-hydroxyethyl 
carbonotrithioate as RAFT agent. The molar ratio of the reagents was: [Raft Agent]: 
[AIBN]: [GMA] = 1: 0.5: 35. The reaction was monitored by 
1
H-NMR to determine the 
conversion. Aliquots of the reaction mixture were withdrawn every 30 minutes until 150 
minutes, when the polymerization was stopped. 
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Figure 3.1. 
1
H-NMR spectrum of poly[GMA] macro-CTA in dmso-d6 with peak assignment. [5% 
of unreacted monomer signals was detected on the spectrum] 
Figure 3.1 shows the 
1
H-NMR spectrum of the final product. The rate of polymerization 
was calculated by comparing the integral variation (arbitrary units, A.U.) of one of the 
vinylic protons in the starting monomer to the integral of the CH of the solvent, DMF, 
used has internal standard. DMF, at the 
1
H-NMR in dmso-d6, provide three singlet peaks 
placed at 7.95 ppm and 2.73 ppm. The peak at 7.95 ppm was chosen as reference peak 
because it does not overlap with the peaks of the growing polymer or the starting 
monomer. DMF has a very high boiling point (153ºC), therefore it can be assumed that its 
concentration is constant during our polymerization, performed at 70 ºC, and its signals 
can be used as reference to measure the decreasing in the vinylic proton integral. The 
conversion of the monomer during the polymerization was determined by comparing the 
value of the vinyl integral at time = 0 and the value of the integral of the sample at every 
given time. The polymerization was stopped at 87% conversion when the DP was 30. 
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3.1.3 SYNTHESIS OF  POLY[GMA]-BLOCK-POLY[IMHEMA] 
 
Scheme 3.11. RAFT polymerization scheme starting from poly[GMA] to obtain the poly[GMA]-
block-poly[ImHeMA] diblock co-polymer. 
Two block co-polymers were generated using the poly[GMA] as the hydrophilic block 
and macro-CTA and the newly synthesized ImHeMA monomer, with different 
polymerization degree of the latter, to understand the influence of this monomer on the 
properties of the final diblock copolymers. The reagent conditions used were:  
1) poly[GMA]: [ImHeMA]= 1: 6 
2) poly[GMA]: [ImHeMA]= 1: 3 
The synthesis of both materials was carried out following a RAFT polymerization 
method, using DMF as solvent and AIBN as radical initiator. The two reactions showed 
different polymerisation rates. The Polymerization of co-polymer (1), with a higher ratio 
of ImHeMA, was found to be slower and its kinetic plot showed a higher deviation from a 
linear first order kinetic compared to polymer (2). The plot showed an initial faster rate of 
polymerization that, after 180 minutes, drastically decreased. Polymerization of co-
polymer (2), instead, proceeded faster and was stopped at theroic 90% conversion, after 
150 minutes. Conversely, the synthesis of polymer (1) was stopped at 75% conversion, 
after 25 hours. Polymerization rate was calculated in both reactions by 
1
H NMR using the 
solvent DMF as internal standard and shown in Figure 3.2. In particular, it was observed 
the decreasing in the intensity of the signal, corresponding to the vinyl protons of the 
ImHeMA monomer, versus the singlet at 7.95 ppm (in dmso-d6) of the DMF. 
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Figure 3.2. 
1
H-NMR stacked spectra in DMSO-d6 of the poly[GMA]-block-poly[ImHeMA] (1) 
(Panel A) and (2) (Panel B) at t=0 and t= end (when the reaction was stopped). The peaks used to 
determine polymer conversion are highlighted in blue (d=6.00 and 5.66) relative to the vinyl 
protons of the ImHeMA. 
GMA/ImHeMA molar ratio in the final diblock co-polymers was obtained comparing the 
integral of protons corresponding to -OCH2 of the polyGMA macroCTA block to protons 
vinyl protons of ImHeMA, corresponding to same protons in the poly[ImHeMA] block. 
B 
A 
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As shown in Table 3.1, the final molar ratio of both materials was found to be different 
than the one estimated in the kinetic study. 
1
HNMR analysis, in fact, indicated a final 
molar ratio [GMA]:[ImHeMA] of 1: 1.4 for the co-polymer (1) and 1: 2.25 for the co-
polymer (2). 
Table 3.1. Molar ratio of GMA/ImHeMa in co-polymer (1) and (2). 
      
It is not fully clear why the molar ratios of the monomers forming the two blocks differed 
from those expected, but it might be due to the difficulty to integrate correctly the signal 
representative of the solvent, used as reference, which is proximal to the polymer peaks. 
Gel Permeation Chromatography (GPC) analyses to determine the molecular weight and 
polydispersity index (PDI) of these samples was difficult to perform due, likely, to 
solubility limits of the materials in the chromatographic eluents or to polymer interactions 
with the stationary phase of the column. Nevertheless, both polymerizations were relevant 
to provide useful materials. Further studies were performed to prove their ability of self-
assembly in pH-swop conditions and select which one was more suitable to generate a 
definitive system to be used for biological applications. 
3.2 REPRESENTATIVE TITRATION AND TURBIDIMETRIC 
ASSAYS OF POLY[GMA]-BLOCK-POLY[IMHEMA] (1) AND (2) 
Potentiometric acid/base titration and back titration on poly[GMA]-block-poly[ImHeMA] 
diblock copolymers (1) and (2) were carried out to evaluate the apparent pKa of these 
materials. Titration was performed in all cases by adding aliquots of 10 μL of 0.1 M 
NaOH and recording the pH value after each addition, to a 1 mg/mL polymer solution at 
pH 3. The titration curve was obtained plotting the pH data in function of the volume of 
the titrant added. The point of inflection (“equivalence point”) was determined as the 
maximum value in the first derivative of the curve. The equivalence points were 6.29 for 
poly[GMA]-block-poly[ImHeMA] co-polymer (1) and 6.47 for poly[GMA]-block-
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poly[ImHeMA] co-polymer (2). The back-titrations were carried out on the same solution 
used for direct titration, starting at pH 10.5; 10 L aliquots of 0.1M HCl were added and 
pH values recorded after each addition until ~pH 3 was reached. The plotted data 
generated by back-titration showed an equivalence point at  9.27 for poly[GMA]-block-
poly[ImHeMA] copolymer (1) and pH 8.52 for poly[GMA]-block-poly[ImHeMA] co-
polymer (2).  
 
 
Figure 3.3. Titration (■) and back-titration (■) curves of poly[GMA]-block-poly[ImHeMA] co-
polymer (1) (Panel A) and (2) (Panel B). 
 
The apparent pKa were derived as the mean value between titration and back titration 
“equivalent points”. Apparent pKa was 7.5 for co-polymer (1) and 7.78 for co-polymer 
(2). A precipitation of all polymers was observed during the titrations from low pH and 
solutions became turbid. Turbidity rose with the increase of the pH due to deprotonation 
of the imidazole lateral groups of the polymers. It suggested the presence of aggregation 
phenomena that is triggered at pH above the pKa found for these materials. 
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Aggregation phenomena could make more difficult the access of the titrant to the amino 
group of the imidazole in the pH-responsive block, causing a delay in the 
protonation/deprotonation process. For this reason, the pKa of the polymer is commonly 
named “apparent pKa” due to the effect of aggregation on the deprotonation of the 
polymer. 
Poly[GMA]-bock-poly[ImHeMA] diblock co-polymer (1) and (2) resulted poorly soluble 
in aqueous media. A turbidimetric analysis was carried out to determine their “cloud 
point”. The “cloud point” for these materials is the pH at which they are no longer 
completely soluble, but they start to aggregate (207). This technique has been widely used 
to understand the behaviour of pH-sensitive polymeric materials, especially in view of a 
practical application of these materials in more complex drug delivery systems. The basis 
of the assay is that the turbidity of a dispersion of scattering particles (e.g. polymer chains 
in water) is an increasing function of the relative refractive index (n) and particle volume 
(Vp). Therefore, an increase in the turbidity with the increasing of the pH correlates with 
n or Vp (or both) increase. Variation of the transmittance at λ 500 nm (due to light 
scattering) was recorded as a function of pH for 1 mg/mL polymeric solution, starting at 
pH 3 (Figure 3.4). Aliquots of 5 μL of 0.1 M NaOH were added to the polymer solution 
and the pH was measured after each addition, allowing few seconds under stirring for 
equilibration. 
         
Figure 3.4. Representative turbidimetric assay for poly[GMA]-block-poly[ImHeMA] co-polymer 
(1) (panel A) and (2) (panel B). 
 
All the experiments were performed in doublicate and the cloud point calculated as the 
mean values of the two results. The cloud point found for poly[GMA]-block-
poly[ImHeMA] co-polymer (1) was pH 5.6 and pH 5.4 for poly[GMA]-block-
poly[ImHeMA] co-polymer (2). These results confirmed that the co-polymer with a 
A B 
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higher hydrophilic/hydrophobic ratio (co-polymer 1) has a solubility with a slightly wider 
pH range in aqueous media with respect to co-polymer (2). Through all these early stage 
pH-studies we confirmed ImHeMA being a highly hydrophobic monomer. Its physic-
chemical features confirm that the polymer responds to pH environmental variations with 
physical aggregation, which underlines the hydrophilic/hydrophobic conversion. The data 
however do not support for the assembly of the two polymers into nanovesicles. 
3.3 SYNTHESIS OF THE TRIBLOCK CO-POLYMER PEG1.9KDA-
BLOCK-POLY[GMA]-BLOCK-POLY[IMHEMA] THROUGH 
PIRYDIL INTERMEDIATE CONJUGATE 
Solubility of the previously described AB block co-polymers, as revealed by all the 
studies performed at different pH conditions, was good. However, the results obtained 
from these block co-polymers confirmed that improved solubility and stability of the 
polymer system was required to allow the generation of more soluble amphiphilic 
materials with self-assembling properties. The polymers might be stable in the blood 
stream at physiologic conditions (pH 7.4) to protect the DNA or siRNA in transit in the 
body, and hydrophilic in the acidic conditions of the cellular endosome compartment 
where, as the aim of the study dictates, they will be delivered. Therefore, an ABC triblock 
co-polymer was synthesized starting from poly[GMA]-block-poly[ImHeMA] (1) by 
reaction with a mPEG2kDa-SH to improve the polymer solubility at higher pH. 
poly[GMA]-block-poly[ImHeMA] (1) was chosen between the two polymers for the 
synthesis of the ABC co-polymer in virtue of its higher hydrophilic/hydrophobic ratio, 
which provide slightly higher solubility in aqueous media. 
 
 
 
 
 
 
 
Scheme 3.12. Reaction of poly[GMA]-block-poly[ImHeMA] with propylamine and 2-2-
dithiopyridine to yield the poly[GMA]-block-poly[ImHeMA] pyridyl conjugate product. 
 
The first step of this reaction involved the simultaneous removal of the RAFT agent 
though propylamine addition and the conjugation of 2,2’-dithiopyridine to the polymer 
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thiol group (Scheme 3.12). Propylamine, through the aminolysis, promotes the conversion 
of the RAFT-end group to a stable reactive thiol suitable to be attacked by the pyridil 
group to yield a pyridyl disulfide-terminated co-polymer. The aminolysis route has 
possible drawbacks, as the thiol group can undergoes further oxidation to disulfide, 
leading to bimodal polymer populations (208). Therefore, to overcome this disadvantage 
the reaction was performed in the presence of a thiol-reactive compound as the 2-2’-
dithiopyridine to have a pyridyl disulfide protective group before the reaction with the 
mPEG2kDaSH. Pyridyl disulfide, as widely reported in the literature, is an efficient active 
group for selective exchange-reactions with thiols under mild conditions. The pyridyl 
disulfide group, in fact, presents a high reactivity towards the attack of free thiol derivates 
(209). Therefore, it is an advantageous functional group towards disulfide-thiol exchange 
reactions used particularly in biological applications for the preparation of cleavable 
conjugates of biomolecules such as protein or thiol-activated oligonucleotide (210). 
The reaction mixture was stirred overnight at room temperature and under nitrogen. After 
evaporation of the solvent, the product was recovered by dissolving the solid residue in 
acidic water (obtained by adding 1 N HCl  to deionised water until pH 3) and, then, 
increasing the pH by adding 1 N NaOH. Precipitation with this method was possible 
because the polymer was completely deprotonated, therefore more hydrophobic, at high 
pH as demonstrated by pH studies previously reported (Section 3.2). From 
1
H-NMR 
spectra of the final product it was not possible to identify the signals corresponding to the 
pyridyl protons. This could be explained considering the small molar fraction of the end-
group compared to the whole polymer. In fact, the peaks corresponding to pyridyl protons 
might be partially covered by the imidazole peaks of the polymer-repeating unit. 
Therefore, it was not possible to determine the functionalization degree of the product at 
this stage by NMR, whereas a “colorimetric assay” by UV-vis was performed. The 
disulfide bond of the poly[GMA]-block-poly[ImHeMA]-thiopyridine was reduced by 
using an excess of DL-dithiothreitol (DTT), a strong reducing agent as shown in Scheme 
3.13 The released thiopyridine was quantitatively detected by spectrophotometric analysis 
at 370 nm. 
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Scheme 3.13. Schematic representation of 2-thiopyridine cleavage from poly[GMA]-block-
poly[ImHeMA]-thiopyridine co-polymer using DTT. 
The concentration of 2-thiopyridine released from the polymer was obtained using the 
molar extinction coefficient value (εM = 5027 mol
-1
cm
-1
) derived from a calibration curve 
of 2-thiopyridine in methanol (Figure 3.5) and the co-polymer activation yield was 
derived as a ratio between the 2-thiopyridine in solution and the polymer dissolved. 
                       
Figure 3.5. Calibration curve of the 2-thiopyridine in MeOH. 
The co-polymer activation yield was found to be only 48%. However the copolymer was 
used for the second step of the synthesis, namely the conjugation of the mPEG-SH to the 
activated terminal end of poly[GMA]-block-poly[ImHeMA]-thiopyridine.  
 
Scheme 3.14. Conjugation of mPEG-SH2kDa to poly[GMA]-block-poly[ImHeMA]-thiopyridine . 
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In the second step, the activated polymer with a disulfide end functionality was reacted 
with the free thiols of the mPEG2kDaSH and allowed the generation of the triblock co-
polymer. The reaction was carried out as shown in Scheme 3.14. This is a thioldisulfide 
exchange reaction, and it requires the presence of an organic base, Et3N, in order to form 
the thiolate that will react selectively with the disulfide bond. Purification of the product 
was done in two steps. At first, a precipitation was carried out following the same method 
used for the precipitation of the poly[GMA]-block-poly[ImHeMA]-S-S-pyridyl co-
polymer. MeOH was evaporated under reduced pressure and the solid residue was 
dissolved in acidic deionized water (pH 3) and, then, 1 N NaOH  was added. A small 
amount of precipitate was observed while the aqueous solution became opalescent, 
probably due to the formation of colloidal assemblies of the triblock copolymer. This 
evidence supported for the generation of a more soluble copolymer with self-assembling 
capacity. Both the precipitate and the suspension, recovered after centrifugation, were 
freeze-dried and analyzed by 
1
H-NMR. Figure 3.6 shows the spectra of the opalescent 
suspension containing mPEG-SH2kDa-poly[GMA]-bkock-poly[ImHeMA] and the 
precipitate obtained by centrifugation. The signal of the mPEG backbone was expected to 
be at about 3.6 ppm and the terminal methoxyl group of the CH3-O-PEG- chain at slightly 
lower value (region highlighted in red). 
                 
Figure 3.6. Stacked 
1
H-NMR in MeOD of opalescent material containing mPEG-SH2kDa-
poly[GMA]-block-poly[ImHeMA] and the precipitate derived from the conjugation of mPEG-SH 
to poly[GMA]-block-poly[ImHeMA]. Highlighted in red the region in the spectrum where PEG is 
expected. 
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Chemical shift and intensity of the peaks are reported in Table 3.2. The peak at 3.67 ppm 
in the spectra of the suspension phase is attributed to the mPEG and overlaps the signal 
corresponding to the ester -OCH2- of the poly[GMA] block. The same pattern of peaks 
was not visible in the spectrum of the precipitate. The suspension was shown to contain 
the triblock co-polymer and the excess of mPEG-SH, while the precipitate was 
determined to be unreacted poly[GMA]-block-poly[ImHeMA]-S-S-pyridyl co-polymer. 
Table 3.2. Chemical shift and integration of the peaks in the precipitate and suspension obtained 
after precipitation of mPEG1.9kDa-p-(GMA)-b-p(ImHeMA) 
              
The crude material of the opalescent suspension isolated from the conjugation of the 
mPEG-SH to the poly[GMA]-block-poly[ImHeMA]-S-S-pyridyl co-polymer was 
dissolved in 20 mM phospate saline buffer, 150 mM NaCl pH 5 and the pH was increased 
to 8 with NaOH 0.1M. The polymeric dispersion underwent size analysis as shown in 
Figure 3.7. From the dynamic light scattering analysis it was evident that the polymer was 
self-organized in a colloidal system with an average size of  about 50 nm. According to 
this evidence, the polymeric dispersion was then dialyzed using a membrane with a 100 
kDa C.O. (cut-off) to remove the excess of unreacted mPEG2kDa-SH.  
                                                      
 
 
Figure 3.7. DLS analysis (Size distribution by % Volume) of the polymeric suspension of 
poly[GMA]-block-poly[ImHeMA]-PEG1.9kDa before dialysis. DLS confirmed the presence of 
assemblies. 
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The diameter of the co-polymer assembly was larger than the pores of the membrane and 
the vesicles were retained inside, while mPEG-SH, considerably smaller then the dyalisis 
membrane pores, could diffuse outside. The cut-off of the membrane allowed the 
diffusion of both single chain mPEG-SH and the dimer mPEG-S-S-mPEG that can 
generate by oxidation as confirmed by dedicated tests performed using mPEG2 kDa-OH 
and and mPEG5kDa-OH. Then PEG-SH conjugation degree to diblock was determined by 
1
H-NMR and estimated to be ~ 60% with respect to the activated poly[GMA]-block-
poly[ImHeMA]-S-S-pyridyl co-polymer. Figure 3.8 reports the 
1
H-NMR spectrum of the 
expected poly[GMA]-block-poly[ImHeMA]-PEG2 kDa.          
            
Figure 3.8. 
1
H-NMR profile of poly[GMA]-block-poly[ImHeMA]–PEG2kDa triblock co-polymer 
after purification. 
3.4 ASSEMBLY OF COLLOIDAL SYSTEMS USING THE 
TRIBLOCK CO-POLYMER OF PEG2KDA-POLY[GMA]-BLOCK-
POLY[IMHEMA] AND TIME STABILITY INVESTIGATION      
Nanoparticles using the triblock co-polymer PEG2kDa-poly[GMA]-block-poly[ImHeMA] 
were physically assembled in 20 mM phosphate buffer, 150 mM NaCl, following the 
method previously described.The pH was gradually increased from pH 3 up to pH 7.4. 
The saline buffer was used to mimic the physiological environment, as salts influence the 
stability of charged polymersomes. The ions, in the media, can affect the particle 
 Results and Discussion     
  
97 
 
diffusion speed by changing the thickness of the electric double layer nameda Z- potential 
(211). Compared to a solely aqueous media, a higher conductivity media will suppress the 
electric double layer increasing the diffusion speed and resulting in a smaller measured 
hydrodynamic diameter by DLS and more stable polymersome assemblies. The slow 
increase of the pH performed in the assembling procedure, allowed the self-assembling of 
the polymer, as clearly confirmed by DLS (Figure 3.9).     
                    
 
 
Figure 3.9. DLS analysis (Size distribution by % Volume) after the self-assembly of poly[GMA]-
block-poly[ImHeMA]-PEG1.9 kDa. 
The analysis showed the presence of a main population (67.6% Volume) of mean 
diameter of 49 ± 5 nm with a PDI of 0.397, which confirmed the ability of the triblock 
copolymer to assembly in colloidal structures at physiological pH although with a not 
high homogeneity. A population with hydrodynamic size of 15.72 nm (29.5% Volume) 
was also observed and it can be attributed to a minimum amount of non-assembled free 
polymer. Moreover, also a population with a size of 5444 nm, (0.9% Volume) was 
detected, perhaps related to a small ratio of aggregated polymer. In order to isolate the 
aggregated polymer and characterize the nanoparticles only, the suspension was filtered 
through a cellulose acetate (CA) filter with a 5 μm cut-off size and analyzed by DLS 
(Figure 3.10). 
                              
Figure 3.10. DLS analysis (Size distribution by %Volume) of colloidal assembled poly[GMA]-
block-poly[ImHeMA]-PEG2kDa after filtration. 
DH = 15.72 nm (29.5% V) 
DH = 5444 nm (0.9% V) 
 Results and Discussion     
  
98 
 
Only one population (100% Volume) with a size of 42 ± 3 nm (PDI = 0.168) was detected 
after filtration, which indicated the nanoparticle sample is rather homogeneous even 
though a limited amount of the material does not self-organize in colloidal systems. 
Kinetic stability of the nanoparticles was also investigated by DLS at 25ºC. Particles size 
was recorded across pH ranges at scheduled times (Table 3.3). Samples were prepared 
using the method previously described, in buffers at pH 5, 6.5 and 7.4 to mimic the 
endosomal compartment, tumor interstitium and blood respectively. 
Table 3.3. DLS analysis of nanoparticles assembled with poly[GMA]-block-poly[ImHeMA]-
PEG2 kDa at pH 5, 6.5 and 7.4, measured at different time intervals.  
          
At pH 7.4 only one population with DH ~ 42 nm was recorded and particles resulted 
stable up to 72 hours. After 72 hours, only a small amount of aggregates (~3% in 
Volume) was found. At pH 6.5 the system rearranged in larger aggregates than at pH 7.4. 
A possible explanation for this behavior might be ascribed to the repulsion between 
positive charges originating from the partial protonation of the polymer pH responsive 
block (poly[ImHeMA]) at this pH which destabilize the system with respect to pH 7.4 but 
are not sufficient to promote the full dissolution of the polymer chains (the pH condition 
is very close to the pKa expected for the imidazole). Assemblies remained stable within 6 
hours at this pH and afterwards their stability decreased, as it was shown by the 
enlargement in the diameter size. However, the PDI of the particles was comparable to 
the one of the particles at pH 7.4 showing the the rearrangement of the polymer does not 
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translate into macroscopic aggregation of the system. At pH 5 the polymer central block 
poly[ImHeMA] was mainly protonated since the pH is lower than the polyer apparent pKa, 
therefore the DLS analysis proved no colloidal assemblies were detectable as confirmed 
by the very high PDI. The value of PDI=1 indicated that the polymer was disperse in 
solution rather than in colloidal suspensions; therefore the size distribution displayed was 
very approximate. This result, in addition, suggested that the triblock copolymer loses its 
ability to assemble with other polymer chains at this pH and rather, being protonated, it 
induces the colloidal system to dissociate. This is a clear evidence that the polymer 
generated can respond to pH alterations with sharp conversion from an associated state to 
a dissociated state. This pH-responsive polymer possess the capacity to generate 
particulate carriers with good stability at physiological pH, and induce destabilization and 
break down of the carrier at slightly acidic pH, as required for the pH-triggered release of 
therapeutics in acidic pathological environment, as aimed in this work. 
3.5 TRIBLOCK COPOLYMERS SYNTHESES 
Evidences described in the previous section show that the ABC amphiphilic triblock 
copolymer poly[GMA]-block-poly[ImHeMA]-PEG2kDa possesses a clear self-assembling 
behavior. This polymer was deemed adequate to generate nanovehicles for the delivery of 
drugs and siRNA. The polymer has been synthesized according to a two steps procedure: 
1. Sequential RAFT polymerization of the poly-GMA block followed by the poly-
ImHeMA;  2. Conjugation of mPEG-SH to the poly-ImHeMA after removal of the RAFT 
agent. However, this material was synthesized with a unsatisfying purity due to the low 
conjugation yield of the mPEG-SH to the diblock co-polymer. In order to obtain the the 
same three block co-polymer with predictable molecular weight and narrow molecular 
weight distribution (PDI), RAFT was the process chosen to successfully polymerize the 
materials. In this work, a small library of well-defined mPEG-block-poly(ImHeMA) 
diblock co-polymers was prepared by polymerization of N-alkyl imidazole monomers 
using either methoxyPEG1.9kDa-OH or t-boc-NH-PEG3.5kDa-OH dithiobenzoates as the 
macrotransfer agents, which were firstly synthesized. Chain extension with glycerol 
methacrylate (GMA) on mPEG1.9kDa-block-poly(ImHeMA) and t-boc-NH-PEG3.5kDa-
block-poly(ImHeMA) co-polymers afforded the required ABC amphiphilic triblock 
mPEG-block-poly(ImHeMA)-block-poly(GMA) co-polymers. The two PEG derivative 
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were chosen to generate the major polymeric self-assembling component of the 
nanoparticles and the polymer for the ligand conjugation.  PEG3.5kDa was chosen to 
provide flexibility and hydrophilicity to the targeting ligand and allow its exposure on the 
nanocarrier surface. 
The chemical syntheses of the block copolymers used in this work are shown in Scheme 
3.15. 
                     
 
 
 
 
 
 
 
Scheme 3.15. Reagents and conditions for the syntheses of mPEG1.9kDa-b-[ImHeMA]67 –b-
[GMA]36 and t-Boc-NH-PEG3.5kDa-b-[ImHeMA]20–b-[GMA]58 block co-polymers. 
The syntheses of methoxy PEG1.9kDa and t-boc-NH-PEG3.5kDa dithiobenzoates were carried 
out following an adaption of the procedure reported by Yamago et al. (212) (Scheme 
3.16) 
                             
 
 
 
Scheme 3.16. Syntheses of mPEG1.9kDa and t-boc-NH-PEG3.5kDa dithiobenzoates; mPEG1.9kDa-OH 
was dried by azeotropic distillation with toluene under reduced pressure before the reaction. 
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The t-boc-NH-terminated PEG3.5kDa-OH was used to obtain a sub-family of block co-
polymers with a protected amino functionality at the polymer chain-end as a chemical 
handle, amenable for subsequent functionalization with a targeting agent. This PEG agent 
was used in the reaction without further purification. Molar ratios used for reaction were: 
[PEG-OH]: [DCC]: [CPADB]= 1:3:3. PEG-OH terminated compounds reacted with 
CPADB in presence of DMAP, as catalyst, and DCC to obtain the dithiocarbonate macro-
CTA at room temperature, under stirring, over 16 hours. The reaction was monitored by 
1
H-NMR by observing the increasing of the signal corresponding to the two ester protons 
(C(O)OCH2) at 4.26 ppm of the newly generated ester bond between PEG-OH and 
CPADB. The insoluble dicyclohexylurea (DCU) by-product was filtered and the polymer 
derivative precipitated several times in Et2O until the complete elimination of unreacted 
DMAP (Scheme 3.17) 
                           
 
 
 
 
 
 
 
Scheme 3.17. Mechanism of the reaction to generate the PEG dithiobenzoates: 1) DMAP drives 
the deprotonation of CPADB, which reacts with DCC to give the reactive O-acyl isourea; 2) The 
binding of deprotonated PEG-OH provides the product and DCU as by-product. 
The reaction is reported in the literature as “Steglich esterification” (213): the 
combination of DMAP, as catalyst, for carboxyl activation affords a useful method for in 
situ activation of the carboxylic acids for reaction with alcohols in mild conditions. 
The polymerizations of all the materials were performed in DMAC as solvent and AIBN 
as radical initiator. Reaction conditions for the imidazolic monomers and the GMA were 
set-up according to the degree of polymerization (DP) required for each block to grow in 
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the co-polymer. Varying the ratio of ImHeMA and GMA monomers in the co-
polymerizations process, it was possible to prepare different molecular masses of mPEG-
block-poly(ImHeMA)-block-poly(GMA). The [PEG macro-CTA]: [AIBN] ratio was left 
the same in each polymerization as 1:1.  
To profile the conversion rate, the reaction mixtures were monitored by 
1
H-NMR at 
scheduled times. 
The block co-polymers were isolated by precipitation in Et2O/petroleum ether 1:1 several 
times, so residual CPADB and unreacted monomers were efficiently removed.  
It has been reported (214) that the dithiobenzoate- CTA end-group confers a certain 
degree of toxicity to the polymers. Therefore, being the polymer intended for in in vitro/in 
vivo testing, the cleavage of this functional group was compulsory in order to perform 
further studies on these materials. The cleavage reactions were performed with an excess 
(1:20) of AIBN at 80 °C in DMSO for 3 hours (AIBN half time at 80ºC is 80 min) using 
the procedure developed by Perrier et al. (215) The block co-polymers were recovered by 
precipitation in THF several times. The structure of all materials was confirmed by 
1
H-
NMR spectra obtained in (D2O). 
Moreover, 
1
H-NMR analyses, through the integral of each signal of the spectra, were used 
to determine the degree of polymerization (DP) of each block co-polymer synthesized and 
to calculate the theoretical molecular weight of each co-polymer and, therefore, the w/w% 
ratio of hydrophilic/hydrophobic sections (Table 3.4). 
 
Table 3.4. Molar ratio of PEG/ ImHeMA/GMA blocks of diblock and triblock co-polymers. 
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Gel Permeation Chromatography (GPC) analyses to determine the molecular weight and 
polydispersity index (PDI) of the products were impossible to perform due, perhaps, to 
solubility problems of the materials in the eluents or to the polymer interactions with the 
GPC. 
3.5.1 SYNTHESIS OF α-FOLATE-NH-PEG3.5KDA-BLOCK-POLY[IMHEMA]20-
BLOCK-POLY[GMA]58  
t-boc-NH-PEG3.5kDa-block-poly[ImHeMA]20-bp[GMA]58 was designed in order to be end 
functionalized with a targeting agent. Amphiphilic macromolecules bearing specific 
ligands conjugated to the hydrophilic polymer block end have been used as site-selective 
targeted nanocarriers. For example, Zhang and co-workers engineered Tet1-
functionalized PEG-block-PCL polymersomes as drug delivery vehicles to the inner ear 
by targeting trisialoganglioside clostridial toxin (GT1b) receptors (216), while 
Upadhayand co-workers exploited poly(γ-benzyl L-glutamate)-block-hyaluronan 
polymersomes to promote intracellular uptake of doxorubicin in a murine model of 
Ehrlich Ascites Tumor (EAT) through CD44 receptor-mediated endocytosis (217). In few 
cases, efficient recognition/endocytic processes do not require high densities of ligands at 
the surface of drug carriers (218), and this can be advantageous when a specific ligand 
production is expensive (201). Furthermore, an excess of exposed ligands can negatively 
affect the ‘stealth’ properties conferred by hydrophilic polymer chains at the surface of 
nanoparticles and reduce the polymer flexibility and mobility. Ligand- and ligand-free 
block copolymers can therefore be combined in a suitable ratio to assemble nanoparticles, 
and in particular polymeric vesicles, and achieve the desired ligand surface density. 
Kokkoli and co-workers used this approach to formulate a mixture of ligand free 
poly(1,2-butadiene)-block-poly(ethylene oxide) with its azido-terminated analogue. The 
mixture spontaneously assembled in vesicle-like particles. The azide functionalities at the 
surface of the resulting polymersomes were then reacted with PR_b - a ligand for α5β1 
integrin targeting – to provide targeted nanocarriers that were able to selectively deliver 
Orai3- specific siRNA to T47D breast cancer cells for tumor treatment (219).  
Therefore, the chain ends of the t-Boc-protected polymer t-boc-NHPEG3.5 kDa-block-
poly[ImHeMA]20-block-poly[GMA]58 were converted to a ligand-functionalized polymer, 
by acid hydrolysis in TFA, followed by coupling of the resulting terminal primary amine 
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with folic acid N-hydroxysuccinimide activated ester (Scheme 3.18). The reactions were 
carried out following a procedure mentioned elsewhere (194, 195). 
          
Scheme 3.18. t-boc removal and folic acid conjugation to t-boc-NH-PEG3.5kDa-block-
poly[ImHeMA]20-block-poly[GMA]58. Reagents and conditions: a. i) TFA/DCM 1:1 vol/vol, 
ambient temperature, 2 h; b. folic acid-NHS ester, DMSO, ambient temperature, 14 h. 
The quantification tests by Uv-Vis spectroscopic analysis showed a conjugation yield of 
folic acid to the polymer of 96% and thus a 1 : 1 folate/polymer molar ratio. 
The analysis of the polymer conjugate by reverse phase high-performance liquid 
chromatography (RP-HPLC) did not show the presence of free folic acid in the 
chromatogram confirming the high degree of purity of the conjugate folate-PEG3.5 kDa-
block-poly[ImHeMA]20-block-poly[GMA]58. 
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3.6 POTENTIOMETRIC TITRATION AND TURBIDIMETRIC 
ASSAYS OF MPEG1.9KDA-BLOCK-POLY[IMHEMA]67-BLOCK-
POLY[GMA]36 
In order to assess the pKa of the polymer, potentiometric acid/base titration and back 
titration were carried out on mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36. 
The titration was performed by adding aliquots of 0.1 M NaOH, to a solution of the 
polymer at pH 3. The maximum of the first derivative titration curve allowed the 
calculation of the point of inflection (“equivalent point”). The “apparent” pKa were 
estimated as mid-points between the titration start pH and equivalence points, using the 
first derivatives of the titration curves to aid in measurement of equivalence points. 
Potentiometric titrations of mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 
showed a suggested an apparent pKa of ~5.9 while the apparent pKa of diblock 
copolymers (1) and (2) were found to be ~7.5 and 7.8. These values should be interpreted 
with care as self-assembly of polymer chains and association of imidazolic units into the 
hydrophobic core/layer of a colloidal system devoid of water could potentially make 
proportion of the acid/base functionalities inaccessible for titration over the timescale of 
the experiment (Figure 3.11). 
Figure 3.11. Titration (Panel A) and back titration (Panel B) of mPEG1.9ka-b-p[ImHeMA]67-b-
p[GMA]36. Adapted from (205) with DOI: 10.1039/c3py00744h - Reproduced by permission of 
the Royal Society of Chemistry. 
Turbidimetric analyses were carried out to determine the cloud point of mPEG1.9kDa.-
block-poly[ImHeMA]67-block-poly[GMA]36. The cloud point was considered here as the 
pH at which the block co-polymers start to form aggregates. Turbidimetric assays were 
carried out by gradually increasing the pH from pH 3 of a solution of mPEG1.9kDa-block-
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poly[ImHeMA]67-block-poly[GMA]36 in 150 mM NaClaq. The triblock co-polymer 
showed a “cloud point” at ~pH 5.7 whereas the diblock co-polymers poly[GMA]-block-
poly[ImHeMA] (1)  and (2) exibited respectively a cloud point at ~pH 5.6 and ~pH 5.4 
(Figure 3.12).  
                                 
Figure 3.12. Turbidimetry titration profile of mPEG1.9kDa-block-poly[ImHeMA]67-block-
poly[GMA]36 showing the cloud point at ~ pH 5.7. Adapted from (205) with DOI: 
10.1039/c3py00744h - Reproduced by permission of the Royal Society of Chemistry. 
We observed that diblock copolymers poly[GMA]-block-poly[ImHeMA] (1)  and (2), by 
addition of aqueous NaOH started from pH 3, was found to produce aggregates that 
precipitated rapidly without forming well defined particles. On the other hand, with the 
same procedure, the turbidimetric assays showed that the triblock copolymer mPEG1.9ka-
block-poly[ImHeMA]67-block-poly[GMA]36 could form nano assemblies.  
To summerize, in Table 3.5 the main features of diblock polymers poly[GMA]-block-
poly[ImHeMA] (1) and (2) and triblock copolymer mPEG1.9kDa-block-poly[ImHeMA]-
block-poly[GMA] are reported in order to better compare their chemico-physical 
behavior. 
Table 3.5. Chemico-physical properties of diblock polymers poly[GMA]-block-poly[ImHeMA] 
(1) and (2) and triblock copolymer mPEG1.9kDa-block-poly[ImHeMA]-block-poly[GMA 
Polymers pKa cloud  
point 
Hydrophilic 
block/polymer 
weight ratio % 
Hydrophobic 
block/polymer 
weight ratio % 
PEG/ImHeMA/GMA 
monomers 
poly[GMA]-b-
poly[ImHeMA] (1) 
7.5 5.6 32 68 30/42 
poly[GMA]-b-
poly[ImHeMA] (2) 
7.8 5.4 23 77 30/68 
mPEG1.9kDa-b-
p[ImHeMA]-b-p[GMA] 
5.9 5.7 32 68 44/67/36 
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Observing the above reported main properties of the synthesized polymers, the first 
difference we perceive between the diblock copolymers and the triblock copolymer is the 
value of the apparent pKa. Indeed, for the triblock copolymer mPEG1.9kDa-block-
poly[ImHeMA]-block-poly[GMA] pKa is lower with a value of ~5.9, compared to the 
diblock copolymers poly[GMA]-block-poly[ImHeMA] (1) and (2) which showed a pKa 
of ~7.5 and ~7.8. According to the results we obtained, it seemed that the triblock 
polymer that posses lower pKa could be the best candidate in order to obtain 
polymersomes with a response in the physiopathological pH range. However, the pKa is 
not the only difference between the produced copolymers. Although the w/w% ratio of 
hydrophilic/hydrophobic blocks of the three polymers is comparable, the disposition of 
the hydrophilic blocks is clearly different for the triblock copolymer. The higher weight 
ratio of the hydrophobic block in the diblock copolymer was expected to allow for the 
self assembly in vesicles (12). However, even though the diblock copolymers are soluble 
in acid conditions, their exposure to higher pH induces the deprotonation of the imidazole 
units at the pH close to the pKa value of the polymer, which induce the precipitation of 
the material. This behavior can be ascribed to the very high molecular weight of the 
hydrophobic blockwhich destabilize the whole system and does not allow the generation 
of vesicles. Thus ,we could assume that the presence of two hydrophilic blocks at the 
terminal ends of the triblock co-polymer better promote the polymer to arrange in vesicles 
once the environment pH is above the polymer pKa. As reported in the literature, for 
triblock copolymers assembled in vesicles, it was found that the polymer shorter 
hydrophilic block is mostly segregated to the outer surface of vesicles due to 
thermodynamic stabilization reasons (220); this conceivably takes place also for our 
triblock copolymer. On the other hand, the GMA segments are mostly segregated to the 
inner vesicle surface.  
The information gained with the colloidal characterization studies of the triblock 
copolymers poly[GMA]-block-poly[ImHeMA] (1) and (2) allowed us to further 
synthesize triblock copolymers with physico-chemical properties and pH responsiveness 
suitable for the generation of performing vesicular systems as aimed in this project thesis.  
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3.7 BLOCK CO-POLYMERS COLLOIDAL RESPONSE TO PH 
ALTERATIONS 
The block co-polymers, with different A, B, and C blocks alternating in 
hydrophilic/hydrophobic nature and block length, were intended to assemble in stable 
vesicular systems at neutral pH but would disassemble at lower pH (205). It was expected 
that these vesicles could encapsulate drug payloads while assembling and that possess the 
capacity to undergo pH-triggered controlled release.  
The 
1
H NMR spectrum of mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 
copolymer was recorded in D2O added of 150 mM NaCl, (conc. 1mg/mL) as shown in 
Figure 3.13. 
 
Figure 3.13. 
1
H NMR spectrum of mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 co-
polymer, 1.0 mg/mL in D2O containing 150 mM NaCl. Traces of Et2O from polymer precipitation 
are visible in the spectrum. Adapted from (205) with DOI: 10.1039/c3py00744h - Reproduced by 
permission of the Royal Society of Chemistry. 
Self-assembly behavior of A-B-C amphiphilic triblock copolymers mPEG1.9kDa-block-
poly[ImHeMA]67-block-poly[GMA]36 and t-Boc-NHPEG3.5kDa- block-poly[ImHeMA]20-
block-poly[GMA]58 as a function of the pH was also investigated, as for the diblock co-
polymer, by 
1
H NMR and DLS. In the NMR spectrum, repeating units of ImHeMA were 
clearly detectable (a, b, c), indicating efficient solvation of the poly (ImHeMA) block 
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under these conditions. However, 
1
H NMR analysis of mPEG1.9kDa-block-
poly[ImHeMA]67-block-poly[GMA]36 at different pH values revealed that, above pH 5.8, 
the area of the imidazole aromatic proton signals (a, b, c) ~7.9 - 9 ppm rapidly decreased, 
and disappeared completely at pH 7.0. This suggested that the polymer assembled into 
supramolecular structures wherein the poly(ImHeMA) domain was poorly solvated and 
therefore not visible in the 
1
H-NMR spectra. This is consistent with a mechanism by 
which at pH > 5.8 corresponding to the apparent the protonated imidazole units were 
progressively deprotonated, loose their positive charge and converted into more 
hydrophobic free-base imidazole moieties, resulting in self-assembled structures as shown 
by the DLS analysis performed at increasing pH (Figure 3.14). 
 
Figure 3.14. Panel A: size changes by DLS analysis of mPEG1.9kDa-block-poly[ImHeMA]67-
block-poly[GMA]36 co-polymer, 1 mg/mL at various pH values in D2O, 150 mM NaCl. Panel B: 
Integral of H1 proton (from C1 of imidazole) in the pH-responsive poly[6-(1H-imidazol-1-
yl)hexyl-methacrylate] block, expressed in arbitrary units, A.U.. Disappearance of the signal at 
pH >6.8 is indicative of the conversion of the deprotonated imidazolyl block into a poorly 
solvated hydrophobic core. Adapted from (205) with DOI: 10.1039/c3py00744h - Reproduced by 
permission of the Royal Society of Chemistry. 
Dynamic light-scattering (DLS) carried out using the samples analyzed by NMR 
confirmed this hypothesis, showing that when the polymer solution pH increased from 3 
to 5.6, the dissolved unimeric polymer chains of mPEG1.9kDa-block-poly[ImHeMA]67- 
block-poly[GMA]36 started to aggregate, generating particles with a size of over 1 μm at 
pH ~ 6.5-6.8. The size sharply decreased under slightly higher conditions, reaching a 
stable size of ~70 nm at pH ≥ 8.0. DLS studies with mPEG1.9kDa-block-poly[ImHeMA]67-
b-p[GMA]36 in salt-free conditions showed a similar size trend, although the smaller 
aggregates (~70 nm) were observed in the 6.5-7.0 ranges with this polymer rather than at 
A B 
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higher pH values.  Furthermore, mPEG1.9kDa-block-[ImHeMA]67-block-poly[GMA]36 
behavior at different pH and its stability over time was investigated by Dynamic Light 
Scattering analysis at 25ºC (Figure 4.13). The triblock co-polymer was dissolved in 10 
mM PBS, 150 mM NaCl, and the pH was changed by adding small aliquots of 0.1 M 
NaOH or 0.1 M HCl. Figure 3.13 shows the results of this study. The polymer started to 
aggregate at pH from 5.6 and achieve a maximum at pH 6. At this pH value, big 
aggregates (DH~ 1 mm) were detectable in the polymer solution up to pH 6.5 (Figure 
3.13, panel A). The size decreased by increasing the pH to 7.4 and 8, where smaller 
aggregates (DH ~ 200-250 nm) were observed. The size of mPEG1.9kDa-block-
poly[ImHeMA]67-block-poly[GMA]36 at all the pH conditions investigated were 
demonstrated to be stable over the time (Figure 3.15, panel B). 
Figure 3.15. Kinetic profiles of mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 by 
Dynamic Light Scattering analysis at different pH, at 25ºC. Particle diameters were recorded 
across pH ranges at scheduled times (Panel A) and over increasing time periods at specified pH 
(Panel B). Adapted from (205) with DOI: 10.1039/c3py00744h - Reproduced by permission of 
the Royal Society of Chemistry. 
The behavior of this polymer was agreed with the preliminary data found for the similar 
polymer poly[GMA]-block-poly[ImHeMA]-PEG1.9kDa reported in Table 3.3 that showed 
the assembly of particles with bigger size at pH 6.5 (about 200 nm), while the particles 
rearranged to about 50 nm when the medium pH was increased to 7.4. This behavior is 
very advantageous for in vivo applications. While the small particles can circulate in the 
blood stream at pH 7.4, they have a size that is adequate to extravasate in the tumor 
according to the EPR effect. The polymeric nanoparticles, however, can suddenly 
rearrange and increase in size at pH conditions of the tumour interstitium (pH 6.5-7), 
which induces the trapping of the particles after extravasation in the tumor. Since the 
A B 
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particles are decorated with targeting agent that stimulate the cancer cell uptake, they 
undergo receptor mediated endocytosis and migrate to acid cellular subcompartments 
such as the endosomes where the pH conditions (pH 5) induce the disassembly of the 
carrier and the release of the encapsulated drugs. The system disassembly at pH 5 is 
immediate as shown in Table 3.3 at time zero. 
Under the same conditions (10 mM PBS, 150 mM NaCl) t-Boc-NHPEG3.5kDa-block-
poly[ImHeMA]20-block-poly[GMA]58 behaviour was also investigated by DLS. This co-
polymer features a shorter hydrophobic p(ImHeMA) central block with respect to the 
above discussed mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36, thus a slightly 
different behavior was expected. This polymer showed a very similar colloidal response 
to pH changes with respect to the previously discussed triblock but arranged in big 
aggregates at lower pH (pH 5). Thus, the different aggregation behavior to pH alterations 
was ascribed to the higher weight ratio of the hydrophilic blocks of t-boc-NHPEG3.5kDa-
block-poly[ImHeMA]20-block-poly[GMA]58 (70%) with respect to the mPEG1.9kDa-block-
poly[ImHeMA]67-block-poly[GMA]36 whose hydrophilic blocks weigh ratio is only 30%. 
Furthermore, the t-Boc terminating polymer generates smaller aggregates of only ~13 nm 
at pH 8.0 (Figure 3.14, panel A), which were stable over time (Figure 3.16, panel B). 
 
Figure 3.16. Kinetic stability profiles of t-boc-NH-PEG3.5kDa-block-[ImHeMA]20-block-
poly[GMA]58 by Dynamic Light Scattering analysis at different pH, at 25ºC. Particle diameters 
were recorded across pH ranges at scheduled times (Panel A) and over increasing time at a chosen 
pH condition (Panel B). Adapted from (205) with DOI: 10.1039/c3py00744h - Reproduced by 
permission of the Royal Society of Chemistry. 
 
A B 
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Dynamic light-scattering results were in agreement with the 
1
H-NMR study performed 
over different pH conditions (Figure 3.17). 
1
HNMR confirmed the arrangement of the 
polymer formation of the aggregates. 
    
Figure 3.17. 
1
H-NMR integral profile of aromatic protons, expressed in arbitrary units, A.U., of 
the imidazole moiety in the central block of t-Boc-NH-PEG3.5kDa-block-[ImHeMA]20-block-
poly[GMA]58 at different pH conditions. Panel A: protons analyzed in the “low field” range of the 
spectra (H2-H3 corresponding to C2 and C3 of imidazole). Panel B: protons in the “high field” of 
the spectra (H1 corresponding to C1 of imidazole). 
3.8 CRITICAL AGGREGATION CONCENTRATION OF 
MPEG1.9KDA-BLOCK-POLY[IMHEMA]67-BLOCK-POLY[GMA]36 
The mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 was designed as 
amphiphilic block-copolymer to assemble polymeric vesicles for drug delivery purposes. 
According to previously reported studies for similar materials (12), it was expected that 
the hydrophilic blocks of the co-polymer (mPEG1.9 kDa and poly(GMA block) participate 
to the inner and the outer face of the polymeric vesicles, and provide for stealth hydrated 
surfaces, whereas the hydrophobic poly(ImHeMA) block assembles to form the vesicle 
water free membrane core. The ability of the mPEG1.9kDa-block-poly[ImHeMA]67-block-
poly[GMA]36 co-polymer to self-assemble in aqueous physiological conditions (pH 7.4, 
37 ºC) was investigated by the estimating the critical aggregation concentration (CAC). 
The experiment was performed as reported in section 2.3.6, following the procedure 
described by Kwon et al.(221). The triblock co-polymer was solubilized in 20 mM 
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phosphate buffer, 150 mM NaCl, at pH 4, and induced to assemble by the ‘pH-switch’ 
method (166, 198) at pH 7.4. Then, the dispersion was further diluted in phosphate buffer 
at pH 7.4, yielding different polymer concentrations. Pyrene was used as fluorescent 
probe. The CAC of co-polymer mPEG1.9kDa-block-poly[ImHeMA]67-b-p[GMA]36 was 
estimated by spectrofluorimetry to be 21 μg/mL. (Figure 3.18).  
                         
Figure 3.18. Pyrene emission intensity profile as a function of mPEG1.9kDa-block-
poly[ImHeMA]67-b-p[GMA]36 concentration. The net increase in fluorescence emission derived 
from the intercept of the two segments represent the CAC. Adapted from (205) with DOI: 
10.1039/c3py00744h - Reproduced by permission of the Royal Society of Chemistry.3.9 
Physical characterization of polymersome formulations. 
Polymersomes were assembled with mPEG1.9kDa-block-poly[ImHeMA]67-block-
poly[GMA]36 at 1 mg/mL polymer concentration according to the “pH-switch” technique 
reported in chapter 2.3.3. The size distribution of the polymerosomes in physiological 
conditions was assessed by DLS above the CAC. As it is shown in Figure 3.19, the 
triblock co-polymer assembled into colloidal systems with DH ~130 nm. The 
polymersomes resulted stable at 25°C for about 24 hours which confirmed the results 
reported in chapter 3.4 (See Figure 3.9); the size only increased of about 10 nm. On the 
contrary, when vesicles were incubated at body temperature (37 °C) and monitored over 
time, they underwent instability phenomena and slight aggregation. After 90 minutes of 
incubation at 37°C, vesicle sizes were 400 nm, ~ 650 nm after 270 minutes and almost the 
same size after 24 hours, and showed also few bigger aggregates. 
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Figure 3.19. Kinetic stability profile of particles assembled with mPEG1.9kDa-block-poly 
[ImHeMA]67-block-poly[GMA]36 by Dynamic Light Scattering at pH 7.4, at 25ºC (Panel A) and 
at 37ºC (Panel B). 
This result was attributed to the short mPEG1.9 kDa chains of the copolymer, which may be 
not adequate to generate a sufficiently stable hydrophilic coating on the top of the vesicles 
or may provoque an imbalanced hydrophilic/hydrophobic ratio within the co-polymer that 
was not suitable to guarantee the stability of the particles. Therefore, in order to stabilize 
the nanoparticles, vesicle formulations were prepared by mixing different weight ratio of 
mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 and t-boc-NHPEG3.5kDa-block-
poly[ImHeMA]20-block-poly[GMA]58. Three different formulations were prepared. In a 
preliminary screening, formulations assembled with mPEG1.9kDa-block-poly[ImHeMA]67-
block-poly[GMA]36/t-boc-NH-PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58 (1 
mg/mL) at 99:1, 95:5 and 90:10 w/w% ratios  were found to possess mean diameters of 
165 ± 6, 162 ± 4 and 119 ± 2 nm, respectively at 25°C. (See Table 3.6). The analysis 
showed that the incorporation of the t- boc-NH-PEG3,5kDa-b-p[ImHeMA]20-b-p[GMA]58 
copolymer did not affect the size of the vesicles. 
Table 3.6. Mean size of polymersomes obtained with different mPEG1.9kDa-block-
poly[ImHeMA]67-block-poly[GMA]36/t-boc-NH-PEG3.5kDa-block-poly[ImHeMA]20-block-
poly[GMA]58 (w/w %). The analisys was performed with freshly prepared polymersome (time = 
0). 
mPEG1.9kDa-b-p[ImHeMA]67-b-p[GMA]36/t-Boc-NH-PEG3.5kDa-b-
p[ImHeMA]20-b-p[GMA]58 w/w% 
DH (nm) - %V 
1% 165 ± 6 
5% 162 ± 4 
10% 119 ± 2 
A B 
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Particle charges were evaluated by Zeta potential (ζ) measurements. The vesicle 
formulations were diluted 10 times in mQ water at 25°C prior to the analysis. The z-
potential profile of the three formulations was neutral (Figure 3.20). This result is rather 
expected since at pH 7.4 of the water (with 10% saline buffer) the poly-imidazolic block 
of the co-polymers result mostly deprotonated and thus devoid of charge. Moreover, the 
PEG chains or the GMA exposed on the surface would be expected to form a hydrophilic 
corona and PEG/p(GMA) are neutral blocks that shield the few charges associated with 
the hydrophobic membrane core.  
 
 
Figure 3.20. z-potential of vesicle formulations obtained with different mPEG1900-block-
poly[ImHeMA]67-block-poly[GMA]36/t-Boc-NH-PEG3500-block-poly[ImHeMA]20-block-poly 
[GMA]58 w/w % ratios: 99:1:0 (panel A); 95:5:0 (panel B); 90:10:0 (panel C). Adapted from 
(205) with DOI: 10.1039/c3py00744h - Reproduced by permission of the Royal Society of 
Chemistry. 
Incubation at 37 °C for 5 hours showed that the formulation obtained with 90:10 w/w % 
of mPEG1900-block-poly[ImHeMA]67-block-poly[GMA]36 / t-boc-NH-PEG3500-block-
poly[ImHeMA]20-block-poly[GMA]58 was the most stable, with virtually no change in 
A B 
C 
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particle size over time, whereas the 99:1 and 95:5 w/w% samples showed a 2-fold 
increase in size, as reported in Figure 3.21. 
                                  
Figure 3.21. Kinetic stability profile of mPEG1.9kDa-block-poly[ImHeMA]67-block-
poly[GMA]36/t-Boc-NHPEG3.5kDa-block-poly[ImHeMA]20-b-p[GMA]58 polymersomes at 37°C 
and increasing weight percentage of the t-BOC terminating polymer: 1% (●), 5% (■), 10% (▲). 
Adapted from (205) with DOI: 10.1039/c3py00744h - Reproduced by permission of the Royal 
Society of Chemistry. 
Hence the presence of 10 % w/w t-boc-NH-PEG3.5kDa-block-poly[ImHeMA]20-block-
poly[GMA]58 was beneficial for the stability of the polymersomes over time. This was 
ascribed to the generation of a thicker, more flexibles hydrophilic coating on top pf the 
polymeric vesicles due to both longher PEG and poly-GMA blocks in the t-BOC 
terminating polymer compared to mPEG1.9kDa-block-poly[ImHeMA]67-block-
poly[GMA]36. It is reported in the literature that PEG and hydrophilic polymer coating of 
liposomes greatly enhance the colloidal formulation stability of this carrier and avoid the 
vesicle aggregation (222, 223). As is possible to imagine, it can be generalized that the 
same concept apply also to polymeric vesicles that possess structurally resembling 
features of the liposomes. 
Consequently, the same formulation was tested by DLS in 20 mM phosphate, 150 mM 
NaCl at pH 7.4 in the presence of 10% of fetal bovin serum at 37°C to mimic a more 
physiological environment that plein saline buffer. These conditions will also be exploited 
further studies in vitro on cancer cells. Figure 3.22 display the kinetic stability profile of 
the polymersome suspension under these conditions. 
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Figure 3.22. Kinetic stability profile of polymersomes obtained with 90:10 w/w% mPEG1900-
block-poly[ImHeMA]67-block-poly[GMA]36/t-Boc-NH-PEG3500-block-poly[ImHeMA]20-block-
poly[GMA]58 at 37 °C in saline buffer, pH 7.4, in the presence of 10% fetal bovin serum. Adapted 
from (205) with DOI: 10.1039/c3py00744h - Reproduced by permission of the Royal Society of 
Chemistry. 
The formulation was stable for about 6 hours, presenting a negligible variation of the PDI. 
The mild size increase was only partially attributed to a rearrangement of block co-
polymers at 37°C. As seen in the test performed withut serum, the vesicle formulation 
obtained with 90:10 w/w% mPEG1900-block-poly[ImHeMA]67-block-poly[GMA]36/t-boc-
NH-PEG3500-block-poly[ImHeMA]20-block-poly[GMA]58 was rather stable. The size 
increase can be due to a limited adsorption of proteins on the vesicles surface or to the 
rearrangement of the polymer conformation in the presence of serum protein that traduce 
in a limited morphological change of the polymersomes. However, a stability of about 6-8 
hours is desirable for in vivo applications, since a blood circulation time of about 6 hours 
is considered ideal for tumor accumulation (218). 
α-Folate-PEG3.5kDa-block-(ImHeMA)20-block-(GMA)58 was used to prepare folate-
targeted polymeric dispersions. In order to set up a stable polymersome formulation,  
three different formulations of the triblock co-polymers were prepared in 20 mM 
phosphate, 150 mM NaCl, pH 7.4 to generate the targeted vesicles: 90:10 w/w% of 
mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 / α- folate-PEG3.5kDa-block-
poly[ImHeMA]20-block-poly[GMA]58, 90:5:5 w/w% mPEG1.9kDa-block-
poly[ImHeMA]67-block-poly[GMA]36/t-boc-NH-PEG3.5kda-block-poly[ImHeMA]20-block 
-poly[GMA]58/ α-folate-PEG3500-block-poly[ImHeMA]20-block-poly[GMA]58 and 90:10 
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polymers mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 / t-boc-NH-PEG3.5kDa-
block-poly[ImHeMA]20-block-poly[GMA]58). The different ratios were chosen on the 
basis of the previous results obtained with the different mPEG1.9kDa-block-
poly[ImHeMA]67-block-poly[GMA]36/t-Boc-NH-PEG3.5kDa-block-poly[ImHeMA]20-
block-[GMA]58 mixtures and that have shown how a 10 w/w% of  the more hydrophilic 
polymer t-Boc-NH-PEG3.5kDa-block-poly[ImHeMA]20-block-[GMA]58  generated vesicles 
with higher stability. The folate targeted formulations were compared for stability to the 
non-targeted formulation assembled with 90:10 w/w% of mPEG1.9kDa-block-
poly[ImHeMA]67-block-poly[GMA]36/t-Boc-NH-PEG3.5kDa-block-poly[ImHeMA]20-
block-poly[GMA]58 already discussed above for stability at 25°C (see Figure 3.21 for 
results). The samples were incubated at 37 °C and analysed by dynamic light scattering at 
scheduled times (Figure 3.23).  
                                    
Figure 3.23. Kinetic stability profile of polymersomes obtained with 90:10 w/w% mPEG1.9kDa-
block-poly[ImHeMA]67-block-poly[GMA]36 / α-folate-PEG3.5kDa-block-poly[ImHeMA]20-block-
poly[GMA]58 (●), 90:5:5 w/w% mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36/t-boc-
NH-PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58 /  α-folate-PEG3.5kDa-block-poly 
[ImHeMA]20-block-poly[GMA]58 (■) and 90:10 w/w% mPEG1.9kDa-block-poly[ImHeMA]67-
block-poly[GMA]36/t-boc-NH-PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58 (▲) at 
37°C. Adapted from (205) with DOI: 10.1039/c3py00744h - Reproduced by permission of the 
Royal Society of Chemistry. 
This experiments showed that the non targeted 90:10 w/w% mPEG1.9kDa-block-
poly[ImHeMA]67-block-poly[GMA]36 / t-boc-NH-PEG3.5kDa-block-poly[ImHeMA]20-
block-poly[GMA]58 polymersomes were stabele over time even at 37°C. On the contrary, 
the presence of the folate on the vesicle surface induces the instantaneous rearrangement 
of the vesicles to particles with bigger size with respect to the folate-free formulation. 
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This can be ascribed to, at least in part, the hydrophobization of the vesicle surface by the 
exposure of the folate that is a vitamin with low water solubility. However, for this 
formulation, the particle size was not found to increase over time, which shows how the 
enlargement induced by the folate is rather limited and the flexibility of the PEG coating 
can control the particle aggregation. The formulation obtained with the 90:5:5 w/w% of 
polymers mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36/t-boc-NH-PEG3.5kDa-
block-poly[ImHeMA]20-block-poly[GMA]58 / α-folate-PEG3.5kDa-block-poly[ImHeMA]20-
block-poly[GMA]58 lead to the smallest polymersomes. The size and kinetic stability 
profile of this formulation overlap the profiles of the non targeted polymersomes obtained 
with the 90:10 w/w% mPEG1900-block-poly[ImHeMA]67-block-poly[GMA]36/t-boc-NH-
PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58 showing that the presence of the t-
boc terminating co-polymer, in virtue of its hidrophylic character, can counterbalance the 
particle enlargement tendency due to the folate. Therefore, the stability of this 
formulation was also tested in 20 mM phosphate, 150 mM NaCl at pH 7.4 in the presence 
of 10 v/v% of fetal bovine serum at 37 °C by DLS. Figure 3.24 shows the kinetic stability 
profile of the assembly obtained with 90:5:5 w/w % of mPEG1.9kDa-block-
poly[ImHeMA]67-block-poly[GMA]36 / t-boc-NH-PEG3.5kDa-block-poly[ImHeMA]20-
block-poly[GMA]58/α-folate-PEG3500-block-poly[ImHeMA]20-block-poly[GMA]58 under 
this condition.  
                                 
Figure 3.24. Kinetic stability profile at 37 °C in 10% serum of polymersomes obtained with 
90:5:5 w/w% of mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36/t-boc-NH-PEG3.5kDa-
block-poly[ImHeMA]20-block-poly[GMA]58/α-folate-PEG3.5kDa-block-poly[ImHeMA]20-block-
poly[GMA]58. Adapted from (205) with DOI: 10.1039/c3py00744h - Reproduced by permission 
of the Royal Society of Chemistry. 
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Similarly to what was found for the non targeted polymersomes containing 10 w/w% of t-
boc-NH-PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58 (Figure Figure 3.22), the 
presence of the serum induces a comparable size increase of the targeted polymersome 
formulation over time that can be ascribed to a slow rearrangement of the polymer chain 
conformation in the presence of serum protein induced by the unspecific interaction of the 
polymer chains with the serum proteins. 
3.10 ENCAPSULATION OF FLUORESCENT PROBES AND 
POLYMERSOMES LABELLING  
The ability of the newly-synthesised block copolymers to spontaneously and reversibly 
assemble into colloidal particles over physiologic pH ranges was encouranging for the 
encapsulation of these systems with small drugs and oligonucleotides for tumour 
targeting.  
With the aim of tracking the polymersomes in vitro studies, we first investigated the 
loading capacity of the vesicles generated in this work with model fluorescent probes 
with different chemical features. At this aim we chose a hydrophilic probe, namely 
5(6)carboxyfluorescein, that may dispose in the aqueous core of the vesicles, and a 
hydrophobic alkylated molecule, namely N-(fluorescein-5- thiocarbamoyl)-1,2-
dihexadecanoyl-sn-glycero-3-phospho-ethanolamine, triethyl-ammonium salt 
(fluorescein-DHPE), that may be associated in the hydrophobic shell core of the 
polymeric vesicles. Scheme 3.19 shows the chemical structures of the two fluorescent 
probes. Besides acting as fluorescent tags to label the polymersomes, these two molecules 
can also provide information on the capacity of polymersomes to load small model 
molecules with specific hydrophilic or hydrophobic properties. The two probes were 
tested with polymersomes assembled with 90:10 w/w% of mPEG1.9kDa-block-poly[ 
ImHeMA]67-block-poly[GMA]36 / t-boc-NH-PEG3.5kDa-block-poly[ImHeMA]20-block-
poly[GMA]58 mixture and  the loading capacity (% LC) and encapsulation efficiency (% 
EE) were investigated.  
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Scheme 3.19. Chemical structure of 5(6)carboxyfluorescein (A) and N-(fluorescein-5- 
thiocarbamoyl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanol-amine, triethylammonium salt 
(fluorescein-DHPE, B). 
The polymersome were induced to assemble by the “pH-switch” method and excess of 
non-loaded fluorescent labels was removed by extensive dialysis. The probe loaded 
polymersomes were analyzed by spectrofluorimetry to quantify fluoresceine.  The 
analysis indicated a Loading Capacity  (LC% = weight of loaded fluorophore / weight of 
polymer %) of 6.4 and 0.05 w/w% for fluorescein-DHPE and 5(6)-carboxyfluorescein, 
respectively. The Encapsulation Efficiency (EC%= loaded fluorophore /initial 
fluorophore concentration) was found to be 45.8 and 0.01 mol/mol% for Fluorescein-
DHPE and 5(6) carboxyfluorescein, respectively. Fluorescein-DHPE displayed very high 
values for both the LC% and EC% with respect to the 5(6) carboxyfluorescein, which 
demonstrates that the phospholipid moiety of this fluorophore participated as an 
anchoring agent to the polymersomes external shell. The carboxyfluorescein was instead 
only marginally encapsulated in the aqueous core of the vesicle despite it was processed 
with the polymer at high concentration. However, it should also be mentioned that the 
low EC% of the 5(6) carboxyfluorescein was rather expected as consequence of the high 
concentration of this probe used in the polymersome assembly process.  
This result also shows that, despite the anionic character of the 5(6) carboxyfluorescein 
that should promote its association to the imidazole containing blocks of the co-polymer 
at pH 5 and then its encapsulation in the assembled vesicles, the loading strategy is not 
adequate for this small molecule or the molecule is not sufficiently retained within the 
polymersome aqueous core. Further studies are required to assess the permeability of the 
vesicle polymeric shell to small molecule.  
A B 
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3.11 OLIGONUCLEOTIDE LOADING STUDIES 
3.11.1 ELECTROPHORETIC MOBILITY SHIFT ASSAY 
In order to investigate if the pH responsive triblock co-polymers selected for the assembly 
of the vesicles can associate with double strand siRNA by ionic interaction and if the 
association is affected by the pH conditions, a dsDNA 19-nucleotides model sequence 
was used. dsDNA was expected to display very similar physico-chemical properties as 
ds-siRNA but did not require formulation under rigorously RNAse-free conditions. 
dsDNA sequence underwent electrophoretic chromatography in the presence of 
increasing ratio of mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 at pH 5 
mimicking the endosomal environment and at pH 7.4 mimicking the blood. 
The Electrophoretic Mobility Shift Assay can also provide information about the stability 
of the DNA/polymer complexes and the extent of DNA/polymer dissociation. A 
polyacrylamide vertical gel with a reticulation degree (concentration of acrylamide/bis-
acrylamide) of 12% w/v was used for this purpose to run the dsDNA polymer mixtures. 
The samples were prepared in citrate buffer at pH 5 using different N/P feed ratios (from 
0.1:1 to 1:20 N/P molar ratios and the gel was run at pH 5 (citrate buffer) and at pH 7.4 
(phosphate buffer). Figure 3.25 shows the electrophoretic profiles of the gels. 
 
 
 
 
 
 
 
Figure 3.25. Electrophoretic Mobility profiles of dsDNA in the presence of mPEG1.9kDa-block-
poly[ImHeMA]67 block-poly[GMA]36 at pH 5 (Panel A) and pH 7.4 (Panel B). 
A B 
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At pH 5, the electophoretic migration do dsDNA shows that for low N/P feed ratios the 
dsDNA migrate along the gel, which confirms that for these feed ratios the polymer was 
not sufficient to complex the dsDNA. On the contrary, for N/P feed ratios above 2:1, the 
dsDNA is completely retained by the polymer and does not migrates along the gel, which 
confirms that for these feed ratios the polymer has sufficient positive charges to complex 
the DNA. The dsDNA retained by the polymer is thus retarded at the loading site where it 
is not detectable because many dsDNA/polymer complexes do not stain using GelRed™ 
Nucleic Acid Gel Stain (224) (Figure 3.28, panel A). Thus the poly-imidazol block, being 
the pH responsive component of the polymer, in virtue of its protonation at low pH, 
generate a polycationic block that is able to associate with dsDNA by charge charge 
interaction. This is expected to help the loading of dsDNA and ds-siRNA according to the 
assembly protocol through the “pH-shift”. 
At pH 7.4, the co-polymer is devoid of most of its charges according to the apparent pKa 
of the polymer (see chapter 3.6), and the dsDNA migrates along the gel regardless of the 
N/P feed ratio (Figure 3.28, panel B). This is ascribable to a net lower capacity of the 
polymer to complex the dsDNA and to retain the polyanionic macromolecule.  
Overall, the retardation assay confirmed the capacity of the mPEG1900-block-
poly[ImHeMA]67-block-poly[GMA]36 co-polymer to complex the dsDNA at acid 
conditions, when it is fully protonated. 
3.11.2 POLYMERSOME DNA LOADING 
A short dsDNA 19-nucleotides was used as model oligonucleotide. mPEG1.9kDa-block-
poly[ImHeMA]67-block-poly[GMA]36 / t-boc-NH-PEG3.5kDa-block-poly[ImHeMA]20-
block-poly[GMA]58 were dissolved at a 90:10 weight ratio in buffer at pH 5, then dsDNA 
was added to achieve a 1:1 N/P feed ratio and the pH was raised to 7.4. Unentrapped 
oligonucleotide was removed by dialysis against PBS pH 7.4.  
Firstly, the loading of the dsDNA was proved by inducing the dissociation of the colloidal 
aggregates at pH 5, and quantifying the encapsulated dsDNA with UV-Vis analysis. In 
this conditions the UV-Vis absorbance of the polymers was negligiable. The analysis 
showed a loading capacity (LC) of 14% mol/mol (mol of dsDNA/ mol of polymer chain), 
corresponding to 7 w/w%. Due to the relatively high encapsulation efficiency, we have 
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speculated that the dsDNA is not just encapsulated in a discrete "water pool" inside the 
polymeric vesicle (which would have yielded a lower LC due to the low concentration of 
the dsDNA in the loading medium), but was, at least partially, complexed with the 
polymer by electrostatic interactions, which drove the encapsulation of the polyanionic 
macromolecule. 
DLS analysis proved the formation of colloidal aggregates with a mean size of 123 ± 11 
nm and a PDI = 0.276, whilst the absence of smaller assemblies ascribable to the dsDNA 
(about 60 nm mean diameter) confirmed the total removal of free dsDNA (Figure 3.26). 
                 
Figure 3.26. Dynamic light-scattering profile of the non loaded polymerosomes obtained with a 
90:10 w/w% ratio of mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 / t-boc-NH-
PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58 (Panel A, mean diameter ~ 50 nm, PDI = 
0.097) and the dsDNA-loaded polymersomes assembled with the same polymers (Panel B). 
Adapted from (205) with DOI: 10.1039/c3py00744h - Reproduced by permission of the Royal 
Society of Chemistry. 
The DLS analysis showed that the size of polymersomes was not dramatically affected by 
the loading of the dsDNA. However, with respect to unloaded polymersomes, the PDI 
was slightly higher, which can be ascribed to a rearrangement of the vesicles when a 
polyanionic macromolecules is loaded in the aqueous core or in proximity of the 
polymeric membrane.  
When the polymer/dsDNA nanoassemblies were brought to pH 7.4, the overall charge 
associated to the particles was close to zero as shown by the zeta potenatial analysis in 
A 
B 
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Figure 3.27 indicating that there was no surface segregation and exposure of the polymer 
cationic blocks or anionic dsDNA. If any charge exist within the nanosystem, it is likely 
shielded by the hydrophilic neutral polymers (PEG and polyGMA). The stability of the 
particles in aqueous suspension was therefore attributable to a hydrophilic but non-
charged outer polymer corona. 
                       
Figure 3.27. z-potential profile of the dsDNA/polymer formulation loaded using a 1:1 N/P feed 
ratio. The zeta potential, measured at neutral pH was found to be -0.172 mV. Adapted from (205) 
with DOI: 10.1039/c3py00744h - Reproduced by permission of the Royal Society of Chemistry. 
A mechanism describing the dsDNA loading in the polymer nanoassemblies can be 
hypotized. At acid pH (pH 5) where the polymer and the dsDNA are dissolved, the 
imidazole containing block of the polymer is mostly in the cationic status, as dictated by 
the “apparent” pKa, which promotes the complexation with dsDNA strands. However, no 
physical crosslinking of the dsDNA strands and the positive polymer chains was observed 
at this pH, which can be ascribable to the steric hindrance of the two hydrophilic blocks 
of the co-polymer (PEG and poly-GMA block) that reduce the generation of 
macroaggregates at this condition. When the pH was slowly increased to induce the 
vesicle assembly, the central block of the polymer starts to lose its charges by 
deprotonation and becomes more hydrophobic thus increasing its surface energy that can 
only be thermodynamically minimized by reducing the exposed surface area and 
undergoing physical association with other polymer chains. However, despite the 
dsDNA/polymer interaction becomes weaker as the pH increases during the assembly 
process and the imidazole containing blocks loose part of their charges, dsDNA remains 
trapped within the aqueous core of the nanoparticles or within the hydrophobic membrane 
core of the vesicles.  
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3.11.3 DNA RELEASE FROM POLYMERSOMES  
Release of the 19-mer dsDNA from 90:10 w/w% mPEG1.9kDa-block-poly[ImHeMA]67-
block-poly[GMA]36 / t-boc-NH-PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58 
nanocarrier was investigated in buffer media at 37 °C at pH 7.4 and 5.0, to mimic the 
conditions found in systemic circulation and in late endosomal/lysosomal intracellular 
compartments respectively. The endosomal condition was chosen because endocitosed 
nanocarriers traffick to the endosomes and the short oligonucleotides loaded in the 
vehicles must be released within the endosomes for therapeutic activity. As apparent from 
Figure 3.28, release of the dsDNA was markedly pH-dependent, with 85% of the original 
encapsulated/complexed nucleic acid released at pH 5.0 after 8 hours, whilst only 15% of 
entrapped dsDNA was released by the nanocarriers at pH 7.4 over the same time.                                                                                                                        
                             
Figure 3.28. Kinetics of release of dsDNA from polymersomes formed by 90:10 w/w % mixture 
of mPEG1.9kda-block-poly[ImHeMA]67-block-poly[GMA]36 / t-boc-NH-PEG3.5kDa-block-
poly[ImHeMA]20-block-poly[GMA]58 at pH 5 (■) and 7.4 (■), at 37°C. Adapted from (205) with 
DOI: 10.1039/c3py00744h - Reproduced by permission of the Royal Society of Chemistry. 
The dsDNA release experiments were an important test of the polymer design criteria, as 
they implied that the imidazole containing blocks of the polymer were at a physico-
chemically critical state over the key cytosol-endosome pH range. The fact that dsDNA 
could be reversibly associated with the co-polymer implied that not enough imidazole 
units in the block were protonated for the polymer as a whole to bind strongly to dsDNA 
at pH 5.0, yet there were nevertheless sufficient numbers of positive charges over the pH 
responsive blocks to repel each other at the lower pH and prevent self-association into 
polymersomes. Furthermore, the positive charges over the pH responsive blocks at acid 
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pH guided the approach of the polymer to the negative charged dsDNA during the 
association process, thus guaranteeing the encapsulation of the dsDNA. 
3.11.4 siRNA LOADING STUDIES 
The ds-siRNA sequence used in this study was 5'- CTT ACG CTG AGT ACT TCG A -3' 
with its complementary sequence. It was loaded in polymeric vesicles according the “pH-
switch” method described previously for the dsDNA loading (Section 3.11.2). As 
mentioned above, dsDNA was used as model oligonucleotide to set up the loading and 
release protocols since it possess similar chemical features to ds-siRNA but higher 
stability than ds-siRNA and thus its handling is easier. Once the procols for efficient 
loading had been set up with dsDNA we moved to ds-siRNA. 
Non targeted vesicles were obtained processing a 90:10 w/w % mPEG1.9kDa-block-
poly[ImHeMA]-block-poly[GMA]/t-boc-PEG3.5kDa-block-poly[ImHeMA]20-block-
poly[GMA]58 polymer mixture.  
The siRNA loaded vesicles obtained after extensive dyalisis to remove siRNA non 
associated to the polymeric particles showed a main diameter of 236 ± 7 nm with a 
polydispersity index of 0.058 as shown in Figure 3.29.  
 
                          
Figure 3.29. Dynamic light-scattering profile of the ds-siRNA loaded polymerosomes obtained 
with a 90:10 w/w% ratio of mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 / t-boc-NH-
PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58. 
 
The result is in agreement with the ones obtained with dsDNA loaded polymersomes (see 
Figure 3.26 B) showing that the assembling behavior of the ds-siRNA with the co-
polymer mixture is comparable to the one of dsDNA. 
The loading capacity of ds-siRNA in the polymersomes was assessed using a Quant-iT™ 
RiboGreen
® 
kit. The ds-siRNA was not detectable by UV-Vis spectroscopy due to the 
very limited amount of the oligonucleotide processed for loading. The intercalating agent 
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provided with the kit for the detection of ds-siRNA is highly sensitive and has a minimum 
detection limit for ds-siRNA in solution equal to 0.25 ng/mL. In order to determine 
loading capacity of ds-siRNA in the polymersomes, the method involving Quant-iT™ 
RiboGreen
® 
was set up.
 
Indeed, the direct addition of the intercalating agent to the ds-
siRNA loaded vesicle suspension was not efficient probably because polymersomes do 
not allow fluorescent probes to diffuse across the polymeric shell. Furthermore, evidences 
with the electrophoretic mobility shift assay (see chapter 3.11.1 for results) showed that 
dsDNA/polymer complexes were not efficiently stained by GelRed
TM
 (that is an 
intercalating agent as well) when the polymer concentration was increased over the 2/1 
N/P ratio.  Thus, in order to quantify ds-siRNA after the dialysis process, vesicles were 
induced to disassemble in acidic conditions. The high sensitive intercalating agent can 
thus compete with the imidazole containing blocks of the polymer for the intercalation 
with the ds-siRNA. This procedure prove the best possible condition for the intercalating 
agent to approach the ds-siRNA since at pH 5 no vesicles are present and thus the ds-
siRNA is not encapsulated. Afterwards, the mixture pH was increased to pH 7.4 which 
should favor the intercalation of the intercalating agent rather than the charge/charge 
complexation of the ds-siRNA with the imidazole containing blocks of the polymer. 
While the ds-siRNA/polymer strength depends on the pH conditions and is weaker at pH 
7.4, the pH does not affect the association of the intercalating agent with the 
oligonucleotide.  
The quantification of ds-siRNA was based on a calibration curve with known dilutions of 
the oligonucleotide as reported in Figure 3.30. 
 
 
 
 
 
 
 
 
 
 
Figura 3.30. Calibration curve of ds-siRNA (0-1000 ng/mL) in RNAses free 10 mM Tris-HCl, 1 
mM EDTA, pH 7.5. 
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The ds-siRNA concentration in the solutions derived from polymersome disassembly  
resulted to be of 2.4 μM. 
The analysis indicated a Loading Capacity  LC% = 3.2 w/w% and an Encapsulation 
Efficiency EC%= 34 mol/mol%. The relatively high value obtained for encapsulation 
efficiency confirmed the positive results obtained for the DNA loading an described in 
chapter 3.11.2. Since a very low PDI (0.002) was obtained for the ds-siRNA loaded 
polymersomes, we can suppose that partially positively charged polymers at pH 7.4 form 
a complex with the loaded ds-siRNA resulting in high homogeneous and spherical shaped 
vesicles. 
3.12 TRANSMISSION ELECTRON MICROSCOPY (TEM) 
The morphology of the different formulation of polimersomes was tested by 
Transmission Electron Microscopy (TEM). dsDNA-free and dsDNA-loaded 
polymersomes assembled with 90:10 w/w % of mPEG1.9kDa-block-poly[ImHeMA]67-
block-poly[GMA]36 / t-boc-NH-PEG3.5kDa-block-poly[ImHeMA]20-block-poly[ GMA]58 
were prepared according to the “pH-shift” procedure at final concentration of 2 mg/mL in 
20 mM phosphate, 150 mM NaCl, pH 7.4. TEM images of dsDNA free and dsDNA 
loaded polymersomes are are shown in Figure 3.31 and 3.32 respectively. 
 
Figure 3.31. TEM images of dsDNA-free polymersomes assembled with 90:10 w/w % of 
mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 / t-boc-NH-PEG3.5kDa-block-
poly[ImHeMA]20-block-poly[GMA]58 at pH7.4. Adapted from (205) with DOI: 
10.1039/c3py00744h - Reproduced by permission of the Royal Society of Chemistry. 
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Figure 3.32. TEM images of dsDNA-loaded  polymersomes assembled with 90:10 w/w % of 
mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 / t-boc-NH-PEG3.5kDa-block-
poly[ImHeMA]20-block-poly[GMA]58 at pH 7.4.  Adapted from (205) with DOI: 
10.1039/c3py00744h - Reproduced by permission of the Royal Society of Chemistry 
TEM results provided supporting evidence of particle formation and also indicated a clear 
difference in nanoparticle structure. Dense, almost spherical, objects were observed in the 
polymer/dsDNA formulations, whereas hollow-looking vesicles were present in the 
samples assembled with polymers alone. Thus, the appearance of the dsDNA-free 
particles supports for the vesicle-like structure of the colloid that collapses when exposed 
to the TEM analytical conditions, which seems not to take place for ds-DNA loaded 
particles that possess a denser matrix. Although the TEM analysis itself can neither 
support nor eliminate the possibility of a polyplex assembly, these observed differences 
on volume and shape between the two particles might arise as a consequence of an active 
role of an additional electrostatic interaction DNA/polymer in the polymersome cohesion 
forces. 
3.13 CO-POLYMER HEMOLYTIC ACTIVITY 
The pH sensitive polymers designed for this work are aimed to deliver ds-siRNA to the 
cytosolic compartment of cancer cell for the silencing of the biological pathways involved 
in tumor progression. In order to achieve this, a nanocarriers must undergo active receptor 
mediated endocytosis by the cancer cell and then escape from the endosomal 
compartment where it is confined to release the siRNA payload in the cytosol. The 
“endosomal escape” of nanocarriers is paramount for ds-siRNA since its molecular target, 
namely the RISC protein complex, is on the cytosol and cytosol is the compartment 
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where the RNAi process will take place. Figure 3.33 schematizes the hypothesized 
pathway of ds-siRNA loaded polymersomes to guarantee the siRNA biological activity. 
                                     
Figure 3.33. Pathway of ds-siRNA loaded polymersomes inside a cancer cell to achieve 
RNA silencing. In red the key step of the carrier endosomal escape. 
The phenomenon of the endosomal escape is also known as "proton sponge effect" and 
can occur in virtue of the physic-chemical properties of the polymers that compose a 
specific nanocarrier. This effect has been observed for cationic polymers with a high pH 
buffering capability over a wide pH range. These polymers usually bear protonable 
secondary and/or tertiary amino groups with pKa close to endosomal/lysosomal pH. 
During the maturation of endosomes, the membrane-bound ATPase proton pumps 
actively transfer protons from the cytosol into the endosomes, which yield the 
acidification of endosomal compartments and the activation of hydrolytic enzymes. 
Polymers with ‘proton sponge’ feature will become protonated when exposed to the 
relatively low pH of endosomes and will buffer, up to a certain extent, the acidification of 
endosomes. As a result, more protons will be continuously pumped into the endosomes 
with the aim of decreasing the pH at the physiologic endosomal condition. The proton 
pumping activity is hyper regulated in endosomes engulfed with polymers with “proton 
sponge” feature and is accompanied by passive entry of chloride ions, which increases the 
endosomal ionic concentration and, as consequence, the water influx (Figure 3.34, panels 
B-C). Eventually the osmotic pressure causes swelling and rupture of endosomes, 
releasing their content to the cytosol (225). 
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Figure 3.34. Mechanism of the “proton sponge” effect featured by certain cationic polymers and 
the consequent endosomal rupture. 
 
The polymer we have synthesize in this project thesis is a good candidate for endosonal 
escape since it possesses imidazole containing blocks and a pKa of 5.9. The polymer is 
thus adequate to perform as a “proton sponge” once inside the endosomes where the pH is 
between ~ 5.5-6.5 (226).  
A dedicated test was selected to evaluate the ability of the pH responsive polymers 
investigated in this project of potentially undergoing endosomal escape. The study was 
carried using red blood cells (RBC) and testing the hemolytic activity of the polymers in 
different pH conditions since a correlation between a polymer hemolytic activity at acidic 
pH and endosomal membrane disruption was reported in the literature
 
(227).  
Synthetic polymer with “proton sponge” features can destabilize the RBC membrane and 
generate pores at acidic pH that allow for the intra and extracellular solutes to diffuse in 
and out generating an osmotic imbalance that causes the red blood cell lysis. 
The Figure 3.35 reports the results for the hemolytic assay carried out by incubating the 
RBC with increasing concentration of mPEG1.9kDa-b-p[ ImHeMA]67-b-p[GMA]36. 
 
 
 
Figure 3.35. Hemolytic activity profiles of mPEG1.9kDa-block-poly[ImHeMA]67-block-
poly[GMA]36 (■), PEI (■), dextran (■) at pH 7.4 (panel A), 6.5 (panel B), 5.5 (panel C) at 
increasing concentration. 
A B C 
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The hemolytic test was performed using the polymer dispersions at different 
concentration. The hemolytic profile shows that the pH responsive mPEG1.9kDa-block-
poly[ImHeMA]67-block-poly[GMA]36 does not possess any hemolytic activity at all 
concentrations tested at pH 7.4, that mimics the pH in bloodstream. The result is 
extremely encouraging since it shows that the polymer has no specific toxicity toward the 
red blood cells and cannot induce RBC membrane rupture in the blood conditions.  
The hemolityc activity of the polymer was also tested at pH 6.5, that mimics the tumor 
interstitium. At this condition the vesicles tend to increase in size as reported in Figure 
3.12 and 3.13. The size increase is beneficial to favor the entrapment of the vesicles in the 
tumor interstitium. At this pH condition the polymersomes are still stable but the 
morphological rearrangement that induces the size increase can partially induce 
unspecific interactions with biological membranes. This might promote a limited 
hemolytic activity of the polymer that was detected only at rather high concentrations 
(above 1 mg/mL).  
Finally, at pH 5.5, that mimics the endosomal environment, the capacity of the polymer to 
induce the rupture of the RBC membrane is considerable even at the lowest concentration 
tested. Over 70% hemolysis was observed in this pH condition. The result confirmed that 
the polymer can induce cell membrane rupture selectively at pH 5.5, which translates in a 
reliable endosomal escape capacity that will not cause cell damage in the blood stream. 
3.14 PHENOTYPIC CHARACTERIZATION OF CANCER CELLS 
AND FOLATE RECEPTOR EXPRESSION 
Folic acid (vitamin B9) is an essential nutrient required by eukaryotic cells for survival. 
Cells physiologically acquire folic acid by specific transporters. However, few cells can 
also internalize folate receptor via receptor mediated endocytosis due to the presence on 
the cell surface of the folate receptors (FR). In particular, cells undergoing a high 
metabolic activity can up regulate FR expression. Among these cells, also many different 
human cancer cells, including ovarian, breast, cervical, renal, colorectal and 
nasopharyngeal cancer cells show significant up regulation of the FR as compared to 
normal tissues (228). As such, folic acid has been successfully exploited as a cancer 
specific targeting moiety for the efficient delivery of chemotherapeutic agents, drug 
carriers, photo sensitizers and diagnostic reporters.  
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The literature report the over expression of FR in a variety of cancer cells by Western blot 
assay that require the isolation of the protein pool from the cell, a gel electrophoretic 
fractionation and the staining of the specific FR (229). We decided to pursue a different 
strategy to characterize the expression of the FR by two cell line. For that purpose we 
performed a cytometric study on KB cells from human cervical carcinoma and MCF7 
cells from human breast adenocarcinoma. The advantage of this method, if compared to 
the other techniques as Western blot, consists of no cells lisys and no possibility to 
overestimate the amount of folate receptor taking in account also the receptors inside the 
cells. It means that with cytofluorimetry we are sure of the effective presence of receptor 
expressed on the cell surface and that we need for our purpose. 
The cell phenotypic profile was investigated by tagging alive cells with specific anti 
folate receptor antibody conventionally used in immunohistochemical  settings. Cell 
samples were then treated with a secondary fluorescent antibody as labeling agent. Figure 
3.36 shows the cytfluorimetric profiles of the two cell lines grown in different medium. 
 
Figure 3.36. KB and MCF7 cell cytofluorimetric profile obtained by FACS analysis after 
treatment with only the secondary antibody (■, control untreated sample) and after treatment with 
anti FR Ig and secondary antibody (■). KB cells were grown in folate containing DMEM medium 
(A), and in folic free DMEM medium (B). MCF7 were grown in folate containing RPMI medium 
(Panel C).  
The cytofluorimetric analysis shows that KB cells express high level of the folate receptor 
since almost 100% of cells resulted positive to this specific receptor (Panel A and B). 
Furthermore, the growth medium was not affecting the KB cells expression level of the 
receptor that is constitutive expressed in this cell line. The receptor expression is not 
A B C 
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increased when cells are grown in folic acid depleted medium (Panel B) with respect to 
the same cell line grown in folic acid containing medium (Panel A).  
Only 13% of the total MCF7 cell population resulted positive to folate receptor (Panel C). 
Notably, this cell line does not grow in folic acid depleted medium, which is conceivable 
being MCF7 devoided of the folate receptor that, in the other hand, supplies KB cells 
with the vitamin even in folate depleted medium (concentration of free folate in folate 
depleted DMEM = 2 nM). Overall the result confirmed that KB cells is an adequate cell 
model for investigating folate targeted nanocarriers and that MCF7 cells can be used as 
negative control being devoid of the folate receptor. 
3.15 BIOCOMPATIBILITY STUDIES 
Having established the primary utility of the polymers as nucleic acid carriers, the 
cytocompatibility of the materials was explored by MTS (3- (4,5- dimethylthiazol - 2-yl) -
5-(3- carboxymethoxyphenyl)-2-(4- sulfophenyl)-2H-tetrazolium, inner salt) cell viability 
assay (230). This test is based on the conversion through the mitochondrial activity of 
viable cells, incubated at 37ºC, of a tetrazolium salt into a colored formazan. The quantity 
of formazan produced by dehydrogenase activity is directly proportional to the number of 
living cells and it is measured at 492 nm.  
The cell viability test showed that the selected untargeted polymersomes obtained with 
90:10 w/w% of mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36/ t-boc-
PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58 and targeted polymersomes 
obtained with the 90:5:5 w/w% of mPEG1.9kDa-block-poly[ImHeMA]67-block-
poly[GMA]36 / t-boc-PEG3.5kDa-block-poly[ImHeMA]20-block-poly[GMA]58 / α-folate-
PEG3500-block-poly[ImHeMA]20-block-poly[GMA]58 were well-tolerated by a range of 
cell lines including KB human cervical carcinoma, MCF-7 breast cancer cells and B16-
F10 mouse melanoma cell (Figure 3.37). No evident cytotoxicity was detected even for 
prolonged cell exposure to the polymersomes. 
 Results and Discussion     
  
136 
 
 
Figure 3.37. MTS cell availability assay on B16F10  cells at 1, 2, 3 mg/mL of 90:10 w/w% of 
mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 / t-boc-PEG3.5kDa-block-poly 
[ImHeMA]20-block-poly[GMA]58 based polymersomes (■)  and 90:5:5 w/w% of mPEG1.9kDa-
block-poly[ImHeMA]67-block-poly[GMA]36 / t-boc-PEG3.5kDa-block-poly[ImHeMA]20-block-
poly[GMA]58 / α-folate-PEG3500-block-poly[ImHeMA]20-block-poly[GMA]58 polymersomes (■), 
after 24 hours (Panel A) and 48 hours (Panel B) incubation at 37°C. Data are reported as mean 
values of 5 measurements with ± standard deviations. 
3.16 CELLULAR UPTAKE OF POLYMERSOMES 
Cell uptake studies were performed using the selected polymersomes formulations. The 
folate targeted polymersomes were constituted of 90:10 w/w% of mPEG1.9k-block-
poly[ImHeMA]67-block-poly[GMA]36/ t-boc-PEG3.5kDa-block-poly[ImHeMA]20-block-
poly[GMA]58 and the control non-targeted vesicles were assembled with 90:5:5 w/w% of 
mPEG1.9kDa-block-poly[ImHeMA]67-block-poly[GMA]36 / t-boc-PEG3.5kDa-block-
poly[ImHeMA]20-block-poly[GMA]58 / α-folate-PEG3.5kDa-block-poly[ImHeMA]20-
block-poly[GMA]58. 
3.16.1 FLUORIMETRIC AND CYTOFLUORIMETRIC UPTAKE STUDIES 
Folate-targeted polymeric formulations loaded with cyanine-DNA were incubated with 
B16F10 cells in order to investigate the time dependant cellular uptake by 
cytofluorimetric analysis. B16F10 cells were selected because they overexpress the folate 
receptor (199, 200) and were also used as model for the silencing studies being 
transfected with luciferase. The polymersomes uptake study was carried out at 37 °C and 
at 4 °C, in order to determine whether the main cell internalization mechanism was 
energy-dependent (231). Incubation at 4 °C allow to selectively inhibit any energy 
dependent process but not the diffusive uptake. Cell associated polymersomes were 
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quantified by flow cytometry. Figure 3.38 shows the cell uptake profile at the two 
different temperature conditions and at different time points of incubation. 
                          
Figure 3.38. Kinetic B16F10 cells uptake profile of folate -targeted polymersomes loaded with 
cyanine-labelled DNA at 37°C (■) and 4°C (■). The normalized uptake was derived by 
subtracting cell associated fluorescence of cells incubated at 4°C from the cell associated 
fluorescence of cells incubated at 37°C (■). 
The unspecific association of the targeted polymersomes obtained by incubating cells at 4 
°C was subtracted from the fluorescence detected in cell samples incubated with 
polymersomes at 37°C to obtain the normalized uptake profile. The normalized uptake 
profile shows that folate tipped polymersomes internalization at 37°C is maximum after 
30 minutes incubation with polymersomes. After this period, the uptake starts to slightly 
decrease, probably according a folate receptor saturation mechanism suggested from in 
vivo studies performed by Leamon and Low (232).  
The kinetic uptake study confirmed that about 30 minutes of dsDNA loaded polymersome 
incubation is required to achieve significative cell internalization of the targeted 
nanosystem by folate receptor expressing cancer cells and that the cell uptake is rather 
saturated after this time frame. 
Based on the outcome from the kinetic uptake study with B16F10  cells, polymer 
formulations with, and without, the folate-terminal functionality were also incubated with 
KB and MCF-7 cells to investigate feasibility for cell delivery by passive or receptor 
mediated internalization mechanisms. The folate-receptor (FR) mediate targeting used in 
this experiment, has been elsewhere reported, to be highly suitable for some cancer cell 
lines (228, 229). KB cancer cell line, as reported above, were shown to over-expresses the 
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folate receptor, while the MCF-7 does not. The polymer nanoparticles for these assays 
were prepared in the presence of cyanine-3 labelled dsDNA (with the same sequence as 
that used in the encapsulation assays) to facilitate cross-comparison. Quantification of 
polymer nanoparticles uptake was carried out via fluorescence intensities of cell lisates 
derived from the cyanine-3 dsDNA emission. The incubation time was selected based on 
the evidences acquired by the above discussed kinetic uptake study. KB and MCF7 cells 
were incubated with polymersome formulation for 30 minutes apparent from Figure 3.32, 
marked differences in cell association occurred dependent on whether the dsDNA loaed 
polymeric particles were ligand-functionalised and if the cells expressed the folate 
receptor. Results are reported in Figure 3.39. 
                            
Figure 3.39. Amount of cyanine-3 dsDNA internalized by KB and MCF7 cells after 30 minuts 
incubation with polymersome formulations. Targeted nanoparticles were prepared from 
mPEG1.9kda-block-poly[ ImHeMA]67-block-poly[GMA]36 with 10 w/w% t-boc-NH-PEG3.5kDa-
block-poly[ImHeMA]20-block-poly[GMA]58 (■) or 5:5 w/w% t-boc-NH-PEG3.5kDa-block-
poly[ImHeMA]20-block-poly[GMA]58 and α-folate-PEG3.5kDa-block-poly[ImHeMA]20-block-
poly[GMA]58 (■). The blank consisted of phosphate saline buffer pH 7.4 (■). 
Targeted polymersomes showed about 2.5-fold higher uptake with respect the non-
targeted control polymersomes with the same cell line. No difference in the cell 
association was instead observed with MCF7 where a negligible unspecific association 
was only recorded. In general, uptake of the nanoparticles was higher in KB cells 
compared to MCF-7 cells, and the highest uptake overall was obtained for the polymer 
formulations containing 5% of the folate-tipped α-folate-PEG3.5kDa-block-
poly[ImHeMA]20-block-poly[GMA]58.  
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The selective uptake of polymersome with the same cell lines (KB and MCF7 cells) was 
also confirmed by cytofluorimetry analysis that provided comparable results in term of 
uptake profile, cell specificity, polymersomes selectivity (Figure 3.40 a) and 3.40 b)). 
                            
Figure 3.40 a). Mean Fluorescence Intensity of cells incubated with polymersomes loaded with 
cyanine-3 dsDNA. Targeted nanoparticles were prepared from mPEG1.9kda-block-
poly[ImHeMA]67-block-poly[GMA]36 with 10 w/w% t-boc-NH-PEG3.5kDa-block-
poly[ImHeMA]20-block-poly[GMA]58 (■) or 5:5 w/w% t-boc-NH-PEG3.5kDa-block-
poly[ImHeMA]20-block-poly[GMA]58 and α-folate-PEG3.5kDa-block-poly[ImHeMA]20-block-
poly[GMA]58 (■).The blank consisted of phosphate saline buffer pH 7.4 (■). 
                 
Figure 3.40 b). Histograms overlay of fluorescent positive KB (Panel A) and MCF7 cells (Panel 
B) to cyanine-3 dsDNA are reported for cells treated  with PBS (■), cells treated with targeted 
vesicles (-) and cells treated with non targeted vesicles (- - -). 
The fact that the polymer nanoparticles were of similar sizes and ζ-potential across the set 
of folate-tipped and non-folate tipped materials, when formulated with dsDNA, strongly 
suggests that the uptake pathways and kinetic profile, investigated with two folate 
receptor expressing cells and using fluorescence spectroscopy and cytofluorimetry, were 
unlikely to have been a function of the nanoparticle geometries. Thus, while specific 
inhibition studies with free folic acid to saturate any folate receptors on the KB cells were 
not carried out, the ability of these folate receptor positive cells to internalize the folate-
A B 
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tipped polymers nevertheless was supportive of a specific uptake pathway for the folate 
polymer formulations. These experiments also highlighted the ability of mixed polymer 
formulations with relatively low ligand densities at their surfaces being able to enter cells 
via a receptor-mediated process.  
3.17 CONFOCAL MICROSCOPY  
Studies of confocal microscopy were performed on vesicles with/without targeting agent 
and loaded with dsDNA fluorescently labeled with cyanin-3 to acquire information about 
the intracellular deposition of the delivered dsDNA after vesicle uptake. As for the uptake 
analysis performed by fluorescence spectrometry and cytofluorimetry KB cells over 
expressing folate receptor and MCF7 as negative control were used. 
In the following Figure 3.41, all the cell samples were obtained by incubating cells with 
polymersome formulations as described in section 2.3.18. 
 
                         
Figure 3.41. Images obtained by confocal microscopy of KB cells incubated with folate targeted 
Cyanin-3 labelled DNA polymersomes (panel A); KB cells incubated with non targeted Cyanin-3 
labelled DNA polymersomes (panel B); MCF7 cells incubated with folate targeted Cyanin-3 
labelled DNA polymersomes (panel C); MCF7 cells incubated with non targeted Cyanin-3 
labelled DNA polymersomes (panel D) are reported. Panel A1 is a magnification of the panel A 
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showing details of KB cell nucleus and intracellular fluorescent organelles. Cell images were 
acquired using blue channel for nuclei detection after labelling with DAPI, green channel for cell 
membrane detection after labelling with fluorescein-DHPE, red channel for cyanin-3 labeled 
polymersome detection.         
Panels A and the magnification (Panle A1) shows clear red spots consisting of cyanin-3 
DNA labelled polymersomes or free cyanin-3 DNA that are detectable both in the cytosol 
of KB cells, and in the cell nucleus. The magnification (panel A1) also highlights that the 
dsDNA loaded polymersomes or the dsDNA alone is associated mostly in confinded in 
cytosolic sub-compartments of the or in the nuclei but spreading over the cytosol is also 
detectable. The red spot confined in the cytosolic compartment could be endosomes at 
some stage of development and migration even though more detailed studies are required 
to precisely confirm this hypothesis. Notably, tt was rather unexpected to find out red 
spots inside the nucleus. We have speculated that the folate can target the nanocarriers 
toward the nucleus; this has one first relevant implication: the vesicles undergo 
endosomal escape and can migrate elsewhere in the cell. A possible explanation of this 
unexpected disposition may be related to the roles of the folate that can operate as 
transcription factor (233) and is cofactor of the synthesis of nucleotides once inside the 
cell nucleus (234). Being both activities and the molecular targets of folate confined to 
the nucleous, it is conceivable that it can direct the migration towards the nucleous of 
conjugated macromolecules.  
This evidence is confirmed by literature, where Chao Zhang managed to deliver 
minicircle DNA to cytosol and cell nucleus using folate–poly(ethylene glycol)–
polyethylenimine polyplexes (235). The images obtained by the confocal analysis, 
together with the results of polymersomes uptake obtained by fluorimetric analysis on cell 
lisate, cytofluorimetry, confirm that targeted oligonucleotide loaded vesicles are 
internalized by receptor mediated endoycotosis and that the vesicle payload or the carriers 
as a whole undergo intracellular trafficking, which, at some extent, allow the deposition 
of the oligonucleotide in the nuclear compartment.  
On the other hand, polymersomes without folate on surface were inefficient in triggering 
the cell uptake and do not cross the cell membrane by diffusion, as demonstrated in panel 
B and D that are devoid of red fluorescent spots. 
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To conclude, the selectivity of the polymersomes was further confirmed by both targeted 
and non targeted polymersomes incubation with MCF7 cells that were used as negative 
control. No internalization was observed with this cell line.  
3.18 SILENCING STUDIES 
To conclude polymersomes were also investigated to assess their biopharmaceutical 
properties and if the intracellular delivery of oligonucleotides allows for their biological 
activity to take place. Folate targeted polymersomes assembled according to the 
description reported in section 2.3.3 and loaded with ds-siRNA with a specific sequence 
to silence luciferase were incubated with B16F10 cells from mouse melanoma 
overexpressing folate receptor and that have been previously transfected with a plasmid 
encoding pGL3 luciferase under the SV40 (236). Luciferace is an ideal enzymatic model 
to test the intracellular delivery of the functional siRNA that silence the expression of the 
enzyme. Thus it is conventionally exploited to investigate the delivery efficiency of 
nanocarriers.  
Luciferase has an apparent molecular weight of 62 kDa and requires luciferin, ATP, and 
O2 as substrates for its enzymatic activity. The structure and physic-chemical properties 
of firefly luciferin is known and the chemical synthesis of this heterocyclic carboxylic 
acid has also been reported (237, 238). The reactions catalyzed by firefly luciferase are: 
           luciferin + ATP → luciferyl adenylate + PPi  
           luciferyl adenylate + O2 → CO2 + oxyluciferin + AMP + light 
where ATP is Adenosine triphosphate, PPi is pyrophosphate and AMP is Adenosine 
monophosphate. 
The first reaction involves the formation of an enzyme-bound luciferyl-adenylate. During 
the second reaction, the luciferyl-adenylate undergoes an oxidative decarboxylation 
which results in the production of CO2, oxyluciferin, AMP, and light. When the luciferin 
substrates is provided in the reaction mixture, firefly luciferase produces a flash of light 
that is proportional to the quantity of luciferase (239).  
A model representation of luciferase activity is reported in Figure 3.42.                             
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3.42. Schematic representation of luciferase activity. 
 
The bioluminescence process can be monitored at  λem 535 nm by spectrophotometric 
analysis. 
The siRNA loaded inside polymersomes has a specific sequence that was selected to 
inhibit the luciferase expression by degradating the mRNA involved in the translation 
process responsible for the synthesis of this enzyme. This is indeed the RNAi process 
described in the introduction chapter 1.1.2.5. Studies reported in literature (240), showed 
that a cellular ds-siRNA anti-luciferase concentration of 25 nM is sufficient to carry out a 
silencing effect of the enzyme, which can be monitored by the decrease in the 
bioluminescence emitted at 535 nm. 
Figure 3.43 reports the silencing profiles obtained by incubating luciferase transfected 
B16F10 cells with folate targeted polymersomes loaded with anti-luciferase ds-siRNA for 
30 minutes. 
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3.43. Luciferase silencing profiles in B16F10 cells treated with, from the left: folate targeted 
siRNA free vesicles (■), targeted vesicles loaded with scrambled siRNA (■), targeted vesicles 
loaded with anti-luciferase siRNA (■); unformulated scrambled siRNA (■), unformulated anti-
luciferase siRNA (■). 
 
According the luciferase silencing profile, after 30 minutes of incubation with cells, the 
folate targeted polymersomes loaded with anti-luciferase ds-siRNA induced an inhibition 
of the luciferase activity of almost 30%. No evidence of silencing effect was observed 
when cells were incubated with empty polymersomes and targeted polymersomes loaded 
with scrambled ds-siRNA. These controls confirmed that the silencing effect detected 
with the targeted vesicles can only be ascribed to the efficient intracellular delivery of the 
oligonucleotide, its release from the polymeric carrier and the endosomal escape in the 
biologically active form. The decrease of bioluminescence cannot be a consequence of 
nanocarrier toxicity since the bioluminescence was not altered by the cell incubation with 
solely the ds-siRNA free polymesomes. Notably, when anti-luciferase ds-siRNA was 
administered to the cells as free unformulated molecule, not effect on the 
bioluminescence was observed due to the inefficient permeability of the polyanionic 
macromolecules to freely permeate the biological membranes.  
The protein expression inhibition achieved with the delivery strategy here discussed is 
unquestionable and promising for further silencing studies of proteins involved in the 
tumor progression for therapeutic purposes. It should be mentioned that the results 
reported in Figure 3.36 were referred to the bioluminescence generated by cells treated 
with the folate targeted ds-siRNA free polymersomes. This formulation, in fact, induced 
an increase in bioluminescence with respect to untreated cells. Studies performed by 
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Boshnjaku et all. (233) showed that [folic acid / folate recetor α] complex can operate as a 
transcription factor. Indeed, this complex translocates to the nucleus, where it can bind 
regulatory elements at regions of promoters and it may modulate the expression of the 
controlled proteins. Thus, a similar activation effect can induce the enhancement of the 
bioluminescence in cell samples treated with folate targeted polymersomes as 
consequence of the [folate-polymer / folate recetor α] complex binding the luciferase 
promoter. Furthermore, an hyper proliferation of cells incubated with folate targeted  
polymersomes was also observed, which can be a consequence of promoters activation. 
Hence, the normalization according folate targeted siRNA free formulation was required. 
To conclude, the potential activation of nuclear promoters is in agreement with the 
massive deposition of the polymeric carrier or the loaded oligonucleotides in the cell 
nucleus opening up novel perspectives for sub-cellular targeting approaches. 
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4. CONCLUSIONS 
In conclusion, this thesis project, in collaboration with University of Nottingham and 
Centro de Investigacion Principe Felipe in Valencia, was aimed at designing, synthesizing 
and characterizing in vitro few responsive AB and ABC block copolymers that changed 
conformation with varying the pH conditions. In particular, in order to develop targeted 
drug-delivery systems for antitumoral therapy, novel monomers with N-alkyl imidazole 
structure, have been successfully designed, synthesized and characterized. The monomers 
were chosen in virtue of their amphiphilic character: the alkyl chains allowed for 
intermingle association with other polymer chains by hydrophobic interaction, while the 
imidazole moiety allows for association/dissociation shift of the polymeric chains as 
consequence of the imidazole protonation equilibrium.  
These monomers were subsequently used for the synthesis of pH responsive block co-
polymers using RAFT polymerization technique. Moreover, polymersome formation tests 
were conducted. The diblock co-polymers responded to pH variations in a range close to 
the one of interest (pH 6.5-5), but early precipitation occurred. Although these materials 
were not all fully soluble in aqueous media at physiological pH, which limits their 
applications, they provided useful information for subsequent studies. It was clear that the 
high hydrophobicity of ImHeMA, needed to be balanced by a higher degree of 
hydrophilicity, potentially improving the solubility in aqueous media and favoring the 
formation of polymersomes over micelles that are more versatile for the loading of very 
hydrophilic macromolecules such as the oligonucleotides.  
Bearing in mind this assumption, an ABC triblock co-polymer poly[GMA]-block-
poly[ImHeMA]-block-PEG1.9kDa was first synthesized according to a two step procedure 
involving a first RAFT polymerization process and a subsequent performed PEG 
conjugation. This co-polymer showed a remarkably high solubility at physiological pH 
(pH 7.4) and the ability to form polymeric assemblies. These particles were reasonably 
hollow vesicles that are conventionally named polymersomes and were stable at pH 7.4 
over three days, but they were easily destabilized at lower pH 6.5, i.e. a similar pH value 
found in the cellular endosomes.  
Despite these results, reactions for a mPEG macroCTA were carried out to engineer a 
simpler ABC triblock co-polymer system, starting from the same materials used in these 
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early stage studies, but aiming an improvement of the yields obtained by the conjugation 
of the PEG to the di-block. The ability of the obtained polymers to change conformation 
over specific biologically relevant pH ranges has been shown by NMR and DLS studies 
and the pH-switching behavior has been used to encapsulate DNA and release the nucleic 
acid in a triggered fashion. Selected polymers and their formulations with DNA have 
been shown to be non-toxic, colloidally stable at ambient pH and temperature and even in 
the presence of serum protein, and able to transport DNA via folate receptor-mediated 
uptake pathway into specific cell lines. 
The polymeric vesicles were thus loaded with a functional ds-siRNA sequence able to 
participate to the RNAi process and silence a model enzyme expressed in transfected 
cancer cells. The synthesis of the target protein was inhibited by the 30% as consequence 
of the efficient intracellular delivery of ds-siRNA by the folate targeted polymersomes. 
The promising result is in agreement with data obtained from cell uptake studies 
performed with the same polymeric vesicles loaded with a model fluorescently labeled 
dsDNA. The images obtained from confocal microscopy studies also confirmed the 
internalization of oligonucleotides loaded polymersomes inside the target cells. 
The results of all studies were thus good indicators of the success of the design strategy 
for these pH-responsive materials. When considered in context, the described materials 
exhibit some key properties that are favorable for pharmaceutical applications. The ability 
to encapsulate biopolymers such as DNA and siRNA is clearly advantageous for 
emerging medical technologies, since many new therapeutic entities (proteins, siRNA) 
are biological in origin and need a delivery system to be used in practice. In addition, the 
ability to fine tune the polymer conformations across physiological pH ranges by mixed 
responsive monomer block combinations may allow control over tissue and cell 
localization. Significant size changes were observed for some of the self-assembled 
polymer structures over pH ranges varying from 5.5 - 6.5, 6.8 -7.0 and 7.2 -7.4, and these 
might in turn result in nanocarrier entrapment and retention in tumors through pH- 
dependent swelling (241), followed by intracellular uptake and drug release. From 
literature we have fascinating examples of shape and size polymer variation in response 
to pH (201) and particle shape itself can be investigated as a means to influence 
biodistribution and cell targeting (205, 242, 243). Finally, the facile route to ligand-
functionalized formulations by mixing two or more co-polymers with different end-
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groups potentially enables multi-modal targeting, whereby much more specific cell- or 
sub-cellular organelle- delivery might be addressed. As a corollary, it should be noted that 
while the imidazole ring on the responsive block components is present in natural 
molecules (e.g. purine, histamine, histidine) and is therefore considered to be 
cytocompatible and non toxic, there are many examples of polymers with positive 
charges (e.g. polylysine) which can be toxic (205, 244). Moreover, imidazole containing 
antifungal agents include potent inhibitors of the CYTP450 enzymes lanosterol α 
demethylase (CYP3A4) and Δ 22 desaturase (CYP2C19), leading to blocking of the 
ergosterol pathway and subsequent membrane destabilization and toxicity (205, 245, 
246). Breakdown in vivo of the polymers used in this study would probably lead to PEG, 
polymethacrylic acid and imidazolic residues which may be tolerable for acute therapies 
but  not acceptable for long-term treatments. Nevertheless, the design rules obtained for 
responsive materials as shown in this PhD project are important to inform further studies 
wherein specific components of each responsive block and/or polymeric amphiphile are 
re-formulated, re-engineered or synthesized from more pharmacologically acceptable 
materials.  
Concluding, the positive results reported in this thesis using this novel pH sensitive 
vesicular system can be reasonably extended to specifically silence therapeutically 
relevant intracellular proteins for cancer therapy. 
The structural rearrangement of the block co-polymers, which may be critical in 
determining their interactions with biological components, need also further 
investigations, as the detailed mechanisms underlying their behavior are still not clear and 
require further investigations involving the soft matter characterization techniques at 
molecular level. Initial results revealed some aspects, but full biological and biophysical 
understanding is still needed in order to maximize their effects in anticancer therapy. 
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